Genetic and Chemical Modulators of JAK/STAT Signalling in Cancer by Thomas, Sally J
 
  
Sally Jane Thomas 
Genetic and Chemical 
Modulators of JAK/STAT 
Signalling in Cancer 
Submitted to the University of Sheffield for the 
Degree of Doctor of Philosophy 
 
September 2015 




Abstract ................................................................................................................................. 6 
Declaration ............................................................................................................................ 7 
Publications ........................................................................................................................... 8 
Acknowledgements ............................................................................................................... 9 
Abbreviations ..................................................................................................................... 11 
List of figures ...................................................................................................................... 13 
List of tables ........................................................................................................................ 16 
CHAPTER 1: INTRODUCTION ........................................................................... 17 
1.1 Overview ....................................................................................................................... 17 
1.2 JAK/STAT signalling ................................................................................................... 18 
1.2.1 Structure of pathway and pathway components ....................................... 18 
1.2.2 JAK/STAT signalling in cancer ................................................................ 27 
1.2.3 JAK/STAT signalling in immunity and inflammation ............................. 39 
1.2.4 The JAK/STAT pathway as a therapeutic target....................................... 42 
1.3 ANKHD1 ....................................................................................................................... 45 
1.3.1 ANKHD1 protein ...................................................................................... 45 
1.3.2 ANKHD1 gene ........................................................................................... 47 
1.3.3 ANKHD1 transcripts ................................................................................. 48 
1.3.4 ANKHD1 functions .................................................................................. 49 
1.3.5 ANKHD1 in cancer ................................................................................... 54 
1.3.6 Rationale behind the investigation of ANKHD1 as a modulator of 
JAK/STAT signalling. ....................................................................................... 54 
1.4 Methotrexate ................................................................................................................. 55 
1.4.1 Structure .................................................................................................... 55 
1.4.2 Pharmacokinetics ...................................................................................... 55 
1.4.3 Methotrexate as a chemotherapy drug ...................................................... 56 
1.4.4 Methotrexate in the treatment of inflammatory conditions....................... 57 
1.4.5 Rationale behind the investigation of methotrexate as a suppressor of 
JAK/STAT signalling ........................................................................................ 58 
1.5 Synopsis ......................................................................................................................... 59 
CHAPTER 2: MATERIALS AND METHODS ................................................... 60 
2.1 Cell culture .................................................................................................................... 60 
2.1.1 Cell lines and culture conditions ............................................................... 60 
2.1.2 Drug and ligand treatments ....................................................................... 63 
2.1.3 Transfection of HeLa cells ........................................................................ 64 
2.2 Protein techniques ........................................................................................................ 65 
2.2.1 Protein extraction ...................................................................................... 65 
2 
 
2.2.2 Western Blotting ....................................................................................... 66 
2.3 DNA techniques ............................................................................................................ 68 
2.3.1 Bacterial culture and starting plasmids ..................................................... 68 
2.3.2 Generation of plasmid encoding fragment of ANKHD1 containing first 
and second ankyrin repeats and the intervening region ..................................... 69 
2.4 RNA techniques ............................................................................................................ 73 
2.4.1 RNA extraction ......................................................................................... 73 
2.4.2 cDNA synthesis ......................................................................................... 73 
2.4.3 Quantitative real-time PCR ....................................................................... 73 
2.5 Drosophila techniques .................................................................................................. 74 
2.5.1 Luciferase assays ....................................................................................... 74 
2.5.3 Preparation of fly media containing drugs ................................................ 74 
2.5.4 Crosses ...................................................................................................... 74 
2.5.5 Tumour assay ............................................................................................ 75 
2.6 Kinase profiling ............................................................................................................ 75 
2.7 Immunofluorescence .................................................................................................... 75 
2.7.1 Preparation of slides .................................................................................. 75 
2.7.2 Fluorescence Microscopy.......................................................................... 76 
2.7.3 Image analysis ........................................................................................... 76 
2.8 Source and initial processing of patient samples ....................................................... 76 
2.8.1 Ethical approval ........................................................................................ 76 
2.8.2 Whole blood and bone marrow aspirate.................................................... 77 
2.8.3 Apheresis material ..................................................................................... 78 
2.8.4 Formalin fixed paraffin embedded melanoma samples ............................ 79 
2.9 Flow cytometry ............................................................................................................. 79 
2.9.1 Development of flow cytometry protocol ................................................. 79 
2.9.2 Fixation and permeabilisation ................................................................... 81 
2.9.3 Immunostaining ........................................................................................ 82 
2.9.4 Assessment of cell viability ...................................................................... 83 
2.9.5 Analysis on flow cytometer ...................................................................... 83 
2.9.6 Gating strategies ........................................................................................ 84 
2.9.7 Flow cytometry calculations ..................................................................... 84 
2.10 Immunohistochemistry .............................................................................................. 89 
2.10.1 Preparation of slides ................................................................................ 89 
2.10.2 Microscopy .............................................................................................. 90 
2.11 Antibody validation .................................................................................................... 90 
2.12 Statistical analysis .................................................................................................... 925 
3 
 
CHAPTER 3: ANKHD1 IN NORMAL BLOOD AND HAEMATOLOGICAL 
MALIGNANCIES .................................................................................................... 96 
3.1 Introduction .................................................................................................................. 96 
3.2 Results ........................................................................................................................... 97 
3.2.1 Patient characteristics ................................................................................ 97 
3.2.2 Quantitative real time PCR ....................................................................... 99 
3.2.3 Western Blotting ....................................................................................... 99 
3.2.4 ANKHD1 expression in normal blood cells ........................................... 101 
3.2.5 ANKHD1 in haematopoietic stem cells .................................................. 104 
3.2.6 ANKHD1 in haematological malignancies ............................................. 104 
3.2.7 Summary of ANKHD1 expression in blood cells ................................... 106 
3.3 Discussion .................................................................................................................... 106 
3.3.1 Assessment of ANKHD1 expression with qPCR and western blotting, and 
modification of original experimental design .................................................. 111 
3.3.2 Flow cytometry as an approach to examine ANKHD1 expression ........ 112 
3.3.3 ANKHD1 expression in normal peripheral blood cells .......................... 113 
3.3.4 ANKHD1 in haematopoietic stem cells and haematological malignancies
 .......................................................................................................................... 114 
3.4 Conclusions ................................................................................................................. 115 
CHAPTER 4: ANKHD1 IN MELANOMA ......................................................... 116 
4.1 Introduction ................................................................................................................ 116 
4.2 Results ......................................................................................................................... 119 
4.2.1 ANKHD1 expression in melanoma cell lines ......................................... 119 
4.2.2 Expression of signalling pathway proteins in melanoma cell lines ........ 119 
4.2.3 ANKHD1 expression in invasive melanoma in engineered skin ............ 123 
4.2.4 Patient Characteristics and histological features ..................................... 123 
4.2.4 Immunohistochemistry and tumour histological features ....................... 124 
4.2.5 ANKHD1 staining patterns ..................................................................... 126 
4.3 Discussion .................................................................................................................... 136 
4.3.1 Expression and cellular localisation of ANKHD1 in melanoma ............ 136 
4.3.2 Ongoing and possible future work .......................................................... 137 
4.4 Conclusions ................................................................................................................. 138 
CHAPTER 5: METHOTREXATE IS AN INHIBITOR OF JAK/STAT 
SIGNALLING ........................................................................................................ 139 
5.1 Introduction ................................................................................................................ 139 
5.2 Results ......................................................................................................................... 140 
4 
 
5.2.1 Methotrexate reduces JAK/STAT activation caused by ligand-binding and 
activation caused by constitutive kinase activation in Drosophila cultured cells
 .......................................................................................................................... 140 
5.2.2 Methotrexate does not affect JAK/STAT dependant tumour formation in 
vivo in Drosophila ............................................................................................ 142 
5.2.3 Examination of expression and phosphorylation of JAK/STAT pathway 
components in human cell lines ....................................................................... 142 
5.2.4 Methotrexate and aminopterin reduce JAK phosphorylation ................. 144 
5.2.5 Methotrexate does not affect the activity of JAK2 in in vitro kinase 
assays, and has little effect on other kinases .................................................... 144 
5.2.6 Methotrexate and aminopterin have selective effects on STAT 
phosphorylation in HDLM-2 cells ................................................................... 148 
5.2.7 The effects of methotrexate on STAT phosphorylation are not the 
consequence of a global reduction in protein phosphorylation ........................ 148 
5.2.8 STAT phosphorylation caused by the JAK2 V617F mutation is reduced 
by methotrexate ................................................................................................ 148 
5.2.7 The effects of methotrexate on STAT phosphorylation appear after 24 
hours of methotrexate treatment....................................................................... 150 
5.2.8 The effect of methotrexate on STAT phosphorylation is not reversed by 
folinic acid ........................................................................................................ 150 
5.2.9 Methotrexate-treated cells can activate JAK/STAT signalling in response 
to EPO .............................................................................................................. 152 
5.2.10 Suppression of STAT5 phosphorylation by methotrexate is comparable 
to that produced by ruxolitinib ......................................................................... 152 
5.3 Discussion .................................................................................................................... 154 
5.3.1 JAK/STAT suppression as a mechanism of action for methotrexate as an 
anti-inflammatory drug .................................................................................... 154 
5.3.2 What is the mechanism through which methotrexate suppresses 
JAK/STAT signalling? ..................................................................................... 155 
5.3.2 Methotrexate as a potential treatment for patients with MPNs ............... 157 
5.3.3 Methotrexate as a potential treatment for patients with other 
haematological malignancies associated with activation of JAK/STAT 
signalling .......................................................................................................... 158 
5.4 Conclusions ................................................................................................................. 159 
CHAPTER 6: EFFECTS OF METHOTREXATE ON PATIENT CELLS ..... 160 
6.1 Introduction ................................................................................................................ 160 
6.2 Results ......................................................................................................................... 161 
6.2.1 RA-FLS show constitutive phosphorylation of STAT1.......................... 161 
6.2.2 The suppression of STAT1 phosphorylation by methotrexate varies 
between patients ............................................................................................... 161 
6.2.3 MF Patient characteristics ....................................................................... 161 
5 
 
6.2.4 Isolation of CD34 positive cells .............................................................. 164 
6.2.4 Viability of CD34 positive cells .............................................................. 167 
6.2.5 Maintenance of phenotype in culture ...................................................... 167 
6.2.6 Flow cytometry as a method to detect changes in STAT5 phosphorylation
 .......................................................................................................................... 167 
6.2.7 Effect of methotrexate on STAT5 phosphorylation in HSCs ................. 172 
6.2.8 Methotrexate causes apoptosis in HSCs ................................................. 176 
6.2.9 Changes in STAT5 phosphorylation in HSCs following methotrexate 
treatment can be detected with western blotting ............................................ 1766 
6.3 Discussion .................................................................................................................... 176 
6.3.1 Development of experimental methods .................................................. 179 
6.3.2 JAK/STAT signalling in RA-FLS ........................................................... 179 
6.3.3 JAK/STAT signalling in HSCs from patients with myelofibrosis .......... 180 
6.4 Conclusions ................................................................................................................. 182 
CHAPTER 7: CONCLUSIONS AND FUTURE DIRECTIONS ...................... 183 
7.1 Overview ..................................................................................................................... 183 
7.2 Summary of findings .................................................................................................. 183 
7.3 Future work ................................................................................................................ 184 
7.4 Impact ......................................................................................................................... 186 






Activation of JAK/STAT signalling is a feature of many haematological 
malignancies and solid tumours. Better understanding of the molecular events 
contributing to JAK/STAT pathway activation, and a greater range of therapies 
acting on the pathway, should lead to improved treatment options for patients with 
malignancies associated with activation of the pathway. This work builds on screens 
that identified genes and drugs which modulate JAK/STAT signalling in the fruit fly 
Drosophila melanogaster, to determine whether these effects occur in the conserved 
human pathway.  
The gene ANKHD1 (Ankyrin Repeat and KH Domain containing 1) has been 
identified as a positive regulator of JAK/STAT signalling in Drosophila, but there 
has been little investigation of ANKHD1 in human tissues. I show that ANKHD1 
protein is expressed in normal blood cells and the malignant clone of cells in acute 
leukaemias. I also show that ANKHD1 protein is expressed in the skin cancer 
malignant melanoma, where it is found in the nucleus and cytoplasm in a range of 
histological sub-types of melanoma. 
Methotrexate was identified as a selective suppressor of JAK/STAT 
signalling in a screen in Drosophila cells. No interaction between methotrexate and 
JAK/STAT signalling has previously been described. I demonstrate that 
methotrexate suppresses JAK/STAT signalling in human cell lines at drug 
concentrations equivalent to those measured in patients, suggesting that suppression 
of JAK/STAT signalling may contribute to the mechanism-of-action of methotrexate 
in inflammatory conditions. Furthermore, the effect occurs when the pathway is 
activated by the JAK2V617F mutation found in patients with myeloproliferative 
neoplasms (MPNs). The potential of methotrexate as a treatment for patients with 
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Chapter 1: Introduction 
1.1 Overview 
In metazoans the behaviour of individual cells must be organised and co-ordinated 
by the whole organism to give rise to functioning organs and tissues. This control is 
achieved through a network of intracellular signalling pathways activated by 
transmembrane receptors at the cell-surface. The behaviour of individual cells, 
therefore, can be controlled by the action of soluble ligands produced locally or 
distantly, enabling cell behaviour to be regulated according to the needs of the whole 
organism.  
In cancer, a clone of cells escapes this regulation and expands irrespectively 
of the needs of the whole organism. One of the mechanisms through which cancer 
cells acquire this property is through inappropriate activation of intracellular 
signalling pathways. Pathway activation becomes independent of or hyper-
responsive to the signals normally promoting cell growth. Understanding this aspect 
of the cellular biology of cancer has led to improvements in the treatment of patients. 
Targeted therapies designed to act selectively on inappropriately activated signalling 
pathways are in clinical use. In some cases our understanding of the mechanisms 
causing pathway activation have enabled the use of molecular pathology techniques 
to identify patients who will benefit from these treatments. Further understanding of 
aberrant activation of intracellular signalling in cancer should lead to benefits for 
patients.  
 The JAK/STAT signalling pathway (Janus Kinase/ Signal Transducer and 
Activator of Transcription) is one of the signalling pathways frequently activated in 
cancer. It has been particularly associated with myeloproliferative neoplasms, a 
group of haematological malignancies in which an acquired mutation in JAK2 that 
causes a valine to phenylalanine change (V617F) occurs in a large proportion of 
patients. Aberrant JAK/STAT signalling also plays a role in other haematological 
malignancies and many solid tumours. In some types of cancer the molecular 
mechanisms underlying JAK/STAT activation have been determined whereas in 
others they are incompletely understood and there is little understanding of the 
factors modulating JAK/STAT activation in cancer. JAK/STAT signalling is a 
therapeutic target in cancer and there have been great advances in the clinical use of 
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drugs targeting the pathway. There are, however, ways in which our ability to target 
the pathway with drugs may be improved. 
 The aims of this work were to investigate genetic and chemical modulators of 
the JAK/STAT signalling pathway in cancer. The work is founded on identification 
of genetic and chemical modulation of JAK/STAT signalling in the fruit fly 
Drosophila melanogaster. Drosophila possess a relatively linear JAK/STAT 
signalling pathway compared to that of vertebrates. In vertebrate evolution 
duplications of genes encoding pathway components has led to increased complexity 
and potential redundancy within the pathway. My work has built on data obtained 
from Drosophila, to establish whether effects of genetic and chemical modulators of 
the pathway are conserved in human cells, and ultimately whether they are relevant 
to JAK/STAT activation in cancer. 
 The work focusses on the effects of the gene Ankyrin Repeat and KH domain 
containing protein 1 (ANKHD1) upon the pathway. ANKHD1 is the human 
homologue of a gene identified as a novel positive regulator of JAK/STAT 
signalling in Drosophila. The aim of this study was to determine the expression of 
ANKHD1 protein in JAK/STAT associated cancers (haematological malignancies 
and the skin cancer malignant melanoma), and examine the mechanism through 
which ANKHD1 promotes JAK/STAT pathway activation.  
A secondary arm of the project examines chemical modulators of JAK/STAT 
signalling, building on findings from a small-molecule screen performed in 
Drosophila cells that showed that the drug methotrexate suppresses JAK/STAT 
signalling. The aim of this study was to establish whether methotrexate could 
suppress JAK/STAT signalling in cancers showing JAK/STAT activation.  
Overall this project is founded on the idea that a better understanding of 
genes and drugs that modulate JAK/STAT signalling will lead to better ways to treat 
patients with cancers showing JAK/STAT pathway activation, by enabling 
stratification of patients according to the mechanism of activation and molecular 
predictors of prognosis, and a creating a wider range of treatment options for patients 
with cancers showing JAK/STAT activation. 
 
1.2 JAK/STAT signalling 
1.2.1 Structure of pathway and pathway components 
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Activation of the pathway 
The JAK/STAT pathway regulates embryonic development and is involved in the 
control of processes such as stem cell maintenance, haematopoiesis and the 
inflammatory response. The pathway transduces signals from cytokines, interleukins 
and growth factors that bind transmembrane receptors, and activate a 
phosphorylation cascade that ultimately regulates gene transcription. Ligand binding 
produces conformational changes in receptors that alter the alignment of receptor-
associated JAKs, enabling phosphorylation of specific tyrosine residues which 
converts inactive JAKs into a catalytically active tyrosine kinases. A detailed 
understanding of the molecular-level events occurring in this process has recently 
been established for the growth hormone (GH) receptor associated with JAK2 
(Brooks, Dai et al. 2014).  
Active JAKs phosphorylate tyrosine residues in the cytoplasmic region of the 
receptor creating binding sites that recruit STATs (Signal Transducers and 
Activators of Transcription). STATs are JAK substrates which form dimers that 
translocate to the nucleus when phosphorylated on certain tyrosine residues (termed 
pSTAT). STAT dimers bind specific promoter sequences and modulate transcription 
of genes controlling cellular processes including proliferation, differentiation and 
apoptosis (Figure 1-1).    
 
 
Figure 1-1. Overview of JAK/STAT signalling. JAKs are constitutively associated with 
transmembrane receptors (1). Ligand binding causes a change in the orientation of receptor sub-units 
which leads to JAK phosphorylation and activation. Activated JAKs phosphorylate intracellular 
regions of the receptors (2). This creates binding sites for STATs which are phosphorylated by JAKs 






Receptors signalling through the JAK/STAT pathway 
The JAK/STAT signalling pathway starts with cell surface receptors, which are 
constitutively associated with JAKs in the absence of ligand (Witthuhn, Quelle et al. 
1993). These receptors are made up of sub-units which contain an extracellular 
domain that binds the cytokine, a transmembrane domain and an intracellular 
cytoplasmic domain, of varying length. The JAK/STAT pathway transduces signals 
from a number of transmembrane receptor families, which are classified according to 
their structural similarities. Type I receptors include the erythropoietin (EPO) 
receptor and the granulocyte colony-stimulating factor (G-CSF) receptor. The 
granulocyte-macrophage colony-stimulating factor receptor is a type IIa receptor and 
the type IIb subfamily includes the receptors for interleukin-6 (IL-6) and leukaemia 
inhibitory factor (LIF) (Watowich, Wu et al. 1996).  
In order to function as receptors, individual receptor sub-units must be 
assembled into complexes. Some receptors consist of homodimers of identical 
subunits, such as the receptors for GH, EPO and thrombopoietin (TPO). For other 
cytokines, receptors consist of heterodimers, often involving a sub-unit which is 
shared between the receptors for several different cytokines. For example 
glycoprotein 130 (gp130) is a component of the receptors for IL-6, oncostatin M 
(OSM) and LIF (Lupardus, Skiniotis et al. 2011), and cytokines signalling through 
JAK3 act on receptor complexes that contain a common γc subunit (Cornejo, 
Boggon et al. 2009). In some cases the cytokine receptor consists of a higher order 
complex containing multiple receptor subunits. This has been demonstrated for the 
receptor for IL-6, where electron microscopy shows that the cytokine-receptor 
complex is a hexamer consisting of two molecules of IL-6, two IL-6 receptor alpha 
subunits and two gp130 subunits (Lupardus, Skiniotis et al. 2011).  
  In early models of receptor activation, ligand binding was considered 
necessary for dimerisation or oligomerisation of receptor subunits. Ligand-mediated 
dimerisation was considered to be the mechanism that initiated the signalling 
cascade (Heldin 1995). Although some receptors do appear to require ligand binding 
to form stable dimers (Russell-Harde, Wagner et al. 1999) for other receptors pre-
formed dimers are present on the cell surface in the absence of ligand. This has been 
demonstrated for the EPO receptor by co-localisation of fluorescently tagged 
receptor subunits (Constantinescu, Keren et al. 2001). The regulation of formation of 
receptor complexes may be a mechanism through which JAK/STAT pathway 
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activity is controlled. Unpublished data from the laboratory where I carried out my 
PhD (generated by Dr. Katie Fisher and Dr. Steve Brown) shows that the Drosophila 
JAK/STAT receptor Domeless (Dome) has a widespread tissue distribution in the 
Drosophila embryo, but only exists as a dimer in certain tissues. Conformational 
changes in relative receptor subunit orientations, rather than a simple dimerisation 
model, are now thought to be responsible for cytokine-mediated receptor activation 
in many cases. 
 
JAKs  
There are four JAK family members in humans, JAK1, JAK2, JAK3 and TYK2, 
varying in size from approximately 1120 to 1190 amino acids. The family is defined 
by the presence of two adjacent kinase domains, resembling the two faces of the 
Roman god Janus from which their name is derived. JAKs act by forming both 
homodimers and heterodimers (Koppikar, Bhagwat et al. 2012). 
JAKs are structurally divided into seven JAK homology regions (JH 1 - 7) 
based on amino acid sequence similarities across all four JAKs (Figure 1-2). The 
JH1 domain is the kinase domain (Cornejo, Boggon et al. 2009, Ghoreschi, Laurence 
et al. 2009). Phosphorylation of specific tyrosines in the JH1 domain is essential for 
JAK activation (Ihle and Gilliland 2007). In JAK2 these tyrosines are at position 
1007 and 1008 (Feng, Witthuhn et al. 1997). JAKs also contain a number of other 
tyrosine residues whose phosphorylation contributes to positive and negative 
regulation of JAK activity (Ungureanu, Wu et al. 2011). Phosphorylation of serine 
residues is another mechanism by which JAK activity is modulated (Ishida-
Takahashi, Rosario et al. 2006, Mazurkiewicz-Munoz, Argetsinger et al. 2006). 
The JH2 domain, in which the V617F mutation occurs in MPNs, regulates 
JAK activity. It is described as a ‘pseudokinase’ as it lacks certain amino acids 
required for catalytic function, but there is evidence that the JH2 domain can act as a 
kinase despite this. The retained kinase activity is thought to mediate the regulatory 
functions of JH2, with the JH2 domain phosphorylating sites in JAK2 that negatively 
regulate its activity (Ungureanu, Wu et al. 2011).   
The N terminal FERM (4.1 protein Ezrin, Radixin, Moesin) domain, 
comprising the JH6 and JH7 domains, mediates receptor binding. JAKs are 
constitutively associated with the intracellular regions of receptor subunits in the 
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absence of ligand (Witthuhn, Quelle et al. 1993). JAK proteins also contain an SH2 
(Src homology 2) domain. This is a domain which binds to phosphorylated tyrosine 
residues, although its function in JAKs is not clear.  
 
 
Figure 1-2. Schematic structure of JAK proteins. The FERM domain (4.1 protein, ezrin, radixin, 
moesin) mediates the interaction with receptor complexes. The SH2 domain is a protein domain that 
binds to phosphorylated tyrosine residues. The JH2 pseudokinase domain regulates kinase activity of 
the JH1 kinase domain. PP marks conserved tyrosine residues in JH1 whose phosphorylation is 
essential for JAK activation. N and C indicate the amino-terminus and carboxy-terminus. 
 
Our understanding of the three-dimensional structures of JAKs is limited. To 
date, no crystal structures have been determined for the full-length protein of any of 
the four JAKs. However, crystal structures have been solved for the kinase JH1 and 
pseudokinase JH2 domains of several JAKs, including JAK2 (Lucet, Fantino et al. 
2006, Bandaranayake, Ungureanu et al. 2012). The structure of JH1 is similar to that 
of other protein kinases, with a small N-terminal lobe consisting mainly of β sheets, 
a larger C-terminal lobe composed mainly of α helices, and an activation loop which 
contains the tyrosine restudies whose phosphorylation regulates activity. The JH2 
domain has a similar structure, although the activation loop is shorter and is not 
regulated by phosphorylation. Despite the availability of these structures, the 
mechanisms causing JAK activation are not definitively determined. 
A recent study of the growth hormone receptor (GHR) in association with 
JAK2 has given us new insight into the molecular events through which ligand 
occupation of receptors may cause conversion of inactive JAKs to active kinases. In 
this model, a receptor that is not occupied by ligand holds the JH1 domain of one 
JAK is in close association with the JH2 of the other JAK in an orientation that 
suppresses JAK activation. Ligand binding causes a conformational change that is 
transmitted through the transmembrane region of the receptor and pulls apart the 
receptor-associated JAKs in a manner which exposes their kinase domains and 
allows activation (Brooks, Dai et al. 2014). This is consistent with the observation 




order to produce the changes in cellular behavior that lead to increased colony 
formation and the MPN phenotype (Sangkhae, Etheridge et al. 2014). 
 
STATs 
Seven STAT family members are found in humans, STAT 1-4, STAT5A, STAT5B 
and STAT6. These range in size from 750 to 850 amino acids. STAT proteins 
contain a number of domains whose function has been defined (Figure 1-3). The C 
terminal regions of STATs contain the transactivation domain needed for activation 
of transcription. STAT activation requires phosphorylation of a specific tyrosine 
residue located near the transactivation domain, at around position 700 (Darnell, 
Kerr et al. 1994). The transactivation domain also contains a number of serine 
residues which can be phosphorylated, a post-translational modification which 
increases the ability of STATs to activate transcription (Decker and Kovarik 2000).  
Adjacent to the transactivation domain is an SH2 domain, which allows 
STATs to bind phosphorylated receptors and form dimers with other phosphorylated 
STATs. A DNA binding domain interacts specifically with particular DNA 
sequences and the N terminal oligomerisation domain stabilises interactions between 
DNA-bound STATs (Bowman, Garcia et al. 2000). 
 
Figure 1-3. Schematic structure of STAT proteins. The SH2 domain binds phosphorylated tyrosines. 
The carboxy-terminus transactivation domain is required for full transcriptional activation. P marks 
the conserved tyrosine residue whose phosphorylation is essential for STAT activation. 
 
Alternative splicing and post-translational modifications generate additional 
diversity amongst STATs. Variants of STAT1 and STAT3 (termed STAT1β and 
STAT3β) which lack the C terminus required for activation of transcription 
negatively regulate the activity of the full-length variants (Caldenhoven, van Dijk et 
al. 1996). Short forms of STAT5 missing the C terminus are produced by proteolytic 
processing and are functionally distinct from the full-length forms (Azam, Lee et al. 




heterodimers, for example STAT1-STAT3 heterodimers observed in melanoma 
(Niu, Bowman et al. 2002).  
 
Regulation of pathway activation 
As in other signalling cascades, activation of the JAK/STAT pathway is tightly 
controlled by negative regulators acting at multiple levels. Cell membrane regions 
containing activated receptors are endocytosed. It appears that signalling from 
receptor-ligand complexes within endosomes may differ from that at the cell surface, 
but endocytosis also regulates signalling by controlling receptor degradation by 
lysosomes (Hitchcock, Chen et al. 2008).  
 Several families of phosphatases remove phosphate groups from tyrosine 
residues in receptors, JAKs and STATs. For example, JAKs may be de-
phosphorylated by receptor tyrosine phosphatases such as CD45, cytoplasmic 
phosphatases including SHP1 and SHP2 and the endoplasmic-reticulum tethered 
phosphatase PTP1B (Babon, Lucet et al. 2014). 
PIAS proteins (Protein Inhibitors of Activated STAT) are a protein family 
involved in negative regulation of JAK/STAT signalling. Co-immunoprecipitation 
experiments demonstrate that PIAS3 physically associates with STAT3 following 
pathway activation. Electromobility shift assays show that it inhibits the DNA 
binding activity of STAT3, and luciferase assays indicate that it reduces transcription 
from STAT3 responsive promoters (Chung, Liao et al. 1997). Examination of the 
structure of PIAS proteins indicates that they also have domains involved in 
interactions with the nuclear matrix and in SUMOylation, the post-translational 
addition of a small ubiquitin-like protein that modifies the biological activity of the 
proteins to which it is bound. It is not clear, however, to what extent these activities 
are involved in the regulation of JAK/STAT signalling and other intracellular 
signalling pathways (Yagil, Nechushtan et al. 2010). 
SOCS proteins (Suppressor Of Cytokine Signalling) are negative regulators 
of JAK/STAT pathway activation whose expression is induced by STATs, creating a 
negative feedback loop that imposes a fine level of control on the pathway. The 
cytokine-induced expression of SOCS proteins was first demonstrated using northern 
blotting in the livers of IL-6 treated mice, and confirmed following in vitro treatment 
of bone marrow cells with a range of JAK/STAT activating cytokines (Starr, Willson 
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et al. 1997). SOCS family proteins have actions at multiple levels of the JAK/STAT 
signalling cascade, having effects upon receptors, JAKs and STATs. For example a 
recently solved crystal structure shows that SOCS3 binds to tyrosine phosphorylated 
receptors via its SH2 domain and simultaneously blocks the substrate-binding region 
of JAK2 (Kershaw, Murphy et al. 2013). SOCS proteins also promote the interaction 
of pathway components with ubiquitin ligases, leading to proteasomal degradation 
(Kamizono, Hanada et al. 2001). 
 Tight regulation of pathway activity, mediated by several mechanisms acting 
at every level of the pathway, enables the JAK/STAT signalling pathway to be 
employed in processes such as development and immunity, whose activity is 
spatially and temporally regulated.  
 
Non-canonical signalling 
JAK and STAT pathway components have effects on the cell beyond the ‘canonical’ 
signalling phosphorylation cascade that positively regulates transcription. These 
include emerging functions of non-phosphorylated proteins, and effects of the 
pathway on cellular processes other than transcription. 
JAKs have been shown to have epigenetic effects on gene expression. 
Activated JAK2 can enter the nucleus, where it phosphorylates the core histone H3, 
altering its binding to the heterochromatin protein HP1 and leading to a chromatin 
conformation that promotes transcription. This effect of JAK2 upon transcription is 
thought to be independent of STAT activation, as the JAK/STAT upregulated gene, 
lmo, examined in these experiments lacked a predicted STAT5 binding site 
(Dawson, Bannister et al. 2009). The extent to which JAKs locate to the nucleus in-
vivo, and the significance this plays in normal JAK/STAT activation and in disease 
remain controversial (Girodon, Steinkamp et al. 2011).  
STATs are traditionally thought of as facilitating activation of transcription, 
but data emerging from large-scale gene expression profiling experiments shows that 
activated STATs also down regulate expression of a substantial number of genes 
(Demaria, Giorgi et al. 2010). It is also becoming apparent that un-phosphorylated 
STATs can enter the nucleus and modulate gene expression. For example, in cells 
transfected with an engineered form of STAT5A in which the conserved tyrosine 
residue required for canonical activation is replaced with phenylalanine, STAT5 has 
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been shown to be present in the nucleus using immunofluorescence. Co-
immunoprecipitation experiments show that it physically associates with HP1 and 
microarray studies indicate that this alters gene expression (Hu, Dutta et al. 2013). 
STATs have also been shown to play roles in cellular activities which are 
independent of transcription, for example STAT3 interacts with stathmin to modify 
microtubule stability and migration, and serine-phosphorylated STAT3 has effects 
on mitochondrial respiration (Mohr, Chatain et al. 2012). 
As roles for JAK/STAT pathway components outside the canonical 
signalling cascade become apparent, there are suggestions that signalling in 
JAK/STAT associated diseases may alter these non-canonical activities (Chen, 
Staudt et al. 2012).   
 
Interactions with other signalling pathways 
Although usually described as discrete pathways, intracellular signalling cascades 
are probably more accurately considered as networks made up of multiple 
interactions between pathways. Physical interactions and functional effects have 
been described for interactions between JAK/STAT signalling and a number of other 
signalling pathways known to be involved in oncogenesis, including signalling 
downstream of the epidermal growth factor receptor (Olayioye, Beuvink et al. 1999) 
and androgen receptor signalling (Tan, Dagvadorj et al. 2008). Interactions between 
JAK/STAT signalling and other pathways include JAKs phosphorylating targets 
other than STATs and STATs being phosphorylated by kinases other than JAKs. 
In addition to its effects on STATs, JAK2 is known to activate signalling via 
the PI3K-AKT and MAPK/ERK pathways (Vainchenker and Constantinescu 2012). 
Effects of the mutant JAK2V617F upon DNA repair are thought to be mediated via 
the PI3K-AKT pathway, as they can be rescued by shRNA-mediated knockdown of 
the catalytic subunit of PI3K (Chen, Ahn et al. 2014). The Ras/MAPK signalling 
pathway appears to interact with JAK/STAT signalling in melanoma in in-vitro 
models. Expression of the mutant pathway intermediate BRAF in melanocytes leads 
to serine any tyrosine phosphorylation of STAT3 which is suppressed by treatment 
with the BRAF inhibitor vemurafenib (Liu, Cao et al. 2013).  
The Src family of kinases can activate STATs independently of JAK 
activation. This was first established for v-Src, a viral oncoprotein, which was 
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demonstrated to bind to and phosphorylate STAT3, leading to nuclear localisation 
and conferring DNA binding activity (Cao, Tay et al. 1996). Endogenous Src kinases 
have subsequently been demonstrated to phosphorylate STATs, for example c-src 
acting downstream of epidermal growth factor receptor (EGFR)(Olayioye, Beuvink 
et al. 1999).   
The JAK/STAT pathway interacts with the NfkB pathway. This pathway is 
involved in the innate and adaptive branches of the immune system, and is often 
activated in cancer. Activators of the pathway include toll-like receptors and 
TNFalpha. Phosphorylated STAT3 promotes activity in the pathway by enhancing 
nuclear retention of RelA, a transcriptional activator in the pathway (Lee, Herrmann 
et al. 2009).  
An understanding of the complex interactions between JAK/STAT signalling 
and other intracellular signalling pathways is of particular relevance when 
considering aberrant signalling in cancer. Combination therapies targeting several 
signalling pathways may be more effective than targeting a single pathway, and in 
future may be used to overcome resistance to individual targeted therapies (Liu, Cao 
et al. 2013, Gallipoli, Cook et al. 2014).   
 
1.2.2 JAK/STAT signalling in cancer 
Aberrant activation of the JAK/STAT signalling pathway is seen in a broad range of 
haematological malignancies and solid tumours. Our knowledge of the mechanisms 
causing this activation and the role it can play in the malignant phenotype of cancer 
cells is growing. In many cases, however, our understanding of the degree to which 
JAK/STAT activation is driving disease is limited.  
 
Mechanisms causing JAK/STAT activation in cancer 
In many cancers where JAK/STAT activation is a feature, the mechanism underlying 
inappropriate pathway activation is not known. However, examining the instances in 
which a mechanism has been identified shows that cancer cells employ a diverse 
range of strategies to activate the pathway.    
In head and neck squamous cell carcinoma, phosphorylation of STAT3 is a 
consequence of increased production of IL-6 by tumour cells (Sriuranpong, Park et 
al. 2003). Increased expression of the G-CSF receptor is observed in high-grade 
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ovarian epithelial tumours, and experiments in cell culture suggest that G-CSF 
contributes to JAK/STAT activation in this disease (Kumar, Fraser et al. 2014).  
Gain-of-function mutations in JAKs have been observed to cause pathway 
activation in haematological malignancies including JAK2 mutations in MPNs and 
JAK1 mutations in T cell acute lymphocytic leukaemia (T-ALL) (Flex, Petrangeli et 
al. 2008). More recently large-scale sequencing efforts have identified genetic 
changes affecting JAKs in certain solid tumours. Protein-altering mutations in JAK1 
have been identified in tumours in 9% of patients with hepatitis B associated 
hepatocellular carcinoma, and validation in cell culture shows that these mutations 
increase phosphorylation of JAK1 and STAT3 and enable cytokine-independent 
growth (Kan, Zheng et al. 2013). In gastric adenocarcinoma, a comprehensive 
molecular characterization project has revealed frequent amplification of the 
chromosomal locus containing JAK2. Corresponding increases in JAK2 messenger 
RNA suggest this may increase JAK2 protein levels and pathway activity (The 
Cancer Genome Atlas Research 2014).  
          Activating mutations in STATs, although generally rare, have been described 
in cancer. In large granular lymphocytic leukaemia 40% of patients have mutations 
affecting the SH2 domain of STAT3. The mutations cluster in the SH2 domain, and 
modelling the amino-acid changes indicated an increase in hydrophobic residues, 
suggesting that the mutations might increase affinity of STAT3 for phosphorylated 
receptors, increasing their availability for phosphorylation by JAKs. Western 
blotting from primary cells indicated that there was increased STAT3 
phosphorylation compared to leucocytes from normal healthy individuals. Gene 
expression profiling showed an increase in mRNA for STAT3 target genes (Jerez, 
Clemente et al. 2012, Koskela, Eldfors et al. 2012). Amplification of the STAT5A/B 
locus has been described in prostate cancer and is associated with increased 
expression and nuclear localization of STAT5 in tumour samples. These 
amplifications increase cell survival in culture and promote tumour growth in a 
xenograft model (Haddad, Gu et al. 2013). 
 Reduced expression of negative regulators can cause increased pathway 
activation. In non-small cell lung cancer (NSCLC) tumour samples, expression of 
SOCS-3 is lost due to promoter hypermethylation. The impact of this on pathway 
activation was validated using a NSCLC cell line, where restoration of SOCS3 
expression reduced constitutive STAT3 phosphorylation (He, You et al. 2003). 
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PIAS3 protein levels have been shown to be reduced in glioblastoma, possibly due to 
increased protein degradation. In glioblastoma tissue samples low levels of PIAS3 
are associated with increased pSTAT3 and increased expression of proteins produced 
from STAT target genes (Brantley, Nabors et al. 2008). 
 
Role of JAK/STAT signalling in the malignant phenotype of cancer cells 
In order for solid tumours to enlarge, cancer cells must not only increase in number 
but also adapt to and alter their microenvironment. Genes controlled by STATs play 
roles in both of these aspects of the malignant phenotype.  
          Pre-clinically, therapies that inhibit STAT activity decrease proliferation and 
increase apoptosis in cell culture studies and tumour xenograft models (Kim, Lee et 
al. 2014). STAT3 facilitates cell cycle progression by promoting activation of cyclin 
dependent kinases (CDKs). It increases transcription of positive regulators such as 
cyclin D2 and downregulates transcription of CDK inhibitors such as p21 (Fukada, 
Ohtani et al. 1998). STAT5 confers protection from apoptosis, by activating 
transcription of Bcl-x, to produce the anti-apoptotic protein Bcl-xL (Dumon, Santos 
et al. 1999).  
          Cancer cells undergo changes in energy metabolism, switching from 
mitochondrial oxidative phosphorylation to glycolysis for ATP production. STAT3 
reduces expression of genes encoding mitochondrial proteins and increases 
expression of genes involved in glycolysis, such as pyruvate dehydrogenase kinase 
1. These effects are dependent upon transcription of the hypoxia-inducible factor 
HIF-1α, which is induced by STAT3 (Demaria, Giorgi et al. 2010). STAT3 plays a 
global role in the adaptation of tumour cells to a hypoxic environment. It physically 
associates with HIF1α and is required for the full transcriptional activation of HIF1α 
regulated genes in hypoxia (Pawlus, Wang et al. 2014). Angiogenesis is required for 
tumour growth, with a key role played by vascular endothelial growth factor 
(VEGF). STAT3 binds to the VEGF promoter and induces VEGF expression. In 
tumour allograft models expression of a constitutively active STAT3 leads to 
increased VEGF expression and increased vasculogenesis (Niu, Wright et al. 2002). 
JAK/STAT activation contributes to acquisition of properties required for 
tumour invasion and metastasis. This is in part mediated by activation of the 
programme of epithelial to mesenchymal transition (EMT), usually involved in 
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embryonic development. The transcription factor TWIST1 is a key regulator of the 
induction of EMT. STAT3 is required for TWIST1 expression, as abrogation of 
STAT3 activity by siRNA knockdown, pharmacological inhibition of STAT3 or 
mutation of the STAT binding site in the promoter of TWIST1 reduces its expression 
(Cho, Jeong et al. 2013). STAT3 can activate transcription of matrix-degrading 
enzymes such as matrix metalloproteinase-2. Inhibiting STAT3 reduces invasion 
through an in-vitro basement membrane model, and prevents the establishment of 
metastatic tumours in a mouse model (Xie, Wei et al. 2004).  
A key feature in the interaction of malignant cells with the tumour 
microenvironment is their ability to suppress anti-tumour immune responses. This is 
illustrated by the importance of the graft-versus tumour effect in allogeneic stem-cell 
transplantation in haematological malignancies (Andersen 2014), and by the effects 
of immune checkpoint inhibitors in certain solid tumours (Victor, Rech et al. 2015). 
As JAK/STAT signalling is involved in inflammation and immunity, there is 
therefore interest in the role of JAK/STAT signalling in the immune response in the 
tumour microenvironment (Yu, Pardoll et al. 2009). Activation of STAT1 by 
interferons promotes immune surveillance and anti-tumour immunity, partly by 
upregulating MHC class I mediated antigen presentation by tumour cells. In contrast, 
STAT 3 and 5 signalling in immune cells appears to suppress anti-tumour immunity. 
Anti-tumour immune responses in mice are enhanced by ablation of STAT3 from 
haematopoietic cells and by drugs that block STAT3 (Kortylewski, Kujawski et al. 
2005). The enhanced anti-tumour immunity observed in these mice is in part due to a 
reduction in tumour-infiltrating regulatory T cells (Treg cells), a cell type whose 




Historically, JAK/STAT signalling has been associated with myeloproliferative 
neoplasms, due to the high proportion of patients with this category of diseases 
possessing acquired activating mutations of JAK2. The myeloproliferative neoplasms 
(MPNs) are a group of haematological malignancies characterised by over-
production of mature blood cells of the myeloid lineage. The group comprises 
polycythaemia vera (PV), essential thrombocytosis (ET) and primary myelofibrosis 
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(PMF). PV and ET result in elevated red cell and platelet counts respectively, both of 
which cause a tendency to thrombosis. In PMF the marrow is effaced by fibrous 
tissue which prevents adequate haematopoiesis. PV and ET can progress to 
myelofibrosis, and all three disorders are associated with a risk of transformation to 
acute myeloid leukaemia (AML)(Campbell and Green 2006).  
Pathological activation of JAK/STAT signalling is a feature of MPNs. 95% 
of patients with PV and 40 – 60% of patient with ET have an acquired point 
mutation in exon 12 of JAK2, a G to T change in the malignant clone. This causes a 
valine to phenylalanine change, V617F, in the JAK2 protein, which causes 
constitutive pathway activation (Baxter, Scott et al. 2005, James, Ugo et al. 2005, 
Kralovics, Passamonti et al. 2005, Levine, Wadleigh et al. 2005). The demonstration 
that JAK2V617F caused a PV phenotype in a mouse model, and that STAT5a/b is 
necessary for development of PV in these mice provided evidence for a causative 
role for JAK2-STAT5 activation in MPNs (Walz, Ahmed et al. 2012).  
There is evidence that individuals in whom the malignant clone lacks the 
V617F mutation nonetheless show increased JAK/STAT activation in 
haematopoietic stem cells (HSCs), the compartment in which the malignant clone 
arises. Flow cytometry to assess STAT5 phosphorylation in HSCs and progenitor 
cells identified by expression of the cell surface glycoprotein CD34+ shows 
comparable STAT5 phosphorylation in patients with JAK2V617F and wild-type 
JAK2 (Anand, Stedham et al. 2011). Comparison of gene expression profiles in 
granulocytes from patients with MPNs with mutant and wild-type JAK2 also show 
similar patterns of expression of genes considered to be JAK/STAT targets (Rampal, 
Al-Shahrour et al. 2014). There have been calls for this data to be interpreted 
cautiously, however, as it depends upon the methods used to define the initial set of 
JAK/STAT target genes (Lau, Hannah et al. 2015).  
 In a proportion of patients with MPNs, acquired mutations in other regions of 
JAK2 or other genes involved in JAK/STAT signalling have been identified and 
account for the observed increase in JAK/STAT signalling. Alternative mutations in 
exon 12 of JAK2, affecting an evolutionarily conserved protein region between 
lysine 537 and glutamic acid 543, occur in around 3% of patients with PV (Scott, 
Beer et al. 2007). These mutations have been demonstrated to activate the signalling 
pathway in cell-culture models and one shown to cause erythrocytosis in a mouse 
model (Scott, Tong et al. 2007). A mutation in the thrombopoietin receptor MPL 
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(originally named myeloproliferative leukaemia protein) occur in a small proportion 
of patients with PMF and ET (Pardanani, Levine et al. 2006). In-vitro models show 
that this mutation confers cytokine-independent growth and constitutive 
phosphorylation of JAK2 and downstream pathway proteins. In a mouse model it 
causes a myeloproliferative disorder characterised by thrombocytosis (Pikman, Lee 
et al. 2006).  
Mutations have also been described in modulators of JAK/STAT signalling 
which are not directly involved in the phosphorylation cascade. Around 2% of 
patients with MPNs have an acquired loss-of-function mutation in SH2B3, a 
scaffolding protein which negatively regulates signalling. Primary CD34+ cells from 
peripheral blood of patients with the mutation show increased STAT3 and STAT5 
phosphorylation in response to ligand stimulation. Experiments in cell culture 
indicate that the mutation prevents SH2B3 from performing its normal inhibitory 
function as overexpression of the wild-type protein inhibits cytokine-dependent 
growth, whereas overexpression of the mutant protein does not (Oh, Simonds et al. 
2010).  
 MPNs were the subject of a further interesting development at the end of 
2013, with whole exome sequencing studies revealing that a substantial proportion 
of  JAK2 negative patients with ET and PMF have mutations in CALR, the gene 
encoding calreticulin (Klampfl, Gisslinger et al. 2013, Nangalia, Massie et al. 2013). 
A diverse range of mutations have been observed all of which cause a frameshift that 
encodes an identical novel c-terminal peptide. The mechanism through which mutant 
CALR contributes to disease pathogenesis is not yet clear. One of the initial studies 
suggested that activation of JAK/STAT signalling plays a role, as expression of the 
mutant CALR was able to confer cytokine independent growth in-vitro that was 
sensitive to JAK inhibition, and led to constitutive STAT5 phosphorylation 
(Klampfl, Gisslinger et al. 2013). However, a study on a cell line, MARIMO, with 
endogenous mutant CALR, derived from a patient with acute myeloid leukaemia 
secondary to ET, suggests mutant CALR does not affect JAK/STAT signalling. 
MARIMO cells showed reduced expression and phosphorylation of JAK2 and 
STATs 1,3 and 5 compared to JAK2V617F positive cell lines, and were resistant to 
concentrations of JAK inhibitors that profoundly affected these lines (Kollmann, 
Nangalia et al. 2015).  
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 In addition to mutations in JAK/STAT pathway components and CALR, 
which are considered ‘driver’ mutations in MPNs, recurrent mutations in other genes 
should also be addressed. These are not unique to MPNs, occurring in other 
haematological malignancies. Loss-of-function mutations in TET2 (Ten-Eleven 
Translocation-2) occur in around 12% of patients with MPNs (Delhommeau, Dupont 
et al. 2009). TET2 mutations are of particular interest in light of a study which 
showed that the order in which TET2 and JAK2 mutations are acquired in the 
malignant clone affects disease phenotype (Ortmann, Kent et al. 2015). TET2 is 
thought to be involved in synthesis of intermediates involved in DNA methylation. 
Mutations in other genes affecting epigenetic modifications such as EZH2 (Enhancer 
of Zeste 2 Polycomb Repressive Complex 2 Subunit), DNMT3A (DNA Cytosine-5-
methyltransferase 5A) and ASXL1 (Additional Sex Combs-Like 1) are also relatively 
common in MPNs. Mutations affecting splicing factors, which are more commonly 
associated with the myelodysplastic syndromes, also occur (Nangalia and Green 
2014). These mutations are of particular relevance as it has been shown that profiling 
of mutations can be used to predict prognosis amongst patient with myelofibrosis 
(Vannucchi, Lasho et al. 2013).   
 
Other Haematological malignancies 
Mutations in JAK/STAT signalling components and increased pathway activity are 
seen in a diverse group of lymphoid and myeloid malignancies. This is covered 
comprehensively in recent reviews (Chen, Staudt et al. 2012, Vainchenker and 
Constantinescu 2012). Examples of genetic changes leading to JAK activation in 
haematological malignancies include translocations that promote JAK 
oligomerisation, such as TEL-JAK2 fusion (Translocation ETS Leukaemia) in 
childhood T-ALL (acute lymphocytic leukaemia) (Lacronique, Boureux et al. 1997), 
amplification of JAK2 in Hodgkin lymphoma (Hao, Chapuy et al. 2014), and 
activating point mutations in JAKs. Other events that lead to pathway activation 
include loss-of-function of negative regulators such as the protein-receptor-tyrosine 
phosphatase CD45 in T-ALL (Raponi, Gianfelici et al. 2015) and activation of 
STATs by other kinases, including FLT-3 (FMS-related tyrosine kinase 3) and BCR-
ABL (Breakpoint Cluster Region-Abelson Tyrosine Protein Kinase 1). 
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In recent years the use of whole-genome and whole exome sequencing 
(WES) has led to identification of genetic changes affecting JAK/STAT signalling in 
an increasing list of haematological malignancies. Particularly notable in the recent 
findings from WES is the identification of STAT mutations in several haematological 
malignancies. Until recently, STAT mutations were surprisingly rare as a mechanism 
of JAK/STAT activation in cancer. In 2012, it was found that around 30-40% of 
patients with T cell large granular lymphocytic leukaemia (LGL) and natural killer 
cell large granular lymphocytic leukaemia possess mutations in STAT3 (Jerez, 
Clemente et al. 2012, Koskela, Eldfors et al. 2012). The presence of such STAT3 
mutations immediately offered potential new diagnostic approaches for these 
disorders, which can be difficult to distinguish from reactive clonal proliferations of 
lymphocytes. Interestingly, no clear difference was observed in disease 
characteristics in the groups of patients with or without mutations. Subsequently, 
mutations affecting STAT5 have been identified in small groups of LGL patients 
with wild-type STAT3 (Rajala, Eldfors et al. 2013).  
WES approaches have also led to the identification of STAT6 mutations in 
around 11% of patients with follicular lymphoma (Yildiz, Li et al. 2015). These 
mutations cluster in the DNA-binding region of STAT6. Immunofluorescence 
showed increased nuclear localisation of STAT6 and increased level of STAT6-
regulated transcripts in flow sorted primary cells from these patients. Functional 
assays in HEK and HeLa cells showed that the mutations increased STAT-6 
responsive transcription and promotes proliferation in the presence of IL-4, a 
cytokine whose levels are elevated in the microenvironment in follicular lymphoma. 
In patients with T cell prolymphocytic leukaemia a WES study identified 
mutations in STAT5B and JAK3 in around 30% of patients each, and rarer mutations 
in JAK1 and the common gamma chain of the IL-2 receptor, which signals via the 
JAK/STAT pathway (Kiel, Velusamy et al. 2014). In some patients with JAK1 
mutations, the mutations cause amino acid changes in the JH2 domain which are 
analogous to the JAK2V617F mutation. Functional experiments in cell culture 
showed that these lead to increased STAT activation. Notably, inhibition of STAT5 
using the antipsychotic drug pimozide led to decreased cell viability in cell lines 
expressing the mutant pathway components, suggesting STAT inhibition as a future 





Early evidence that JAK/STAT signalling is activated in solid tumours was derived 
from cancer cell lines. There is now substantial data demonstrating tyrosine 
phosphorylation and nuclear localization of STATs, indicative of STAT activation, 
in tumour tissue derived from a large number of patients across a range of tumour 
types. A relationship between JAK/STAT activation and prognosis has been 
observed in many of these tumour types (Table 1-1). In general activation of STAT3 
or STAT5 is associated with a worse prognosis, although in breast cancer and in 
some studies in colorectal cancer and head and neck squamous cell carcinoma it 
appears to be associated with more favourable outcomes. In breast cancer this 
relationship is consistent with the role of pSTAT5 in normal physiology – 
constitutive phosphorylation of STAT5 is a feature of normal breast epithelial cells, 
where it is thought to promote differentiation (Peck, Witkiewicz et al. 2011). For 
other tumour types, differences in the strategies used to quantify STAT 
phosphorylation, which vary across all the studies described below, may account for 
the apparently conflicting associations between STAT phosphorylation and outcome 
(Monnien, Zaki et al. 2010).  Activation of STAT1, in contrast, is generally 
associated with better outcomes across all tumour types. Although STAT activation 
has now been observed in a wide range of tumour types, in many cases the 
mechanisms causing STAT activation have not been well defined.    
 
 Table 1-1. Summary of studies describing STAT activation and its clinical implications in solid 
tumours 





of STAT activation 
NSCLC  
(Xu and Lu 
2014) 
 




analysis of 17 
studies) 
Positivity for STAT3 
or pSTAT3 associated 
with reduced overall 
survival (Hazard ratio 
(HR) 0.67, p<0.0001) 
Prostate 
(Mirtti, Leiby 
et al. 2013) 
Nuclear STAT5A/B, 
immunohistochemistry 
on tissue microarrays 









Presence of nuclear 
STAT5 associated 
with early recurrence 
(HR 1.6, p 0.012) 
 
Presence of nuclear 
STAT5 associated 
with prostate cancer 
specific death (HR 
1.59, p 0.034) 
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for nuclear pSTAT5 











with  no 
adjuvant 
therapy 
Presence of pSTAT3 
associated with 
improved overall 
survival in patients 
receiving adjuvant 
chemotherapy (10 year 
survival 79% for 
pSTAT3 positive, vs 
61.5% for pSTAT3 
negative, HR 0.48, p 
0.01). 
Absence of activated 
STAT5 associated 
with decreased cancer 
specific survival (HR 





























Presence of activated 
STAT3 associated 
with better overall 





Presence of activated 
STAT3 associated 
with worse overall 




et al. 2011) 
 
(Pectasides, 
Egloff et al. 
2010) 
Immunohistochemistry 













associated with shorter 
median disease free 
survival (13months vs 
64 months, p 0.019). 
 
High nuclear STAT3 
associated with 
improved overall 
survival (Mean 119 
months vs 57.3 





Ushijima et al. 
2009) 
Immunohistochemistry 






survival (5 year 
survival 79.2 months 
vs 95.3 months, p 
0.006) 
Malignant Immunohistochemistry 6/14 primary In patients with lymph 
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of STAT activation 
melanoma 
(Messina, Yu 
et al. 2008) 












node metastases higher 
rates of recurrence 
with high pSTAT3 
staining compared to 
low-grade staining 
(9/16 vs 3/10). Lower 
rates of recurrence 
with high pSTAT1 
staining 8/23 vs 2/6) 
activation in lymph 





Oya et al. 
2002) 
Immunohistochemistry 











Uzeir et al. 
2010) 
Immunohistochemistry 
for pSTAT3 on tissue 
microarrays 
58.8% of 111 
positive 
High or very high 
numbers of cells 
positive for pSTAT3 
associated with 
reduced overall 
survival (p 0.001) 
 
Melanoma 
Activation of intracellular signaling pathways plays a role in melanoma, and an 
understanding of signaling in melanoma has become particularly relevant in recent 
years, with the clinical success of BRAF (B Rapidly Accelerated Fibrosarcoma) 
inhibitors.  
40-60% of patients with melanoma have an acquired mutation in the 
serine/threonine kinase BRAF, most commonly causing a valine to glutamic acid 
change, V600E, that leads to constitutive activation of the Ras/Raf/MEK/ERK 
signaling cascade (Davies, Bignell et al. 2002). This signaling pathway is activated 
by several families of cell surface receptors and regulates gene expression through a 
cascade of intracellular kinases, ultimately controlling cell behaviours such as 
proliferation, differentiation and migration (Holderfield, Deuker et al. 2014). 
Inhibitors of BRAF have shown benefit in patients with metastatic melanoma 
(Chapman, Hauschild et al. 2011), although tumours develop resistance to inhibitors 
by re-activation of the pathway, or activation of alternative signaling pathways 
(Fedorenko, Gibney et al. 2015). N-RAS mutations are also a relatively common 
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event in melanoma leading to altered intracellular signalling, although these have so 
far proven more difficult to target than BRAF mutations. 
Activation of STAT3 is seen in melanoma cell lines and primary tumour 
tissues (Niu, Bowman et al. 2002). Cell and animal studies demonstrate that STAT3 
can contribute to the malignant phenotype in melanoma by promoting metastasis 
(Xie, Wei et al. 2004, Xie, Huang et al. 2006) and angiogenesis (Niu, Wright et al. 
2002), and preventing apoptosis (Niu, Bowman et al. 2002). Inhibition of STAT3 
signalling causes apoptosis in melanoma cells (Bill, Fuchs et al. 2010). In patients 
with melanoma, STAT3 phosphorylation is associated with increased risk of 
recurrence and death (Messina, Yu et al. 2008, Wu, Cheng et al. 2011).  
STAT1 phosphorylation is seen in tumour tissue from a proportion of 
patients with melanoma, and the presence of phosphorylated STAT1 appears to be 
associated with better outcomes, although the patient numbers in the study showing 
this were small (Messina, Yu et al. 2008). It is also notable that treatment with 
interferon has been shown to lead to a change in the ratio of STAT1 and STAT3 
phosphorylation, to the apparently beneficial pattern of high STAT1 phosphorylation 
and low STAT3 phosphorylation. This small study did not show, however, whether 
this led to better outcomes (Wang, Edington et al. 2007). 
JAK/STAT signaling also plays a role in the immune response to tumour 
cells in melanoma. This is highly relevant, as immune ‘checkpoint inhibitors’ such 
as ipilimumab are showing success as a treatment for melanoma (Victor, Rech et al. 
2015). Previous immunotherapies for melanoma include interferon and IL-2, both of 
which are JAK/STAT pathway ligands. Cell surface expression of MHC class II is 
positively regulated by JAK/STAT signaling in response to interferons, suggesting 
that loss of STAT1 activity facilitates immune evasion by melanoma (Osborn and 
Greer 2015). Immune evasion by tumours is in part mediated by induction of 
regulatory T cells (Tregs) which suppress anti-tumour immunity. STAT3 and 
STAT5 modulate expression of the transcription factor FoxP3, a key regulator in the 
differentiation of Tregs that suppress anti-tumour immunity (Zorn, Nelson et al. 
2006). In a mouse model employing melanoma cell lines, deletion of STAT3 in the 
haematopoietic cells or treatment with an inhibitor of STAT3 lead to a reduction in 
the number of FoxP3 Tregs in the tumour (Kortylewski, Kujawski et al. 2005). 
Together, this data from patient samples and experimental models suggests 
that STATs play a role in the malignant behavior of melanoma cells and their 
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interaction with the microenvironment. Better understanding is needed, however, of 
the mechanisms contributing to STAT activation in melanoma. In particular, there is 
conflicting evidence regarding the kinase which phosphorylates STATs in 
melanoma, with one study suggesting that src is responsible (Niu, Bowman et al. 
2002) and another indicating JAKs are responsible (Liu, Cao et al. 2013).  
 
1.2.3 JAK/STAT signalling in immunity and inflammation 
The JAK/STAT signalling pathway is responsible for transducing signals from 
several families of cytokines, including interferons, colony-stimulating growth 
factors and many interleukins. It therefore has a role in controlling behaviour of cells 
involved in immune function, including proliferation, survival, differentiation and 
response to inflammatory stimuli (Ghoreschi, Laurence et al. 2009). Pathological 
alterations of JAK/STAT signalling are involved in autoimmune diseases and 
immunodeficiencies, indeed much of our understanding of the roles of JAK/STAT 
signalling components in normal immune function originates from examination of 
individuals with immunodeficiencies caused by mutations in signalling components. 
 
JAK/STAT signalling in normal immune function and immunodeficiencies 
JAK1 is essential for transduction of signals from receptors for interferons, making it 
important in innate immunity and the response to viruses (Muller, Briscoe et al. 
1993). Consideration of the role of JAK3 in immunity is significant because its 
expression is predominantly limited to haematological cells (Cornejo, Boggon et al. 
2009). JAK3  is particularly important in T cell activation (Kawamura, McVicar et 
al. 1994), as well as being found in Natural killer cells (Kawamura, McVicar et al. 
1994) and dendritic cells (Yamaoka, Min et al. 2005). Furthermore JAK3 binds only 
to cytokine receptors containing the common gamma chain (γc) which are also 
mostly restricted to blood cells (Cornejo, Boggon et al. 2009). Mutations in JAK3 
cause a severe combined immunodeficiency (SCID) involving a defect in activity of 
T and NK cells, and lesser effects on B cells (Macchi, Villa et al. 1995). Mutations 
in γc cytokine receptors cause a similar SCID phenotype to JAK3 mutations 
(Noguchi, Yi et al. 1993). Evidence for the role of TYK2 in immune function also 
comes from examination of patients with immune deficiencies. An individual with a 
homozygous TYK2 loss-of-function mutation suffered from recurrent bacterial, viral 
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and fungal infections, including infections from organisms which are not normally 
highly pathogenic. In addition TYK2 deficiency produced allergic symptoms due to 
alterations in the balance of helper T lymphocyte subgroups (Minegishi, Saito et al. 
2006).  
STATs play many roles in the innate and adaptive branches of the immune 
system (O'Shea and Plenge 2012). In particular, STAT1 and STAT2 are required for 
the response to interferons. STAT 4 and 6 have also recently been identified to act as 
key regulators of helper T cell differentiation (Vahedi, Takahashi et al. 2012). 
STAT3 is involved in neutrophil migration in acute inflammation (Panopoulos, 
Zhang et al. 2006). STAT3 and STAT5 interact to control T cell differentiation, and 
loss of function mutations in STAT3 cause an immunodeficiency syndrome due to 
absence of differentiation of the Th17 subset of helper T lymphocytes (Holland, 
DeLeo et al. 2007).  
The use of whole exome sequencing has led to the recent identification of 
germline STAT mutations in individuals with autoimmune syndromes. Three papers 
published at the beginning of 2015 describe gain-of-function STAT3 mutations in 
autoimmune syndromes. The initial group of patients was identified due to extremely 
early onset diabetes (Flanagan, Haapaniemi et al. 2014). Examination of further 
individuals with germline STAT3 mutations show that they are in fact associated 
with a diverse spectrum of autoimmune features, and that the mutations show 
incomplete penetrance as some family members carrying the STAT3 mutations are 
unaffected (Haddad 2015). The functional effects of some of the STAT3 mutations 
was examined in cell culture in the interleukin dependent mouse BAF-3 cell line, 
where they do not affect basal STAT3 phosphorylation, but lead to increased STAT3 
phosphorylation and STAT3 dependent transcription following stimulation with IL-6 
(Milner, Vogel et al. 2015). Slight increases in STAT3 phosphorylation were 
observed in peripheral blood lymphocytes and bone-marrow cells from affected 
individuals (Haapaniemi, Kaustio et al. 2015). Interestingly patients also had 
immune deficiencies, attributed to decreased STAT1 and STAT5 activity. These 
STATs are affected by the increased levels of SOCS3 that result from STAT3 
activation, illustrating the complexities of JAK/STAT signalling that arise from 




JAK/STAT signalling in Rheumatoid Arthritis and autoimmune diseases  
Rheumatoid arthritis is a chronic inflammatory disorder characterised by swelling, 
deformity and bone erosion in the small joints of the hands. In addition other joints 
may be affected, and systemic complications and early mortality are associated with 
the disease. Rheumatoid arthritis is caused by a combination of genetic and 
environmental factors. Pathogenesis is incompletely understood but appears to be 
mediated by auto-immunity. Affected joints have an infiltrate of macrophages, 
neutrophils and lymphocytes in the synovial membrane and synovial fluid. The 
synovial membrane is thickened by proliferation of activated fibroblast-like-
synoviocytes (RA-FLS). Cartilage erosion is caused by production of matrix 
metalloproteases by RA-FLS, and bone is eroded by osteoclasts stimulated by 
cytokines from the inflammatory environment of the synovium (McInnes and Schett 
2011). 
 It is recognised that the JAK/STAT signalling pathway plays a role in 
rheumatoid arthritis (Walker and Smith 2005, Malemud 2010). Single-nucleotide 
polymorphisms (SNPs) in STAT4 are associated with increased risk of rheumatoid 
arthritis (Remmers, Plenge et al. 2007). Increased expression of STAT1 and STAT1 
responsive genes is seen in synovial tissues in a subgroup of patients with 
rheumatoid arthritis (van der Pouw Kraan, van Gaalen et al. 2003), with 
phosphorylated STAT1 observed in lymphocytes and fibroblast-like synoviocytes 
(Kasperkovitz, Verbeet et al. 2004). Experimental manipulation of JAK/STAT 
pathway components in rheumatoid arthritis mouse-models shows increased 
inflammation following knockout of STAT1 (de Hooge, van de Loo et al. 2004) and 
STAT6 (Finnegan, Grusby et al. 2002), and reduced inflammation in when STAT4 
is knocked out (Finnegan, Grusby et al. 2002). Although these studies indicate that 
the JAK/STAT pathway is activated in rheumatoid arthritis, it is not entirely clear 
which of the cell types involved in pathogenesis this activation is important in. 
Neither is it completely clear to what extent JAK/STAT activation is promoting 
inflammation and to what extent it is exerting anti-inflammatory effects (Walker and 
Smith 2005).   
 Independent of these details, the significance of JAK/STAT signalling in 
rheumatoid arthritis is underlined by the effect of JAK inhibition upon the disease.  
An inhibitor of JAK3 has shown efficacy in clinical trials in rheumatoid arthritis 
(van Vollenhoven, Fleischmann et al. 2012). Other anti-inflammatory drugs used in 
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rheumatoid arthritis have also been demonstrated to have effects on JAK/STAT 
signalling (Siemasko, Chong et al. 1998, Choe, Park et al. 2013). 
JAK/STAT signalling is implicated in a number of other diseases mediated 
by activation of the immune system. STAT3 activation is observed in epithelial cells 
(Li, de Haar et al. 2010) and immune cells (Mudter, Weigmann et al. 2005) from 
patients with Ulcerative colitis and Crohn’s disease. Increased STAT1 activation is 
also seen in mucosa of patients with these diseases, and STAT1 activation decreases 
following remission (Schreiber, Rosenstiel et al. 2002). A mutation has been 
identified in TYK2 which increases risk of multiple schlerosis (Dyment, Cader et al. 
2012), whereas a polymorphism in a separate region of TYK2 appears to protect 
from multiple sclerosis by decreasing TYK2 activation and altering the balance of T 
lymphocyte subsets (Couturier, Bucciarelli et al. 2011). Polymorphisms in STAT3 
and two JAK-associated receptor components, IL-23R and IL-12B, affect risk of 
ankylosing spondylitis and Crohn’s disease (Danoy, Pryce et al. 2010). 
Polymorphisms of STAT4 affect risk of systemic lupus erythematous (Sigurdsson, 
Nordmark et al. 2008). Although caution is needed when considering disease 
associations with genetic changes, these studies do suggest that the JAK/STAT 
signalling pathway plays a role in a broad group of inflammatory and immune-
mediated conditions. 
 
1.2.4 The JAK/STAT pathway as a therapeutic target 
The JAK/STAT pathway is a promising target for the development of new therapies 
for cancer and inflammatory diseases, and JAK inhibitors have shown benefit in 
clinical studies in these conditions. 
 
Haematological malignancies 
The effectiveness of targeting JAK/STAT signalling has been demonstrated in phase 
3 trials in patients with PMF and myelofibrosis secondary to PV and ET. The 
JAK1/2 inhibitor ruxolitinib improves symptoms and prolongs survival (Harrison, 
Kiladjian et al. 2012). More recently, ruxolitinib has been shown to improve 
haematocrit, reduce spleen volume and improve symptoms in patients with PV 
(Vannucchi, Kiladjian et al. 2015). There have been calls for JAK2 inhibitors to be 
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examined in the treatment of patients with other haematological malignancies with 
genetic changes affecting JAK2 (Bain and Ahmad 2014).  
 
Solid tumours 
In solid tumours, where the cause of JAK/STAT activation and its role in driving 
disease is less clear than MPNs, JAK inhibition has been less successful. In a phase 1 
trial of a JAK1/2 inhibitor in patients with solid tumours no response was seen, when 
assessed according to RECIST criteria (Response Evaluation Criteria in Solid 
Tumours). There was, however, a reduction in pSTAT3 in granulocytes and in 
tumour tissue in one patient who had pre and post-treatment biopsies. Furthermore, 
as phase 1 trials are primarily for dose finding they are not powered to detect a 
response (Plimack, Lorusso et al. 2013). It may be that JAK inhibitors show greater 
success in solid tumours when examined in stratified trials, where tumour JAK 
mutational status has been defined. 
 
Immune-mediated conditions 
Tofacitinib, a JAK3 inhibitor, has been shown to improve joint signs and symptoms 
and reduce joint damage in patients with rheumatoid arthritis in phase 3 trials 
(Fleischmann, Kremer et al. 2012, van Vollenhoven, Fleischmann et al. 2012, Lee, 
Fleischmann et al. 2014). Ruxolitinib has shown benefit in alopecia, an autoimmune 
condition affecting hair growth (Xing, Dai et al. 2014) and dermatomyositis, an 
inflammatory condition affecting skin and muscle (Hornung, Janzen et al. 2014). 
Tofacitinib is being examined in a number of other conditions involving activation 
of the immune system, including psoriasis, inflammatory bowel disease (Sandborn, 
Ghosh et al. 2012) and renal transplantation (Vincenti, Tedesco Silva et al. 2012).   
 
 
Therapies under development 
Approaches to develop therapies have also been directed towards suppressing the 
activity of STATs. The beneficial effect of reducing STAT3 and STAT5 activity in 
cancer has been demonstrated in cell culture and animal models using 
overexpression of dominant negative STATs and knockdown of STAT expression 
with siRNAs. Translating findings based on experimental genetic techniques into 
therapies that can be administered to patients has been challenging, however. 
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Approaches that disrupt protein–protein interactions needed for STAT 
phosphorylation or inhibit STAT-DNA binding have shown promise in pre-clinical 
studies. Both strategies have been shown to affect cancer cell proliferation and 
apoptosis, and decrease tumour growth in mouse models.  
Drugs that act by blocking protein-protein interactions include the natural 
product withacnistin, which inhibits the binding of STAT3 and STAT5 to the 
cytoplasmic region of receptors, preventing the recruitment of STATs for 
phosphorylation (Zhang, Blaskovich et al. 2014). High throughput methods to 
develop peptide drugs with the capacity to enter cells have been employed to create 
an inhibitor of STAT3 activation, which acts by binding the SH2 domain (Kim, Lee 
et al. 2014). A small-molecule inhibitor of STAT3 which is thought to interact with 
the SH2 domain has been examined in a phase 1 trial in patients with solid tumours. 
No further investigation of this molecule is planned, however, as pharmacokinetic 
studies showed that plasma concentrations in patients were extremely variable and 
substantially lower than those observed in pre-clinical models (Bendell, Hong et al. 
2014).  
A synthetic inhibitor of STAT-DNA binding has shown promise in cell and 
animal models, including in-vitro effects on tumour cells from the ascites of patients 
with ovarian cancer (Rath, Naidu et al. 2014). The STAT-DNA interaction has also 
been disrupted by ‘decoy oligonucleotides’ which contain STAT binding sequences 
and competitively inhibit STAT binding to genomic DNA. A decoy oligonucleotide 
targeting STAT3 has been shown to decrease expression of STAT target genes in 
head and neck squamous cell carcinoma when injected into tumours intra-operatively 
(Sen, Thomas et al. 2012). 
 It is hoped that some of the JAK/STAT targeted therapies shown to be 
beneficial in pre-clinical models will soon enter clinical trials. Combining strategies 
to target STAT activation with those affecting other signalling pathways, such as B-
RAF and BCR-ABL may be particularly effective, as has already been demonstrated 
in pre-clinical models of melanoma and chronic myeloid leukaemia (Liu, Cao et al. 





ANKHD1 (Ankyrin Repeat and KH domain containing protein 1, also called 
hMASK, human Multiple Ankyrin Repeats Single KH domain) is a large protein 
encoded by a gene on chromosome 5q. It plays roles in regulation of proliferation, 
apoptosis and migration, and has been identified as a modulator of a number of 
signalling pathways.  
 
1.3.1 ANKHD1 protein  
Structure 
Full-length ANKHD1containins 2542 amino acids and has a predicted molecular 
weight of 269kDa (Figure 1-4). The protein contains two blocks of ankyrin repeats 
and a KH domain.  
 
Figure 1-4. Schematic representation of the primary structure of ANKHD1. The principal features of 
the protein are two blocks of ankyrin repeats and a KH domain.  
 
The protein also contains two predicted coiled-coil domains, at amino acids 775 to 
852 between blocks of ankyrin repeats, and at 1415 to 1485, between the second 
block of ankyrin repeats and the KH domain. Coiled-coil domains consist of alpha 
helices that are arranged into bundles, a feature which creates a relatively inflexible 
region within the protein.   
 
Post-translational modifications 
Information on post-translational modifications in Uniprot (Consortium 2015) 
suggests that the methionine residue at position 1 is acetylated in ANKHD1, and that 
there is phosphorylation of a serine residue at position 101 and a threonine residue at 
position 1653. This is based on work on large-scale experiments examining 
thousands of proteins however, and has not been replicated in experiments 
specifically examining ANKHD1. Although there is no suggestion of 
phosphorylated tyrosine resides in proteomics databases, ANKHD1 has been 
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examined for phosphorylated tyrosine residues by immunoprecipitating the protein 
and blotting with anti-phosphotyrosine antibodies. It was not found to contain 
phosphorylated tyrosine in this experiment (Traina, Favaro et al. 2006).  
 
The ankyrin repeat domain 
Ankyrin repeats are a protein domain which mediate protein-protein interactions 
(Sedgwick and Smerdon 1999, Mosavi, Cammett et al. 2004, Li, Mahajan et al. 
2006). They are named due to their presence in the cytoskeletal erythrocyte protein 
ankyrin, but occur widely in the human proteome, and are conserved in bacteria and 
archaea. The domain consists of 33 amino acids which fold into two alpha helices 
and a loop or beta hairpin. High resolution structures have been determined for the 
ankyrin repeat regions of several proteins, and show that the domains have an L 
shaped structure. Binding to other proteins occurs on the concave surface of this L.  
The ankyrin repeat domain appears to bind to a wide range of substrates of 
different structures. Variation in the amino acid residues exposed on the concave 
surface mediates substrate binding specificity. This property is being exploited to 
generate novel peptide drugs consisting of ankyrin repeats with high binding 
affinities for different molecules (Eggel, Baumann et al. 2009). Ankyrin repeats tend 
to be found in multiple copies in the proteins in which they occur, but numbers of 
repeats as high as 25, as found in ANKHD1, appear to be relatively unusual. 
 
The KH domain 
KH domains (hnRNP K homology domains, named due to their identification in 
human heterogeneous nuclear ribonucleoprotein K) bind single stranded nucleic 
acids – RNA and single stranded DNA (Valverde, Edwards et al. 2008).  They are a 
widespread protein domain showing evolutionary conservation from prokaryotes and 
archaea, and play roles in transcription control and RNA processing.  
The domain consists of around 70 amino acids, which are arranged to create a 
binding cleft that spans four DNA or RNA bases. The RNA binding function of KH 
domains has been studied in detail in FMRP (fragile X mental retardation protein), a 
KH domain containing protein involved in the pathogenesis of fragile x syndrome. 
The RNA targets and the recognition elements that are common to RNAs bound by 
this protein have been identified (Ascano, Mukherjee et al. 2012). ANKHD1 is 
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unusual in having only a single KH domain, usually proteins contain more than one 
KH domain, with the multiple copies thought to bind nucleic acids cooperatively. 
 
1.3.2 ANKHD1 gene 
Genomic location 
The gene encoding ANKHD1 is located on chromosome 5q 31.3. Of relevance to 
haematological malignancies, deletions of large regions of 5q give rise to a sub-type 
of myelodysplastic syndrome (MDS), a clonal disorder of haematopoietic stem cells 
that leads to the generation of abnormal mature blood cells. ANKHD1 lies within the 
genomic regions frequently deleted in 5q- syndrome (Boultwood, Pellagatti et al. 
2010). Altered ribosomal function due to haploinsufficciency of RPS14 (Ribosomal 
Protein S14) is known to play a large role in disease pathogenesis. Although 
ANKHD1 lies outside the critical deleted region, 5q32-33, haploinsufficiency for 
ANKHD1 could co-operate in disease pathogenesis.       
Deletion of 5q31.3 – q32 has been described in colorectal cancer and a 
correlating change in ANKHD1 mRNA observed. ANKHD1 may merely be a 
passenger in this region of genomic loss, but it is interesting that the deletion is 
associated with reduced progression-free survival in patients treated with certain 
chemotherapy regimens (Haan, Labots et al. 2014). 
 
Homologues 
In humans, ANKHD1 has a paralogue on chromosome 4, named ANKRD17 (ankyrin 
repeat domain 17) or GTAR (gene trap ankyrin repeat), and more recently referred to 
as ‘hMASK2’ (human multiple ankyrin repeats single KH domain 2) (Sansores-
Garcia, Atkins et al. 2013, Sidor, Brain et al. 2013). The two proteins share 71% 
identity, with greater sequence similarity in the regions of ankyrin repeats and the 
KH domain (Poulin, Brueschke et al. 2003).  
As ANKHD1 and ANKRD17 are thought to have arisen from a duplication 
event, it might be expected that they would have similar biological roles, and an 
understanding of ANKRD17 function might provide insight into ANKHD1 function. 
ANKRD17 has been demonstrated to physically interact with intracellular  receptors 
involved in the innate immune response, and plays a role in the release of cytokines 
(Menning and Kufer 2013) and interferons (Wang, Tong et al. 2012). These include 
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IL-6 and IFN-β, known ligands of the JAK/STAT pathway. Curated databases which 
include ANKHD1 do not show any nuclear localisation sequence (NLS) or nuclear 
export sequence (NES), whereas these have been defined in ANKRD17, between the 
second ankyrin repeat cluster and the KH domain. ANKRD17 is a substrate of cyclin 
E, which phosphorylates several serine residues within the protein (Deng, Li et al. 
2009). Of particular relevance increased expression of p21 is seen following 
ANKRD17 knockdown, an effect also described following ANKHD1 knockdown 
(Dhyani, Machado-Neto et al. 2015). These results based on siRNA knockdown 
should be interpreted cautiously, however, as sequence similarities between the two 
genes might cause both to be knocked down by the same siRNA.  
 
1.3.3 ANKHD1 transcripts 
Splice variants 
Ensembl lists 14 splice variants of ANKHD1 that appear to be protein coding, as 
they contain an open reading frame, although evidence for the existence of these 
variants at the protein level is lacking for most. A few ANKHD1 splice variants have 
been examined in some detail. One variant encodes a short 627 amino acid form of 
the protein, named by different groups as ‘splice variant 4’(Duarte, Traina et al. 
2005) and VBARP-L (HIV-1 viral protein R – binding ankyrin repeat protein, long 
form) (Miles, Janket et al. 2005). In most tissues and cell lines examined mRNA for 
this variant is expressed at a comparable level to full-length ANKHD1. However, in 
an in-vitro model of erythroid differentiation in which the Hl-60 cells (a line derived 
from a patient with acute promyelocytic leukaemia) are induced to differentiate by 
the addition of erythropoietin, levels of the mRNA encoding splice variant 4 show a 
much greater increase than levels of mRNA encoding the full-length protein (Duarte, 
Traina et al. 2005). This suggests differential regulation or function, although it is 
not known to what extent changes in mRNA levels are indicative of changes in 
protein levels.  
 
Fusion transcript 
In addition to variants generated through alternative splicing, ANKHD1 also encodes 
two variants of a fusion transcript produced by read-through into the adjacent gene, 
EIF4EBP3 (eukaryotic translation initiation factor 4E binding protein 3).  
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The EIF4EBPs are a family of three proteins involved in the regulation of 
translation. Ribosome assembly on mRNA requires the assembly of a complex on 
the mRNA cap that includes the protein EIF4E. The assembly of this complex is in 
part modulated by 4EBPs, which sequester EIF4E and prevent complex assembly. 
EIF4EBP3 is the least well understood member of the family. It has been shown to 
bind to EIF4 (Kleijn, Scheper et al. 2002), and appears to also function in the 
regulation of nuclear export of mRNA (Chen, Lee et al. 2012).  
The ANKHD1 transcripts that include read-through into EIF4EBP3 are 
named ANKHD1-EIF4EBP3 or hMASK-BP3ARF. The variants are 636 amino acids 
and 2617 amino acids in length. The larger of the two variants generates a form of 
ANKHD1 with a novel c-terminus consisting of 94 amino acids encoded by an 
alternative reading frame of EIF4EBP3. This alternative reading frame-encoded 
sequence does not display similarity to any known proteins. Although the function of 
the ANKHD1-EIF4EBP3 transcript is not clear, it’s conservation in mouse and 
human suggests it may have a biological function (Poulin, Brueschke et al. 2003). 
The formation of read-through transcripts has been said to in some cases indicate 
proteins that act within the same biological pathways, in the case where the reading 
frames are preserved. Fusion transcripts that use different reading frames are rare 
(Akiva, Toporik et al. 2006). Interestingly, levels of ANKHD1-EIF4EBP3 mRNA 
transcripts in human lymph node are about five-fold higher than levels of ANKHD1 
mRNA (Duarte, Traina et al. 2005).    
 
1.3.4 ANKHD1 functions 
Relatively little is understood about the functions of ANKHD1. It appears to be a 
widely-expressed protein that acts as a modulator of intracellular signalling 
pathways, promotes cell cycle progression and protects cells from apoptosis. These 




Evidence that ANKHD1 performs essential functions comes from considering the 
effects of knocking down or knocking out its activity in animal models. In 
Drosophila, mutations in dMASK cause lethality in most homozygous flies early in 
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larval development (Smith, Carroll et al. 2002). These mutations introduce 
premature stop codons, presumably leading to nonsense-mediated-decay of the 
mRNA, Attempts to generate an ANKHD1 knockout mouse have thus far been 
unsuccessful as it appears to cause early embryonic lethality, thought to be due to 
effects on gastrulation (S.Constantinescu, unpublished observations).  
 
Tissue distribution 
ANKHD1 appears to be expressed ubiquitously in human tissues. This is based on 
mRNA expression (Duarte, Traina et al. 2005, Miles, Janket et al. 2005), and 
corroborated to some extent by publically available data on immunohistochemistry 
in several types of normal and malignant human tissue (Uhlen, Oksvold et al. 2010). 
 
Intracellular signalling 
It has been proposed that ANKHD1 acts as a scaffolding protein in intracellular 
signalling pathways, with the multiple ankyrin repeats creating a platform for protein 
binding that brings together proteins involved in the same signalling cascade (Traina, 
Favaro et al. 2006). This is consistent with published work indicating interactions 
between ANKHD1 and three signalling cascades, the EGFR/RAS/MAPK pathway, 
JAK/STAT pathway and Hippo pathway.  
Evidence for an interaction between ANKHD1 and EGFR/RAS/MAPK 
comes from a study in Drosophila. Expression of a dominant-negative form of the 
phosphatase corkscrew in the eye gives flies a roughened eye phenotype as it reduces 
EGFR signalling leading to a decreased number of photoreceptors. The phenotype 
was worsened following the removal of one genomic copy of dMASK, a Drosophila 
homologue of ANKHD1. This suggests that dMASK is a positive regulator of the 
pathway. Interestingly, levels of diphosphorylated MAPK, an effector of pathway 
activation, were not altered, suggesting that dMASK acts in parallel to or 
downstream of MAPK (Smith, Carroll et al. 2002). Some evidence that this 
interaction is conserved to humans comes from co-immunoprecipitation experiments 
in leukaemia cell lines. SHP2, the human homologue of corkscrew, has been shown 
to bind to ANKHD1 (Traina, Favaro et al. 2006) (and D. Pugazhendhi, M 
Fragiadaki, M Zeidler unpublished). The roles of SHP2 do extend to other signalling 
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pathways, however, so this does not necessarily indicate a function in 
EGFR/RAS/MAPK signalling.  
Evidence for the role of ANKHD1 in JAK/STAT signalling also comes from 
work in Drosophila. dMASK was identified as a positive regulator of JAK/STAT 
signalling in a genome-wide RNAi screen in Drosophila cells, where a luciferare 
based transcriptional reporter was used to assess the effect of an RNAi library upon 
STAT responsive transcription (Müller, Kuttenkeuler et al. 2005). Subsequent 
examination of the human homologues of the genes identified in the screen in flies 
suggested that ANKHD1 had a similar positive effect on JAK/STAT signalling in 
the more complex JAK/STAT pathway of humans. RNAi knockdown of ANKHD1 
in HeLa cells led to a reduction in phosphorylation of STAT3 following stimulation 
with OSM, demonstrated using western blotting (Müller 2012).  
ANKHD1 interacts with the Hippo signalling pathway. This pathway is 
involved in regulation of cell proliferation, in particular in relation to control of 
organ size. Although upstream activators of the pathway in vertebrates are 
incompletely characterised, the pathway is known to modulate transcription. In 
vertebrates the effectors of the pathway are the transcriptional activator YAP (yes-
associated protein) and TEAD, and in Drosophila the homologous protein is Yki 
(yorkie). Phosphorylation of YAP leads to its export from the nucleus, and cessation 
of transcriptional activation (Pan 2010).  In both Drosophila and human cells, 
ANKHD1 has been shown to physically associate with Yki/YAP, translocate to the 
nucleus, and modulate expression of yki/YAP regulated genes (Sansores-Garcia, 
Atkins et al. 2013, Sidor, Brain et al. 2013). 
 
Cell cycle progression 
Evidence from experiments in Drosophila and human cell lines indicates that 
ANKHD1 promotes progression through the cell cycle. In Drosophila the heat-
shock-FLP system allows the effect of homozygous dMASK mutation to be 
examined despite its lethality, by enabling stochastic genomic rearrangement in 
larvae following heat shock. This system was used to generate larvae with eye 
imaginal discs containing adjacent clones of homozygous mask loss-of-function and 
homozygous mask wild-type cells. Antibody staining for phosphohistone H3, which 
is found in the nuclei of cells undergoing mitosis, was used to examine the effect of 
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mask loss-of function upon stereotyped waves of cell proliferation that normally 
occur in eye development. Mitosis was rare in cells lacking dMASK. However, this 
effect was not seen in larger clones, suggesting that the effect of loss of dMASK was 
related to competition with surrounding cells (Smith, Carroll et al. 2002). It is not 
clear from these experiments whether the effects of dMASK on the cell cycle are 
indirect, a consequence of its effect on intracellular signalling. 
In human cell lines originally derived from patients with prostate cancer and 
multiple myeloma, knockdown of ANKHD1 with siRNA led to a reduction in cell 
proliferation assessed using a methylthiazoletetrazolium (MTT) assay. Flow 
cytometry of cells stained with propidium iodide indicated that ANKHD1 loss led to 
accumulation of cells in S phase of the cell cycle (Dhyani, Duarte et al. 2012, 
Machado-Neto, Lazarini et al. 2014). A mechanistic link is suggested by increased 
levels of the cyclin-dependent kinase inhibitor p21, and it was subsequently found 
that ANKHD1 suppresses transcription from the p21 promoter (Dhyani, Machado-
Neto et al. 2015).   
 
Apoptosis 
Current evidence for the effect of ANKHD1 on apoptosis is conflicting. The 
suggestion that ANKHD1 protects cells from apoptosis came from the Drosophila 
eye development experiment described above. In this study there were substantially 
more apoptotic cells in the clones lacking dMASK compared to clones with wild-
type dMASK, when apoptotic cells containing fragmented DNA were identified 
using TUNEL staining (Terminal deoxynucleotidyl transferase dUTP Nick End 
Labelling) (Smith, Carroll et al. 2002).  
Evidence that ANKHD1 protects human cells from apoptosis comes from 
examination of two short isoforms of ANKHD1 that contain some of the ankyrin 
repeats but lack the KH domain. These variants were originally identified in a yeast-
two-hybrid screen for proteins that bind to HIV-1 viral protein R (Vpr), and named 
VBARP-L and VBARP-S (Vpr-binding ankyrin repeat protein, long and short 
forms). Knockdown of these ANKHD1 isoforms in cells from the teratocarcinoma 
cell line NT2 led to increased cell death, assessed using trypan blue exclusion, and 
increased Caspase 3 activation indicated that this was due to increased apoptosis 
(Miles, Janket et al. 2005).  
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Several other experiments in human cell lines, however, suggest that 
ANKHD1 has little effect on apoptosis. Knockdown of ANKHD1 in prostate cancer 
and multiple myeloma cell lines does not lead to increased apoptosis, when assessed 
using TUNEL staining or staining with propidium iodide and labelled Annexin-V 
(Machado-Neto, Lazarini et al. 2014). Furthermore, experiments in myeloma and 
acute leukaemia cell lines indicate that ANKHD1 knockdown does not affect 
apoptosis induced by UV exposure or cytotoxic drugs (Machado-Neto, Lazarini et 
al. 2014). 
The conflicting evidence for the role of ANKHD1 in protecting cells from 
apoptosis may be due to species and cell-type specific effects, or due to differential 
effects of ANKHD1 splice variants. As all the experiments in human cells depend 
upon siRNA-mediated knockdown of ANKHD1 it is possible that off-target effects 




There is some evidence that ANKHD1 may have a role in regulation of transcription. 
Chromatin immunoprecipitation assays (ChIP) show that ANKHD1 is associated 
with the gene encoding p21, and knockdown of ANKHD1 leads to decreased 
transcription from the p21 promoter (Dhyani, Machado-Neto et al. 2015). The same 
group have also shown that ANKHD1 associates with the promoters of several 
histone genes using ChIP (A. Dhyani, P. Favro, S. Saad, presented at American 
Society of Haematology Annual Meeting, December 2014).  
 ANKHD1 appears to affect cell migration, since ANKHD1 knockdown leads 
to reduced migration of multiple myeloma cell line cells towards foetal bovine serum 
(FBS) or the chemokine CXCL12 (Dhyani, Machado-Neto et al. 2015). A 
mechanism has recently been described for this, whereby ANKHD1 promotes 
microtubule stability via indirect inactivation of the microtubule-stabilising protein 
Stathmin 1, mediated by a physical interaction with the protein SIVA (Machado-
Neto, Lazarini et al. 2014). 
 A role for dMASK in regulating mitochondrial morphology and turnover by 
mitophagy has recently been described in Drosophila, but effects of ANKHD1 on 
mitochondria in vertebrates have yet to be described (Zhu, Li et al. 2015).  
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1.3.5 ANKHD1 in cancer 
The roles of ANKHD1 in positive regulation of intracellular signalling pathways 
activated in cancer, promoting proliferation and migration, and possibly protecting 
cells from apoptosis suggest it may contribute to the phenotype of cancer cells. There 
is some data from patient tissues to suggest that ANKHD1 expression may be 
upregulated in cancer and affect cancer cell behaviour in haematological 
malignancies and solid tumours.  
ANKHD1 mRNA levels are elevated in peripheral blood mononuclear cells 
in patients with acute myeloid leukaemia and acute lymphocytic leukaemia, 
compared to healthy individuals (Traina, Favaro et al. 2006). ANKHD1 mRNA is 
also increased in the malignant cells in patients with multiple myeloma, compared to 
plasma cells from individuals without myeloma. Furthermore, knockdown of 
ANKHD1 reduces tumour size in a myeloma xenograft mouse model (Dhyani, 
Machado-Neto et al. 2015). 
 ANKHD1 protein expression has been examined in a small number of 
tumour samples from epithelial cancers, and compared to the corresponding normal 
tissue, using immunohistochemistry. In these samples ANKHD1 protein was seen in 
the tumour tissue, and in the basal layers of the normal epithelia (Sidor, Brain et al. 
2013). The only published data that examines ANKHD1 expression in a large 
number of patients comes from examination of microarray data from a cohort of 
patients with breast cancer. Compellingly, increased expression of ANKHD1 was 
associated with reduced survival (Sansores-Garcia, Atkins et al. 2013). 
  
1.3.6 Rationale behind the investigation of ANKHD1 as a modulator 
of JAK/STAT signalling. 
Unpublished data from the Zeidler lab adds to the published data, showing that 
ANKHD1 promotes STAT dependent transcription, physically interacts with 
JAK/STAT pathway proteins and affects JAK/STAT dependent phenotypes (this 
data was produced by Katie Fisher, Maria Fragiadaki, Kirsty Johnstone and 
Dhamayanthi Pugazhendhi).  
Transient transfection with a plasmid encoding ANKHD1 leads to increased 
STAT transcriptional activity in HeLa cells, as assessed by SOCS3 mRNA levels. In 
addition, STAT5 responsive transcription in γ2A cells is preferentially increased by 
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overexpression of ANKHD1 in the presence of JAK2V617F, compared to wild-type 
JAK2 (Constantinescu lab, unpublished).  
Co-immunoprecipitation experiments in HeLa cells indicate that ANKHD1 
physically interacts with JAK2 and with the cytokine receptor subunit gp130.  
Effects of ANKHD1 on JAK/STAT signalling have also been demonstrated 
in-vivo. The hopTuml fly strain has a mutation in Hopscotch, the fly JAK, which 
causes constitutive activation and leads to the formation of melanised tumours due to 
accumulation of haemocytes, a macrophage-like blood cell. When dMASK 
expression is reduced, the number and size of these tumours is reduced. dMASK 
knock down also alters development of structures associated with the wing, causing 
an ‘outstretched’ wing phenotype which is characteristic of reduced JAK/STAT 
activation (Johnstone, Wells et al. 2013). 
 
1.4 Methotrexate 
Methotrexate is a drug which has been widely used for many years, given 
intravenously at high doses in chemotherapy regimens and given orally at lower 
doses for the treatment of inflammatory conditions such as rheumatoid arthritis. 
Methotrexate is a folate analogue which inhibits dihydrofolate reductase, although 
not all of its biological effects are accounted for by effects on folate metabolism. 
 
1.4.1 Structure 
The chemical structure of methotrexate is similar to that of folic acid (Figure 1-5). 















Oral methotrexate is absorbed in the small intestine via active transport, through 
reduced folate carrier 1 (RFC1). When the transporter is not saturated, bioavailability 
is around 70%. At concentrations at which the folate carriers are saturated, there is 
little further increase in absorption with increased doses. Serum concentration peaks 
about two hours after administration. Methotrexate distributes rapidly into interstitial 
fluid, and is excreted predominantly by the kidneys – serum half-life is 6-8 hours. 
Around 10% of absorbed methotrexate is converted to 7-hydroxymethotrexate in the 
liver, a metabolite which is also renally excreted (NCBI , Tian and Cronstein 2007).  
 Methotrexate is actively transported into cells, by reduced folate carriers. 
Increased expression of folate transporters has been described in cancer cells, an 
adaptation which facilitates cell proliferation (Chen, Ke et al. 2013). At serum 
concentrations above 100µM, passive diffusion also makes a major contribution to 
cellular uptake (NCBI ) (PubChem database). In the cell, methotrexate, like 
physiological folates, is a substrate for the enzyme folylpolyglutamate synthetase 
which attaches glutamate molecules to create a peptide chain up to eight residues 
long. Unlike methotrexate, methotrexate polyglutamates are not exported from the 
cell by multidrug resistance proteins, so they accumulate in cells and can be retained. 
The inhibitory effect of methotrexate polyglutamates on dihydrofolate reductase is 
similar to the effect of methotrexate (Visentin, Zhao et al. 2012).  
 
1.4.3 Methotrexate as a chemotherapy drug 
The use of methotrexate in chemotherapy originates from development of 
aminopterin, a structurally similar molecule in which the methyl group is replaced by 
an amino group. Aminopterin was the first drug shown to slow the progression of a 
malignant disease, heralding the development of chemotherapy. It was designed as 
an antagonist to folate and employed in children with acute leukaemia, following the 
observation that treatment with folates led to an acceleration of disease progression. 
Aminopterin treatment produced temporary remission, although it was associated 
with significant toxicity and side-effects (Farber and Diamond 1948). Methotrexate 
replaced aminopterin due to an improved side-effect profile, although aminopterin is 





Methotrexate is now used in chemotherapy regimens in some solid malignancies and 
in regimens for several haematological malignancies. In these situations it is given 
intravenously, at high doses (e.g 5000mg/m2) and high plasma concentrations (over 
50µM) are achieved (Radtke, Zolk et al. 2013).  
 
Mechanism of action 
Methotrexate exerts its effects as a chemotherapy drug through impairment of folate 
metabolism, via competitive inhibition of dihydrofolate reductase (DHFR) (Visentin, 
Zhao et al. 2012). This inhibition reduces intracellular levels of intermediate 
compounds required for nucleotide synthesis, resulting in impaired DNA replication 
and repair that ultimately causes cell death (Li and Kaminskas 1984). 
 
1.4.4 Methotrexate in the treatment of inflammatory conditions 
Methotrexate is also used to treat autoimmune and inflammatory diseases. It is 
particularly associated with rheumatoid arthritis, but is also used in other situations 
where immune activation is harmful, such as in the suppression of graft-versus-host 
disease following allogeneic haematopoietic stem-cell transplant.  
 
Doses 
In rheumatoid arthritis methotrexate is given orally, at much lower doses than are 
used for chemotherapy, typically 5-20mg once-weekly.  
 
Mechanism of action 
The mechanism of action of methotrexate in this context is not well understood. It is 
thought to be at least partially independent of effects on folate metabolism since 
folate supplementation has little effect on efficacy (Whittle and Hughes 2004). It has 
been suggested that methotrexate has a greater effect on lymphocytes proliferating in 
active inflammation, compared to less proliferative cells (Nakajima, Hakoda et al. 
1996). Other proposed mechanisms include effects on cytokine release by 
leucocytes, effects on the expression of adhesion molecules on vascular endothelium, 
and increased release of adenosine (Wessels, Huizinga et al. 2008). Members of the 
adenosine receptor family have anti-inflammatory effects (Saze, Schuler et al. 2013) 
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and methotrexate causes adenosine release indirectly via inhibition of the enzyme 5-
aminoimidizole 4-carboxamideribonucleotide (AICAR) (Tian and Cronstein 2007). 
Despite these hypotheses, the mechanism mediating the clinical effects of 
methotrexate is uncertain.   
 
1.4.5 Rationale behind the investigation of methotrexate as a 
suppressor of JAK/STAT signalling 
Prior to the start of my PhD, members of the laboratory carried out a luciferase based 
screen to identify compounds that suppress JAK/STAT pathway activity in 
Drosophila cell culture. This system has been used previously to identify JAK/STAT 
pathway inhibitors (Kim, Oh et al. 2010). Drosophila KC167 cells were transfected 
with a plasmid encoding firefly luciferase under the control of a STAT responsive 
promoter. In addition cells were transfected with a plasmid encoding Renilla 
luciferase under the control of a constitutively active promoter, and a plasmid 
expressing the Drosophila JAK/STAT pathway ligand Unpaired (Upd). Autocrine 
and paracrine effects of Upd triggered pathway activation, and the luminescence 
from the firefly luciferase gives a measure of the degree of pathway activation. 
Renilla luminescence acts as a control for transfection efficiency. 
 This system was used to screen a small-molecule library containing 2000 
compounds – 60% FDA approved drugs, 25% natural products and 15% other 
bioactive compounds (Spectrum Collection)(Kocisko, Baron et al. 2003) . 
Methotrexate and aminopterin were independently identified to produce a substantial 
reduction in pathway activation. Their chemical structures are similar, which 
reinforces their interest by suggesting that they are true hits produced by a common 
mechanism of action on the pathway.  
The independent identification of chemically similar compounds in the 
screen, the use of methotrexate in inflammatory conditions where the JAK/STAT 
pathway is activated, and the unanswered question of the mechanism of action of 
low-dose methotrexate suggested further investigation of the effect of methotrexate 





The aims of this study are to investigate the modulation of JAK/STAT signalling by 
the gene ANKHD1 and the drug methotrexate, with particular emphasis on the 
implications these have for JAK/STAT signalling in cancer. The clinical relevance of 
ANKHD1 is addressed in Chapters 3 and 4, which describe the expression of 
ANKHD1 in blood and haematological malignancies and malignant melanoma. The 
effect of methotrexate on JAK/STAT signalling in cancer cell lines and Drosophila 
is examined in Chapter 5, and in Chapter 6 these findings are built upon by an 
examination of methotrexate effects in primary cells from patients with diseases 
associated with JAK/STAT activation. Chapter 7 draws conclusions from the work 
and contains a discussion of implications for patients and potential future study.   
 




Chapter 2: Materials and methods 
2.1 Cell culture  
2.1.1 Cell lines and culture conditions 
Hodgkin’s Lymphoma cell lines 
Hodgkin’s Lymphoma cell lines HDLM-2 and L-540 were obtained from the 
German Collection of Microorganisms and Cell Cultures (DSMZ, Leibniz Institute, 
Germany). The HDLM2 line was derived from a pleural effusion in a 74 year old 
man with stage IV Nodular Sclerosing Hodgkin’s Lymphoma. The L-540 cell line 
was established from bone marrow from a 20 year old woman with stage IVB 
Nodular Sclerosing Hodgkin’s lymphoma. 
          Cells were grown in RPMI 1640 + GlutaMAX medium (Gibco) supplemented 
with 20% heat-inactivated Foetal Bovine Serum (FBS) (Sigma) and penicillin (100 
units/ml)/ streptomycin (100μg/ml) (Gibco), in a 37oC humidified incubator with 5% 
CO2. HDLM2 cells were seeded at a density of 1 x 106 cells per ml and L-540 cells 
seeded at 0.5 x 106cells per ml. Cells were centrifuged at 12,000 rpm for five 
minutes and resuspended in new media, splitting at a ratio of 1:2 Every 2 – 3 days. 
 
HeLa cells 
HeLa cells were a gift from Dr. V. James and Dr. M. Fragiadaki. Cells were grown 
in DMEM+GlutaMAX medium (Gibco), supplemented with 10% FBS and 
penicillin/ streptomycin in a 37oC humidified incubator with 5% CO2. Cells were 
released from culture vessels with Trypsin/ EDTA (Gibco) and split 1:7 every 2 – 3 
days. 
 
Rheumatoid Arthritis fibroblast-like-synoviocytes 
Primary rheumatoid arthritis fibroblast-like-synoviocytes were a gift from Professor 
G. Wilson (University of Sheffield, Department of Infection and Immunity). Cells 
were obtained from patients who gave informed consent for ethically approved 
research to study Rheumatoid Arthritis (REC reference SSREC/03/106). Cells were 
used between passages 6 and 8. Cells were grown in DMEM/F-12 (1:1) + 
GlutaMAX medium (Gibco) supplemented with 5% FBS and penicillin/ 
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streptomycin, in a 37oC humidified incubator with 5% CO2. When confluent, cells 
were released from culture vessels using trypsin and split 1:5.  
 
Myeloma cell lines and primary cells 
Myeloma cell lines JJN-3 and U-266 and the primary cells CB-1 were a gift from Dr. 
A. Chantry (University of Sheffield, Department of Oncology). The JJN-3 line is a 
sub-clone of JJN-1, originally derived from the bone marrow of a 57 year old woman 
with plasma cell leukaemia (IgA1kappa). The U-266 line was derived from the 
peripheral blood of a 53 year old man with IgE secreting multiple myeloma 
refractory to treatment. CB-1 primary cells were derived from the peripheral blood 
of a 68 year old man diagnosed with plasma cell leukaemia. The patient gave 
informed consent for ethically approved research to study myeloma (Rec reference 
05/Q2305/96). 
          Cells were grown in a 37oC humidified incubator with 5% CO2, in RPMI 1640 
+ GlutaMAX medium (Gibco) supplemented with 10% heat-inactivated Foetal 
Bovine Serum (Sigma), penicillin (100 units/ml)/ streptomycin (100μg/ml) (Gibco), 
non-essential amino acids (Gibco) and sodium pyruvate (1mM) (Gibco). Cells were 
split every 2 – 3 days, the U-266 cells at a ratio of 1:3 and the JJN3 cells at a ratio of 
1:5. For this project, CB-1 cells were used for analysis after a few days in culture and 
were not passaged. 
 
HEL cells 
Cells from the HEL cell line were a gift from Dr. M. Fragiadaki. The cell line was 
originally derived from peripheral blood from a 30 year old male patient who had 
relapsed acute myeloid leukaemia (WHO AML classification acute erythroid 
leukaemia). The patient had previously been treated for Hodgkins Lymphoma. 
Sequence analysis has demonstrated that cells of this line are homozygous for the 
JAK2 V617F mutation, and they show constitutive phosphorylation of JAK2 and 
STAT5 (Levine, Wadleigh et al. 2005). Cells were grown in the same media and 





Melanoma Cell lines 
Melanoma cell lines were a gift from Prof. Sheila MacNeil in the Faculty of 
Engineering at the University of Sheffield. The cell line HBL was originally 
established in the laboratory of Prof. Ghanem, from a lymph node metastasis of a 
nodular melanoma (Ghanem, Comunale et al. 1988). The C8161 cell line was 
donated to Prof. MacNeil by Professor F Meyskens (USA) via M. Edwards 
(University of Glasgow). The cell line was established from an abdominal wall 
metastasis from a woman with recurrent malignant melanoma. Cells from the C8161 
cell line are highly invasive and are used to model metastatic melanoma (Welch, Bisi 
et al. 1991).  Cells were grown in DMEM+GlutaMAX medium (Gibco), 
supplemented with 10% FBS and penicillin/ streptomycin in a 37oC humidified 
incubator with 5% CO2. HBL cells were split 1:5 every 3-4 days, and C8161 cells 
were split 1:5 every 2-3 days. 
 
Tissue engineered skin to model melanoma invasion 
Formalin fixed paraffin embedded specimens of engineered skin containing invading 
melanoma cells from the C8161 cell line were a kind gift from Ceyla Yorocu in the 
Faculty of Engineering at the University of Sheffield. The tissue was grown in 
culture as previously described (Eves, Layton et al. 2000). 
 
Primary CD34+ haematopoietic stem cells 
Cells were obtained from stored apheresis samples, from patients who gave informed 
consent (see patient samples materials and methods section for details. Cells were 
grown in StemMACS HSC Expansion Media Xeno Free (Miltenyi) supplemented 
with StemMACS HSC Expansion Cocktail (Miltenyi) containing recombinant 
human Flt3-ligand, recombinant human Stem Cell Factor and recombinant human 
TPO. No serum or antibiotics were added to media. Cells were grown in a 37oC 
humidified incubator with 5% CO2. Cells were seeded at 0.5 x 106/ml.    
 
Drosophila Kc167 cells 
Drosophila Kc167 cells were a gift from the Sheffield RNAi Screening Facility. Cells 
were maintained in Schneider’s Drosophila media supplemented by 10% foetal calf 
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serum and 100units/ml penicillin and 100µg/ml streptomycin, and grown at 25oC in 
a humidified incubator.  
  
2.1.2 Drug and ligand treatments 
Estimation of drug doses 
The range of concentrations of drugs used for cell culture experiments was selected 
based on existing data and literature. A dose corresponding to the value measured in 
the serum of individuals who had taken the drug was included, with a range to cover 
at least on order of magnitude above and below this. For methotrexate, this is 0.4µM 
for oral dosing for rheumatoid arthritis (Hobl, Mader et al. 2012), although peak 
serum concentrations in individuals receiving methotrexate intravenously as a 
chemotherapy drug may be over 50µM (Radtke, Zolk et al. 2013). In the 
pharmacokinetic studies of ruxolitinib a peak plasma concentration of around 1µM 
was recorded (Shilling, Nedza et al. 2010). For folinic acid, concentrations 
corresponding to those advised in the British National Formulary for methotrexate 
overdose were examined as a high concentration. To represent a clinically relevant 
lower concentration, a concentration equivalent to that measured in the plasma of 
individuals taking an oral dose corresponding to that recommended for methotrexate 
toxicity in rheumatoid arthritis was used (Whittle and Hughes 2004, McEvoy 2005). 
 To calculate appropriate EPO concentrations a conversion was made from 
international units to nanograms (Jelkmann 2009). Physiological levels of EPO in 
normoxic individuals are low, but EPO concentrations rise exponentially when 
stimulated by hypoxia. To estimate an EPO concentration equivalent to that triggered 
by hypoxia we used EPO values measured in individuals with secondary 
polycythaemia (Spivak 2002). 
 
Treatment with methotrexate, aminopterin and ruxolitinib 
Methotrexate and Aminopterin (Sigma) and ruxolitinib (Cayman Chemicals) were 
dissolved in 100% dimethyl sulphoxide (DMSO). Stock solutions were stored at –
20oC and diluted in media prior to use. All treated cells experienced a final 
concentration of DMSO 1:1000 volume: volume in addition to the dissolved drugs.  
          Suspension cells were seeded in 12 well plates (1 x 106 cells/ml for HDLM2, 
0.5 x 106 cells/ml for HEL, up to 0.5 x 106 cells/ml for primary cultures) and grown 
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for 24 hours prior to application of drugs. Cells continued to grow for a further 48 
hours before being pelleted at 6000rpm for 5 minutes and washed with TBS prior to 
protein or RNA extraction. 
          RA-FLS were seeded in t25 flasks in 5ml media and grown to confluence. 
Media was exchanged for 5ml of fresh pre-warmed media and drugs applied. Cells 
were exposed to drug-containing media for 48 hours. After removal of media cells 
were washed in 1.5ml TBS, detached from the flask using a cell scraper, then 
pelleted at 8000rpm for 5 minutes prior to protein extraction.  
  
Treatment with folinic acid 
Leucovorin (calcium folinate, Refolinon®) was obtained from Pharmacia as a 
3mg/ml solution for injection and stored in the dark at 4oC. HEL cells were seeded 
into 3ml wells and grown for 24 hours. Methotrexate was added to these wells and 
the cells grown for a further 24 hours. For each methotrexate concentration paired 
1ml samples of cells were transferred to new wells, and folinic acid added to one of 
these wells. Final folinic acid concentrations of 21µg/ml, 3µg/ml and 0.3µg/ml were 
used. Cells were treated with folinic acid for 48 hours before protein extraction. 
 
Stimulation with OSM, IL-2 and EPO 
Recombinant Human Oncostatin M (R&D systems), recombinant human IL-2 (Cell 
Signalling Technology) and recombinant human EPO (Sigma) were dissolved in 
sterile TBS to generate a 10μg/ml stock solution, stored at -20oC. Cells were 
stimulated with OSM and IL-2 at a final concentration of 10ng/ml. Cells were 
stimulated for 30 minutes prior to RNA extraction and 6 hours prior to protein 
extraction. For stimulation with EPO cells were grown for 48 hours in the presence 
of methotrexate, split into separate wells, and one set of wells stimulated with 15 
ng/ml EPO for 20 minutes prior to protein extraction. 
 
2.1.3 Transfection of HeLa cells  
Forward transfection 
HeLa cells were seeded in 12 well plates at a density of 1 – 2 x 105 cells per well, in 
DMEM GlutaMAX media (Gibco) supplemented with 10% FBS and penicillin/ 
streptomycin. Cells were grown for 24 hours then media was replaced with fresh 
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media free of antibiotics. Transfection using Fugene HD (Promega) transfection 
reagent was carried out according to the manufacturer’s instructions. Cells were 
transfected with 2μg of plasmid DNA per well, using 6μg of Fugene transfection 
reagent per well. Cells continued to grow for a further 48 hours before ligand 
stimulation or extraction of protein or RNA. 
 Drosophila Kc167 cells were transfected with Effectene (Qiagen) according to 
the manufacturer’s instructions.  
 
Reverse transfection 
HeLa cells were seeded into 12 well plates at a density of 1 x 105 cells/ml, 1ml per 
well in DMEM GlutaMAX media (Gibco) supplemented with 10% FBS. At the time 
of plating cells were transfected with siGENOME SMARTpool siRNA ANKHD1 or 
siGENOME Non-Targeting siRNA (Thermo Scientific) at a final concentration of 
10nM. Target sequences of the SMARTpool siRNAs are listed in table 2-1. 
Transfection was performed with Lipofectamine RNAiMAX Reagent (Invitrogen) 
according to the manufacturer’s instructions. Cells were grown for 72 hours before 
protein or RNA extraction.   
Table 2-1 Target sequences of siRNA to knock down ANKHD expression. 






2.2 Protein techniques 
2.2.1 Protein extraction 
Cell pellets were lysed on ice in a buffer containing 50mM Tris HCL pH 7.4, 
250mM NaCl, 5mM EDTA, 0.3% Triton X-100 and protease inhibitor (Complete 
mini EDTA free protease inhibitor cocktail, Roche). For adherent cells, wells were 
washed twice with TBS and cells lysed in their wells using the buffer described 
above. Large samples were sonicated at 10 microns for two ten second bursts then 




2.2.2 Western Blotting 
Samples were boiled for 5 minutes in an equal volume of Laemmli sample buffer 
(125mM Tris HCL pH 6.8, 20% glycerol, 4% SDS, 0.005% Bromophenol blue and 
5% Beta Mercaptoethanol). Samples were separated on 4-15% polyacrylamide pre-
cast gels (Mini-Protean TGX, Bio-Rad) run at 75mV for 10 minutes and 90mV for 
1hour 20 minutes. Separated samples were transferred to a nitrocellulose membrane 
(Amersham Hybond ECL, GE Healthcare) at 85mV for 1 hour 20 minutes. 
Membranes were blocked for thirty minutes in 5% skimmed milk in Tris buffered 
saline (pH 7.4) with 0.1% Tween-20 then probed with appropriate antibodies in 5% 
bovine serum albumen (BSA)/TBST overnight at 4oC. Primary antibodies are listed 
in table 2-2 (antibodies binding both phosphorylated and non-phosphorylated forms 
of the specified protein) and table 2-3 (antibodies binding only the phosphorylated 
form of the specified protein). 
 
Table 2-2. Primary antibodies used in western blotting, antibodies binding both phosphorylated and 
non-phosphorylated forms of the specified protein  
Protein Antibody source Species Dilution 
JAK1 Cell Signalling 
Technology 
Rabbit 1:1000 
JAK2 Cell Signalling 
Technology 
Rabbit 1:1000 
JAK3 Cell Signalling 
Technology 
Rabbit 1:1000 
STAT1 Cell Signalling 
Technology 
Rabbit 1:1000 
STAT3 Cell Signalling 
Technology 
Rabbit 1:1000 
STAT5 Cell Signalling 
Technology 
Rabbit 1:1000 
Beta Actin Abcam Mouse 1:2000 
c-myc (9E10) Santa-Cruz 
Biotechnology 
Mouse 1:400 
Flag (clone M2) Sigma Mouse 1:1000 









Sigma Rabbit 1:1000 
ANKHD1 (N-TERM) 
(SAB1302423) 
Sigma Rabbit 1:250 
ANKHD1 Abcam Rabbit 1:2000 
ANKHD1 (clone D-
12) 
Santa-Cruz Goat 1:200 
ANKHD1 (clone N-
14) 
Santa-Cruz Goat 1:200 
YAP Cell Signalling 
Technology 
Rabbit 1:200 




Table 2-3. Primary antibodies used in western blotting, antibodies specific for protein phosphorylated 
on the residues stated. 
Protein Phosphorylated 
residues 
Antibody source Dilution 
phospho-JAK1 Tyr 1022/1023 Millipore 1:1000 
phospho-JAK2 Tyr 1007/1008 Cell Signalling 
Technology 
1:1000 
phospho-JAK3 Tyr 980/981 Cell Signalling 
Technology 
1:1000 
phospho-STAT1 Tyr 701 Cell Signalling 
Technology 
1:1000 
phospho-STAT3 Tyr 705 Cell Signalling 
Technology 
1:1000 
phospho-STAT5 Tyr 694 Cell Signalling 
Technology 
1:1000 






Erk1 – Thr 202 and 
Tyr 204 









Membranes were incubated in horseradish peroxidase conjugated secondary 
antibodies (Dako) at a dilution of 1:10,000 for 45 minutes and imaged using ECL 
reagent or ECL select reagent (GE healthcare). All blots using cell lines were 
repeated on three independent samples. 
 
2.3 DNA techniques 
2.3.1 Bacterial culture and starting plasmids 
E-coli transformation with plasmid DNA 
Plasmids containing full-length ANKHD1 (RC223067) and empty vector (PCMV6-
entry PS100001) were obtained from Origene. 
50 μl of 10-beta competent E. coli cells (New England Biolabs) were defrosted on 
ice. 1μ1 of plasmid DNA was added to cells and the mixture incubated for 10 
minutes at 37oC. Cells were then incubated with 1ml of Luria-Bertani (LB) medium 
(10g/l tryptone, 5g/l yeast extract, 5g/l NaCl) for 1 hour at 37oC shaking at 250rpm. 
Cells were concentrated by centrifuging at 13000rpm for 10s and removing the 
supernatant, before plating on LB agar containing 50μg/ml kanamycin. 
 
Bacterial culture 
E-coli were grown in Luria-Bertani medium containing 50µg/ml kanamycin or 
50μg/ml ampicillin. Cultures were incubated at 37oC and shaken at 250rpm. For 
minipreps a single colony from a selective agar plate was grown overnight in 1.5 to 
2ml selective LB. For midipreps a single colony from a selective agar plate was used 
to set up a starter-culture in 2ml selective LB. After 8 hours incubation 250μl of this 




Plasmid DNA extraction 
Plasmid DNA was extracted from bacterial cultures  using a QIAprep Spin miniprep 




2.3.2 Generation of plasmid encoding fragment of ANKHD1 
containing first and second ankyrin repeats and the intervening 
region 
Cloning strategy 
The plasmid was generated with the PCMV6-entry vector backbone, containing the 
fragment of ANKHD1 in frame with the sequences for the myc and DKK tags, 
between Sgf-1 and Mlu-1 restriction sites. The plasmid RC223067, containing the 
full-length ANKHKD1 sequence was used as a template for PCR using primers 
containing Sgf-1 and Mlu-1 restriction sites. The PCR product had deoxyadenosine 
overhangs added and was ligated into TA vectors. This plasmid was then subject to 
restriction digest with Sgf-1 and Mlu-1, separated by agarose gel electrophoresis, 
and ligated into the PCMV6-entry vector backbone.  
 
Restriction digests 
Restriction enzymes Sgf-1 and Mlu-1 were obtained from Promega. BglII was 
obtained from New England Biolabs. Digests were carried out for 1 hour at 37oC 
using the buffers and bovine serum albumen supplied and recommended by the 
manufacturer.  
 
Agarose gel electrophoresis 
Digested DNA fragments were separated on agarose gels made with TAE (40mM 
Tris, 20mM Acetic Acid, 1mM EDTA), in TAE at 100mV for 1 – 1½ hours. 1%, 
1.5% or 2% agarose gels were chosen depending on expected fragment sizes.  
Agarose gels contained 0.1μl/ml SYBRSafe DNA gel stain (Invitrogen) and DNA 





Primers used to generate fragments of the ANKHD1 coding sequence flanked by 
appropriate sgf-1 or mlu-1 restriction sites are listed in Table 2-4. Primers were 
obtained from Integrated DNA Technologies. 
 
Table 2-4. Primers used to generate ANKHD1 fragments.  
Primer Sequence (5’ to 3’) 
1st Ankyrin repeat domain 
forward 
GCG ATC GCC ATG AAA GCA GAA AAC AGC CAC 
AAT G 
2nd Ankyrin repeat domain 
reverse 
ACG CGT GGT TTC GAC ACA TTG ATG ACA TTT 
TTT C 
 
The forward and reverse primers were combined to produce sequences encoding 
regions of the ANKHD1 protein described in table 2-5. 
 
Table 2-5. Primer combinations to generate ANKHD1 coding fragments, and sizes of PCR products. 
Protein domains 
encoded 
Forward primer Reverse primer Product 
size 
1st and 2nd ankyrin 
repeat domains and 
intervening sequence 
1st ankyrin repeat 
domain forward 




Primers were diluted to a concentration of 100μM in DNAse/RNAse free distilled 
water (Gibco) to make a stock solution. This stock was used to make working 
dilutions of primers at a concentration of 10μM. PCR was performed in a 50μl 
reaction volume, containing 2.5μl of 10μM primer and 10 ng template (RC223067 
Origene plasmid containing full-length ANKHD1 cDNA). PCR was carried out 
using Q5 High-Fidelity DNA Polymerase (M0491) (New England Biolabs). Primer 
annealing temperatures were calculated using the NEB Tm calculator 
(www.neb.com/tools-and-resources/interactive-tools/tm-calculator) and the 
instruction in the product literature used to create the following thermocycling 
conditions: 
 
1) Initial denaturation – 98oC, 30s. 
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2) Denaturation – 98oC, 7s. 
3) Annealing – variable temperature (table 2-6), 20s. 
4) Extension – 72oC, variable time (table 2-6). 
5) Repeat steps 2-4 for total of 25 or 30 cycles. 
6) Final extension – 72oC, 2 minutes. 
 
Table 2-6 Annealing temperatures and extension times for primer pairs. 
Forward primer Reverse primer Annealing temp Extension 
time 
1st ankyrin repeat 
domain forward 




Addition of deoxyadenosine overhangs 
Q5 High-Fidelity DNA Polymerase produces PCR products with blunt ends. To add 
‘A’ overhangs 6.5μl of PCR product in a was incubated in a 10μl reaction (or 13μl 
PCR product in a 20μl reaction) with Taq polymerase (New England Biolabs), 
thermopol buffer (New England Biolabs), dATP (Fermentas) at a final concentration 
of 5mM and MgCl2 (Fermentas) at a final concentration of 2.5mM, at 72oC for 30 
minutes.  
 
Purification of PCR products 
PCR products were purified using a QIAquick PCR Purification Kit (Qiagen) 
according to the manufacturer’s instructions. 
 
TA cloning 
A TOPO TA Cloning Kit (Invitrogen) was used to ligate PCR products into the pCR 
2.1-TOPO vector, according to the manufacturer’s instructions.  
 
E.coli transformation with ligated plasmids 
10-beta competent E. coli cells (New England Biolabs) were transformed with the 
product – 50μl of cells were thawed on ice then mixed with 4μl of the cloning 
reaction product and left to stand on ice for 15 minutes. Cells were then heat-
shocked at 42oC for 30 seconds, chilled on ice, then incubated in 250μl SOC or LB 
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medium for 1 hour at 37oC at 250 rpm. 10μl or 50μ of this cell suspension was 
spread onto LB agar plates containing 50μg/ml ampicillin, previously spread with 
50μl of 33mg/ml X-gal in dimethylformamide.  
          To identify positive transformants DNA was extracted from cultures of white 
colonies, and an Sgf-1 and Mlu-1 double-digest performed. Digested DNA was 
separated by agarose gel electrophoresis as described above. Digests from positive 
transformants produced two bands, corresponding to the size of the vector and insert.  
 
Gel extraction  
RC222623 (Origene plasmid containing Myc and DKK tagged ANKHD1 Splice 
Variant 3) and pCR 2.1 TOPO containing PCR products were digested with Sgf-1 
and Mlu-1 and separated by agarose gel electrophoresis as described above. Gel 
blocks containing the appropriate vector and insert bands were excised and DNA 




Vector and insert fragments were ligated using T4 DNA Ligase (Roche) at 16oC 
overnight. The molar ratio of insert: vector DNA in the ligation reaction was 
approximately 3:1. A vector-only control ligation reaction was also set up. 10-beta 
competent E.coli cells were transformed as described above. After the 1hr incubation 
in SOC, cells were centrifuged for 10s at 13,000rpm, the supernatant removed and 
all the possible transformants plated on selective LB agar containing 50μg/ml 
kanamycin.   
 
Identification of positive transformants and sequencing 
To identify positive transformants DNA was extracted from cultures of colonies, and 
an Sgf-1 and Mlu-1 double-digest performed. Digested DNA was separated by 
agarose gel electrophoresis as described above. Digests from positive transformants 
produced two bands, corresponding to the size of the vector and insert. To confirm 
that the selected plasmids contained the correct insert and to check that no mutations 
had been introduced during PCR inserts were sequenced at the Core Genomic 




2.4 RNA techniques 
2.4.1 RNA extraction 
RNA was extracted from cells using an RNeasy Mini Kit and Qiashredder columns 
(QIagen) according to the manufacturer’s instructions. RNA was eluted in 
DNAse/RNAse free distilled water (Gibco) and stored at -80oC.  
 
2.4.2 cDNA synthesis 
1μg of RNA was reverse transcribed to cDNA in a 20μl reaction using a High 
Capacity RNA-to-cDNA Kit (Applied Biosystems). Control reactions lacking the 
reverse transcriptase enzyme were run in parallel. The 20μl cDNA was diluted 1:1 in 
DNAse/RNAse free distilled water (Gibco) for use as a template in quantitative real-
time PCR.    
 
2.4.3 Quantitative real-time PCR 
Quantitative real-time PCR was carried out in 96 well plates on a Bio-RAD CFX96 
Real-Time System C1000 touch thermal cycler.  
Primers used for real-time PCR are described in table 2-7. 
Table 2-7. Sequences of primers used for real-time PCR. 
Target transcript Forward primer (5’ to 
3’) 
Reverse primer(5’ to 3’) 
Full-length ANKHD1 CCT GCT TGG AAC CCT 
CTG ATA AA 
CGT GCC AGG CCA AAT 
CTG 
Actin ATC ATT GCT CCT CCT 
GAG CG 
GAC AGC GAG GCC AGG 
ATG 
 
Each primer was diluted in DNAse/RNAse free water to make a 100 μM stock 
solution. To make working dilutions of primers, forward and reverse primers for 
each target gene were mixed together in DNAse/RNAse free water at a concentration 
of 2.5μM for each primer. 
 For quantitative real-time PCR each well contained 5μl SYBR green 
(BioRAD), 1μl cDNA template (diluted as described above) and 4μl primers (diluted 
as described above).  
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  Melt curves were examined to ensure these primers were producing a single 
product. For both primer pairs standard curves were generated using serial twofold 
dilutions of template, performed in duplicate. The slopes of these curves (ANKHD1 
-3.07+0.13, efficiency 112%, actin -3.01+0.07, efficiency 115%) met the 
requirements for the ΔΔCt method to be used for quantification.   
 
2.5 Drosophila techniques 
2.5.1 Luciferase assays 
Media was removed form Drosophila Kc167 cells in 96 well plates by tipping and 
cells were lysed before adding the substrate for firefly luciferase (D-luciferin, Apollo 
Scientific) and read on a Varioskan plate reader (Thermo-Fisher). Buffer containing 
substrate for Renilla luciferase (Coelenterazine, Apollo Scientific) was then added 
and measured using a 500nM long pass filter.  
 
2.5.3 Preparation of fly media containing drugs 
Freshly prepared molasses agar was obtained whilst molten. A 50mM or 0.5mM 
stock solution of methotrexate was diluted in DMSO to create the following working 
concentrations: 750μM, 500μM and 100μM. 100μl of DMSO, or 100μl of each of 
the working solutions was thoroughly mixed into 100ml of media, to give final 
concentrations of 1:1000 DMSO, 0.75µM, 0.5µM and 0.1µM methotrexate. 
Approximately 10ml of drug-containing media was aliquoted per tube. Media was 




HopT42/FM7, Act-GFP virgins were crossed with w1118 males, with approximately 
eight females and two males per vial.  
Adults were maintained at room temperature on standard molasses agar with 
yeast for 48 hours before being transferred to tubes of drug-containing media. Adults 
were left to lay eggs for approximately 24 hours before being transferred to a fresh 
tube. Tubes containing eggs were maintained at room temperature for approximately 




2.5.5 Tumour assay 
HopT42 heterozygous females were scored for tumour formation after hatching. Each 
fly was examined for tumours, which were scored as follows: tumour the diameter of 
one abdominal segment = 1, diameter of two abdominal segments = 2, larger than 
two abdominal segments = 4, half an abdominal segment = 0.5, a quarter of an 
abdominal segment = 0.25. For each fly the size of each tumour was multiplied by 
the number of tumours of that size, and the values summed. At least 150 flies were 
assessed for each drug concentration. The tumour index for each drug treatment was 
the mean value for all the flies at that drug concentration.  
 
2.6 Kinase profiling 
In-vitro kinase profiling was carried out by the International Centre for Kinase 
Profiling, at the University of Dundee. The effect of 10µM methotrexate upon the 
activity of 50 kinases was measured with a radioactive filter binding assay using 33P 
ATP (Hastie, McLauchlan et al. 2006). The incubation time with 33P is not uniform 
across all kinases examined, but varies according to the optimal incubation time for 
each kinase. Each assay is performed in duplicate, and the plate on which the assay 
is performed includes reference compounds and blank wells for quality control.   
 
2.7 Immunofluorescence 
2.7.1 Preparation of slides 
Cultured cells were grown on glass coverslips. After removal of media, coverslips 
were washed three times in ice-cold TBS before fixing with 100% methanol at -20oC 
for 30 minutes. Coverslips of cultured cells or slides of fixed blood or marrow films 
were washed in TBST then incubated in blocking solution (5% dried skimmed milk 
in TBST) at room temperature for 30 – 60 minutes. Coverslips or films were then 
incubated overnight at 4oC in primary antibody diluted in 1%BSA/TBST. Primary 
antibodies and the concentrations at which they were used are listed in table 2-8. 
Table 2-8 primary antibodies used in immunofluorescence 




Mouse anti-FLAG, clone Sigma 5µg/ml 
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The slides were washed in TBST then incubated for one hour in the dark at room 
temperature in secondary antibody diluted 1:1000 in 1% BSA/TBST. Details of 
secondary antibodies are listed in table 2-9. 
Table 2-9 secondary antibodies used in immunofluorescence.  
Antibody Source 
Mouse anti-rabbit IgG heavy and light 
F(ab’)2 fragment Alexa Fluor (R) 488 
conjugate 
Cell signalling technology 
Donkey anti-rabbit IgG Alexa Fluor 568 
conjugate 
Invitrogen, Molecular Probes 
Goat anti-mouse IgG Alexa Fluor 488 
conjugate 
Life Technologies 
Coverslips or slides were then washed in TBST and mounted in Fluoroshield with 
DAPI (Sigma).   
 
2.7.2 Fluorescence Microscopy 
Images were gathered using an Olympus BX61 epifluorescence microscope with a 
Hamatsu orca monochrome camera and Volocity imaging software, in the Wolfson 
Light Microscopy Facility in the Department of Biomedical Science at the 
University of Sheffield.  
 
2.7.3 Image analysis 
Images were prepared and analysed using ImageJ software (v1.48). 
 
2.8 Source and initial processing of patient samples 
2.8.1 Ethical approval 
The study on ANKHD1 was reviewed by the Yorkshire and the Humber-Bradford 
Research Ethics Committee (13/YH/0018). All participants for whom personal data 
was accessed in the study gave written informed consent. A substantial amendment 
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to the study that allowed the use of un-linked de-identified tissue that was surplus to 
requirements for clinical care without specific patient consent was approved by the 
Research Ethics Committee. 
 The study on the effect of methotrexate on primary cells from patients with 
MPNs was reviewed under the proportionate review scheme by the North West-
Greater Manchester South Research Ethics Committee (14/NW/1524). Participants 
gave written informed consent for the use of stored material surplus to requirements 
for their clinical care, and access to their medical records.  
 
2.8.2 Whole blood and bone marrow aspirate 
Origin of samples 
3-4 ml of whole blood was drawn from peripheral sites into an EDTA tube. For 
individuals with a Hickman line, blood was drawn from the line at the time of 
routine sampling for clinical management, and transferred to an EDTA tube. During 
bone marrow biopsies performed for clinical reasons an additional 1 – 4 ml of 
aspirate was drawn and transferred to an EDTA tube. For de-identified samples 
supplied by the diagnostic haematology laboratory blood or bone marrow aspirate 
was supplied as a 100-200µl aliquot from EDTA samples that would otherwise be 
disposed of as waste following clinical testing or were surplus to requirements for 
clinical care. Samples of blood to be used as normal controls were selected as 
samples with a normal full blood count obtained from individuals attending as an 
out-patient at a clinic for a specialty other than haematology or oncology. 
             
Preparation of blood and bone marrow films 
Fresh blood or bone marrow in EDTA was mixed and approximately 2µl spread on a 
glass slide. Films were air dried, fixed in room temperature 100% methanol for 30s 
then air dried again. Fixed films were stored at room temperature.  
Films which were stained were stained in Wright’s stain (Sigma) for 15 
seconds before washing in deionised water for 30s and rinsing in deionised water.  
Films which were examined with immunofluorescence were prepared using 
the protocol used for cultured cells (section 2.7.1) starting at the blocking step, and 




Isolation of peripheral blood and bone marrow mononuclear cells 
Mononuclear cells were separated from whole blood or bone marrow using 
Histopaque-1077 (Sigma-Aldrich) according to the manufacturer’s instructions. 
Following fractionation mononuclear cells were counted on a haemocytometer and 
processed to obtain protein (see section 2.2.1) and RNA (see section 2.4.1). 
 
2.8.3 Apheresis material  
Fresh apheresis waste for ANKHD1 study 
50ml of blood/ saline mixture (waste remaining in machine tubing following harvest) 
was centrifuged at 1200rpm for 5 minutes) to concentrate the blood cells. 
Mononuclear cells were obtained from 3ml of the blood-rich fraction using 
Histopaque-1077 (Sigma-Aldrich) according to the manufacturer’s instructions. 
Mononuclear cells were separated into CD34+ and CD34- fractions using a magnetic 
bead kit (CD34 MicroBead Kit human, Miltenyi Biotec) according to the 
manufacturer’s instructions. Cells in each fraction were counted on a 
haemocytometer and processed to obtain protein as described in the section 2.2.1. 
 
Stored apheresis material for methotrexate study 
0.5ml aliquots of apheresis material in 10% DMSO (samples stored for quality 
assurance testing) were retrieved from liquid nitrogen storage at NHS blood and 
transplant, transported on dry ice, and immediately transferred to liquid nitrogen. 
Cells were thawed in a 37oC water bath until only a small ice crystal remained and 
transferred to a 15ml tube. 1ml of pre-warmed HSC expansion media (without 
cytokines) was used to rinse the cryotube, and added drop by drop (approx. one drop 
every 5s) down the side of the 15ml tube. Cells were centrifuged at 1200 rpm at 
room temperature for 5 minutes, supernatant removed, the washing step repeated 
with fresh media, and cells resuspended. The cell suspension was passed through a 
40µm nylon mesh filter, and suspended in 15ml chilled separation buffer (PBS Ph 
7.2, 0.5% BSA, 2mM EDTA, de-gassed). Cells were centrifuged at 1200rpm at 4oC 
and resuspended in 300µM separation buffer. Isolation of CD34+ cells was carried 
out using a CD34 MicroBead Kit UltraPure (Miltenyi Biotec), following the 
manufacturer’s instructions. The isolated cells were suspended in 5ml HSC 
expansion media supplemented with cytokines (as described in section 2.1.1). 
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Seeding densities varied between patients, but were around 0.3 x 105 cells/ml. Cells 
were analysed for CD34+ enrichment and viability 24-48 hours after isolation. Cells 
were expanded for 3-4 days before seeding for drug treatments.  
 
2.8.4 Formalin fixed paraffin embedded melanoma samples  
Slides were prepared from tissue blocks by NHS laboratory staff. 4µM sections were 
cut onto coated slides from formalin-fixed paraffin embedded (FFPE) tissue samples 
and dried overnight at 55oC. Slides labelled with an un-linked identifier, and 
supplied with the age and gender of the patient and the skin site of the melanoma. 
 
2.9 Flow cytometry 
2.9.1 Development of flow cytometry protocol 
A protocol to detect ANKHD1 using flow cytometry was developed using the 
myeloma cell line JJN-3 and HeLa cells, both of which express ANKHD1. None of 
the large antibody suppliers produce fluorophore-conjugated anti-ANKD1 
antibodies, so two approaches were investigated to label cells for flow cytometry. A 
commercial kit was used to label the ANKHD1 antibody, but when JJN-3 cells 
stained with conjugated anti-ANKHD1 were compared to cells stained with 
polyclonal IgG labelled using the same kit there was no difference in the median 
fluorescence intensity of the two populations (data not shown). A second approach, 
using an unlabelled primary antibody and a fluorescently-conjugated anti-rabbit 
secondary FAB fragment was more successful. The median fluorescence intensity of 
the cell population stained with anti-ANKHD1 and anti-rabbit Alexa Fluor 488 was 
seventeen-fold higher than in cells from the same passage stained with the same 
concentration of polyclonal rabbit IgG and anti-rabbit secondary (Figure 2-1A).  
To determine the specificity of the flow cytometry method to detect 
ANKHD1 a cell population that does not express ANKHD1 was required. siRNA 
was used to knock down expression of ANKHD1 in HeLa cells, and western blotting 
showed the ANKHD1 level was reduced to 3% of the level seen in untreated cells 
(Figure 2-1B). Flow cytometry on cells from the same population showed that the 
median fluorescence intensity of the cells in which ANKHD1 was knocked down 


























Figure 2-1 . Flow cytometry using an unlabelled primary antibody and a labelled 
secondary antibody can be used to detect ANKHD1. A In the myeloma cell line JJN-3, 
fluorescence in the presence of ANKHD1 primary antibody is seventeen fold higher than 
that seen when a polyclonal rabbit IgG is used as the primary antibody. B Western 
blotting shows that ANKHD1 protein levels are substantially reduced by siRNA 
treatment. C Flow cytometry of cells from the same population as shown in the western 
blot. The median fluorescence intensity of the ANKHD1 siRNA treated cells is 60% of 




comparing western blotting and flow cytometry for measurement of protein have 
described a similar disparity between the two methods (Anand, Stedham et al. 2011).  
 The flow cytometry method was considered adequate to proceed to 
examining whole blood. Further optimisation was carried out using whole blood to 
optimise secondary antibody concentrations and to combine staining for ANKHD1 
with other antibodies and fluorophores. 
 
2.9.2 Fixation and permeabilisation  
Cell lines and primary cells in culture 
Prior to fixation and permeabilisation cell grown in suspension were centrifuged at 
12,000 rpm for five minutes, the supernatant was discarded and the pellet 
resuspended in 1ml phosphate buffered saline (PBS) (138 mM NaCl, 2.7 mM KCl, 
1.1 mM KH2PO4, 8.1 mM Na2HPO4.2H2O, pH 7.4). For experiments in which flow 
cytometry and western blotting were being compared, cells grown in a single well 
were separated into aliquots for each experimental procedure at this stage. HeLa 
cells were released from cell culture flasks by digestion with trypsin and resuspended 
in media containing 5% or 10% FBS before centrifugation and resuspension in PBS 
as described above.  
 Fixation was performed by adding formaldehyde to the cell suspensions to a 
final concentration of approximately 2.5 – 3% and incubating at 37oC for 10 
minutes. Cells were then cooled on ice for one minute before permeabilising by 
adding ice-cold 100% methanol to a final concentration of 90% methanol, and 
incubating on ice for 30 minutes. Cells were either stained immediately, or stored in 
90% methanol at -20oC. 
 
Whole blood or bone marrow aspirate 
100µl of blood was prepared from each sample. When larger volumes of peripheral 
blood were available volumes were scaled up accordingly. Cells were fixed by 
adding 65µl of 10% formaldehyde/PBS to each tube, vortexing briefly, and 
incubating at room temperature for 15 minutes. 1ml of 0.1% Triton X-100 was then 
added to each tube, which was vortexed and incubated at room temperature for 30 
minutes. Cells were washed by adding 2ml of incubation buffer (0.5% BSA in PBS) 
to each tube and pelleting cells at 1250rpm for 5 minutes. The wash step was 
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repeated, before resuspending cells in 1ml of 50% methanol/PBS. Cells were 
incubated on ice for 10 minutes and stained immediately or stored at -20oC.  
 
2.9.3 Immunostaining 
Fixed and permeabilised cells 
Cells suspended in methanol were vortexed to thoroughly resuspend them. 
Approximately 1 x 106 cells were aliquotted per condition for cultured cell lines, 
determined by counting cells suspended in methanol on a haemocytometer or by 
counting cells growing in suspension prior to fixation and permeabilisation. For 
primary cells in culture initial cell numbers were lower. For blood or bone marrow 
cells, 0.5ml of methanol-suspended cells, corresponding to 50µl whole blood or bone 
marrow, was used for each condition. Where the white blood cell count was elevated 
the volume of methanol-suspended cells was reduced . 
All wash steps were carried out by adding 2ml incubation buffer (0.5% BSA 
in PBS) and centrifuging at 1250rpm for 5 minutes. Cells were washed twice, 
resuspended in 100µl incubation buffer and blocked by a 10 minute incubation in 
this buffer at room temperature. Primary antibodies were then added, and cells 
incubated for 1 - 2 hours at room temperature. For fluorescently conjugated 
antibodies this incubation was done in the dark. Fluorescently conjugated primary 
antibodies and the concentrations are listed in table 2-10, unlabelled primary 
antibodies in table 2-11. 
Table 2-10. Fluorescently conjugated primary antibodies used in flow cytometry. Dilution factors are 
those recommended by the manufacturer. 
Antibody Antibody source Dilution factor/ 
final 
concentration 
PerCP anti-CD45 BD Biosciences 1.25µg/ml 
PE anti-CD34 Miltenyi Biotec 1:11 
Alexa Fluor 488 anti-STAT5 
(pY694), clone 47, mouse IgG1κ 
BD Biosciences 1:20 
Alexa Fluor 488 mouse IgG1κ 
isotype control 





Table 2-11. Un-labelled primary antibodies used in flow cytometry. 
Antibody Antibody source Final 
concentration 









Cells were washed twice, and resuspended in PBS or incubated in incubation buffer 
with a 1:1000 dilution of fluorescently conjugated secondary antibody (Anti-rabbit 
IgG heavy and light F(ab’)2 fragment Alexa Fluor (R) 488 conjugate, Cell Signalling 
Technology). Cells were incubated at room temperature in the dark for 30 minutes. 
Cells were washed twice in incubation buffer as above and resuspended in PBS.  
 
Un-fixed cells 
24-48 hours after isolation of CD34+ HSCs from stored apheresis material an 
assessment of CD34+ cell enrichment was performed. 1 x 105 cells were washed and 
resuspended in 95µl incubation buffer. Cells incubated with labelled antibodies at 
4oC in the dark for 15 minutes, washed, resuspended in PBS and analysed 
immediately.  
 
2.9.4 Assessment of cell viability 
Flow cytometry to assess cell viability was performed on fresh cells, using an 
Annexin V-FITC Early Apoptosis Detection Kit (Cell Signalling Technology) 
according to the manufacturer’s instructions.   
 
2.9.5 Analysis on flow cytometer 
Cells were analysed on a BD LSRII or BDFACSCanto II. Data was analysed using 
BD FACSDiva software  or Flowjo. Compensation for spectral overlap between 
fluorophores was based on values used for clinical tests in the diagnostic laboratory, 






Table 2-12. Compensation matrix for flow cytometry 
Fluorochrome % Fluorochrome Spectral Overlap 
PerCP FITC 3.32 
PE FITC 16.65 
FITC PerCP 0.00 
PE PerCP 0.00 
FITC PE 1.07 
PerCP PE 22.15 
 
2.9.6 Gating strategies 
Cell populations were identified with flow cytometry using side scatter and staining 
with PerCP-conjugated anti-CD45, a method routinely used in diagnostic flow 
cytometry. CD45, also known as the leucocyte common antigen, is a receptor 
tyrosine phosphatase expressed on the surface of white blood cells whose expression 
levels vary in a manner that is useful to separate cell populations.  Gating strategies 
used to identify cell populations are shown as follows: 
Normal blood cell populations Figure 2-2 
CD34+ cells from stem cell donors Figure 2-3 
Blasts from patients with acute leukaemia Figure 2-4 
CD34+ cells from a patient with MF and a patient with myelodysplasia with high 
circulating CD34+ counts Figure 2-5. 
 
2.9.7 Flow cytometry calculations 
Staining index was calculated using the formula (MFI positive – MFI negative)/ 2 x 
SD negative, where MFI is median fluorescence intensity and SD is the robust 
standard deviation. Fold change in MFI was calculated as MFI positive/ MFI 
negative. Percentage inhibition was calculated as (1-[treated cells MFI – isotype 









































Figure 2-2 Gating strategy used to define populations of leucocyte types in normal blood 
using flow cytometry . The positions of the populations varied slightly between patients.
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Figure 2-3 The gating strategy to identify CD34+ cells in peripheral blood is adapted from the 
approach used by the diagnostic haematology laboratory:
Step 1: Collect data for 300,000 events
Step 2: Gate to identify CD45+ cells
Step 3: Gate to isolate CD34+ cells
Step 4: Re-examine and re-gate CD34+ population using CD45


























































































Figure 2-4 Gating strategy to identify blasts in samples from patients with acute 
leukaemia.The blast population appears in slightly different areas of the 
CD45-PerCP/Side scatter plot for each patient. For some patients, a blast cell 
population could not be identified. This may be where the sample was taken after 
treatment had been started, or due to degradation of the sample. 
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Figure 2-5 Gating strategy to identify CD34+ cells in two patients with haematological 
malignancies with high circulating CD34+ cells in peripheral blood. A Patient A7, an individual 
with MDS. B Patient A8, an individual with MF. The gating strategy is the same as that used in 
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2.10.1 Preparation of slides 
Samples were dewaxed in xylene twice for five minutes each, then washed twice in 
absolute ethanol and once in 95% ethanol each for two minutes. Endogenous 
peroxidase activity was blocked by incubating slides in 3% hydrogen peroxide in 
methanol for 20 minutes. Slides were then washed in tap water for one minute.  
Heat-induced epitope retrieval was performed by heating slides in a pressure-
cooker in a 10mM solution of trisodium citrate with 1mM EDTA at ph 6.5. The 
pressure-cooker cycle consisted of 4 minutes at 125oC, followed by 45 minutes of  
cooling to approximately 90oC. After the pressure-cooker cycle was complete, slides 
were washed in tap water for 1 minute.  
Immunostaining was carried out employing the streptavidin-biotin-
peroxidase method, using a Vectastain ABC Universal kit (Vector Laboratories, 
Peterborough) according to the manufacturer’s instructions. Slides were incubated in 
normal horse serum diluted in PBS for 30 minutes, before incubating in primary 
antibody for 30 minutes. Anti-ANKHD1 antibody HPA008718 by Atlas Antibodies, 
obtained from Sigma was used. All slides were stained with antibody from the same 
lot. Optimal primary antibody dilutions were established on sections of tonsil. A 
final antibody concentration of 8µg/ml (a 1:25 dilution of the stock antibody) was 
used. A rabbit polyclonal IgG antibody was used at the same concentration to stain 
an adjacent tissue section, as a control for non-specific antibody binding.  
Slides were then washed with PBS and incubated in biotinylated secondary 
antibody, blocked in horse serum, for 30 minutes. After washing with PBS, slides 
were incubated with a mixture of streptavidin and biotin-conjugated horseradish 
peroxidase for 30 minutes. Regions of antibody binding were visualised by 10 
minutes incubation with a solution of diaminobenzidine and horseradish peroxidase 
(Vector DAB kit). After washing, a nuclear counterstain was performed by 
immersing slides in Gill’s haematoxylin for 30 seconds, washing in tap water and 
blueing in Scotts’s tap water for 10 seconds. Slides were dehydrated through 70% 







Slides were photographed on a Leica DMI4000B inverted widefield microscope. 
 
2.11 Antibody validation 
A number of anti-ANKHD1 antibodies are available from the major antibody 
suppliers. These are raised against different epitopes in the protein, shown in Figure 
2-6. All antibodies are polyclonal, purified by affinity purification. With the 











Figure 2-6. Regions of ANKHD1 containing the sequences of the epitopes to which anti-ANKHD1 
antibodies investigated for use in this study were raised. 
 
These antibodies were examined with western blotting in two myeloma cell lines (U-
226 and JJN-3) and HeLa cells. To examine for possible nonspecific binding, HeLa 
cells in which ANKHD1 expression had been knocked down with siRNA were also 
examined (Figure 2-7 and 2-8). Sigma antibody HPA008718 gave the best 
combination of sensitivity and specificity based on western blots, although it is 
notable that some prominent bands were still seen with this antibody when 
ANKHD1 was knocked down.   
 Several of the antibodies were also compared using immunofluorescence in 
Hela cells (Figure 2-9). Sigma antibody HPA008718 was further examined in Hela 
cells in which a plasmid encoding the region of ANKHD1 containing the epitope the 
antibody was raised against was expressed, and in which ANKHD1 expression was 
knocked down with siRNA (Figure 2-10). 
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Sigma Anti-ANKHD1 (N-terminal) antibody SAB2700098 
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ANKHD1 siRNA    - - - + - - - +
Figure 2-7..Western blotting comparing sigma anti-ANKHD1 antibodies. Molecular 



























































































Film exposure          1-2 minutes                                       10 – 20 minutes
ANKHD1 siRNA    - - - + - - - +
Figure 2-8. Western blotting comparing Santa Cruz and Abcam anti-ANKHD1 









Increased FITC exposure, 
different field
Figure 2-9. Comparison of different anti-ANKHD1 antibodies using 
immunofluorescence in HeLa cells (sc-160960 D-12 and sc-160962 N-14 were 
not examined using immunofluorescence). Green anti-rabbit FITC, rabbit 
primary antibodies indicated on left. Blue DAPI nuclear counterstain. 
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Figure 2-10.Validation of anti-ANKKHD1 antibody HPA008718 (Sigma) using 
immunofluorescence in HeLa cells. In all images green = Alexa Fluor 488 conjugated 
anti-rabbit secondary antibody, blue = DAPI nuclear counterstain, scale bar = 10uM. 
Images A-D taken with identical exposure conditions. (A) Cells transfected with empty 
vector pCMV6. (B) Cells transfected with a construct encoding the first and second 
ankyrin repeat domains and intervening region, including the epitope the antibody was 
raised against. (C) Cells transfected with non-target siRNA. (D) Cells transfected with 
siRNA targetting ANKHD1. (E) Different field of view of cells from experiment shown in 







2.12 Statistical analysis 
Statistical analysis was carried out using Prism (Graphpad). Mean and standard 
deviation were used to describe continuous data. One-way ANOVA with Dunnett’s 
multiple comparisons test or Tukey’s multiple comparisons test was used to make 
comparisons between multiple groups. Paired t tests were used to make comparisons 






Chapter 3: ANKHD1 in normal blood and haematological 
malignancies 
3.1 Introduction 
Given the evidence that ANKHD1 positively regulates JAK/STAT signalling in 
laboratory models, I hypothesised that ANKHD1 may be involved in JAK/STAT 
activation in haematological malignancies. I wished to examine ANKHD1 
expression in haematological malignancies and the corresponding blood cells from 
healthy individuals. 
 
ANKHD1 in normal blood cells 
There has been some examination of ANKHD1 mRNA expression in blood cells, but 
little description of its expression at the protein level. ANKHD1 mRNA, as well as 
ANKHD1-EIF4EBP3 and a short isoform termed splice variant 4 have been detected 
in peripheral blood leucocytes, lymph node, spleen and bone marrow mononuclear 
cells using RT-PCR. In lymph node, expression of ANKHD1-EIF4EBP3 is higher 
than that of the other splice variants (Duarte, Traina et al. 2005). A second group has 
performed a similar examination of mRNA expression for these transcripts, although 
differences in the approaches used to normalise mRNA expression levels make 
comparisons between the two studies difficult (Miles, Janket et al. 2005). This group 
also examined mRNA expression in macrophages and dendritic cells differentiated 
in-vitro from monocytes extracted from PBMCs. Both expressed all three splice 
variants, and expression of the short isoform was particularly high in dendritic cells. 
In an in vitro model of myeloid differentiation in which the acute 
promyelocytic leukaemia cell line HL-60 is induced to differentiate by the addition 
of retinoic acid, expression of these transcripts is upregulated, with the greatest 
increase seen in ANKHD1-EIF4EBP3. This contrasts with the changes seen in a 
model of erythroid differentiation, in which non-adherent sub-cultures of PBMCs are 
treated with erythropoietin, where the greatest increase is see in ANKHD1 splice 
variant 4. These results suggest ANKHD1 may play a role in differentiation in 
haematopoiesis (Duarte, Traina et al. 2005).  
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ANKHD1 protein expression has been detected in lymph node but not 
peripheral blood mononuclear cells using western blotting. Using 
immunofluorescence, however, ANKHD1 has been detected in PBMCs. PBMCs 
consist of a heterogeneous group of blood cells, so this tells us little about which 
sub-types of blood cells ANKHD1 is expressed in (Traina, Favaro et al. 2006). 
 
ANKHD1 in haematological malignancies 
ANKHD1 mRNA expression has been shown to be higher in bone marrow from 
individuals with AML and ALL than bone marrow or PBMCs from healthy donors 
(Traina, Favaro et al. 2006). ANKHD1 mRNA expression is also higher in myeloma 
cells from patient bone marrow than it is in plasma cells purified from bone marrow 
or tonsils of healthy individuals (Dhyani, Duarte et al. 2012). ANKHD1 protein 
expression has not been examined in haematological malignancies. 
 
I designed a study protocol to allow examination of ANKHD1 expression in blood 
cells in individuals with haematological malignancies and healthy individuals.  
 
3.2 Results 
3.2.1 Patient characteristics 
Five groups of patients were included in the study: 
• Individuals under the care of haematology for a bone marrow biopsy or care 
for a haematological malignancy, who provided consent for an additional 
sample to be taken for the study (denoted by prefix B, summarised in Table 
3-1). 
• A 55 year old lady undergoing apheresis as a sibling donor (patient S1) who 
gave permission for the use of apheresis waste. 
• De-identified samples from presumed healthy individuals (denoted by prefix 
N). These samples were supplied by the diagnostic haematology laboratory 
from material that would otherwise be discarded as waste. Samples were 
selected from individuals attending an outpatient clinic which was not 
haematology or oncology, who had a normal full blood count. Five samples 
were examined. Three individuals were female, and two were male. Mean 
age was 52, range 28 – 65. 
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• De-identified samples from individuals undergoing apheresis  (denoted by 
prefix CD34, summarised in Table 3-2) 
• De-identified samples from individuals with a haematological malignancy 
(denoted by prefix A, summarised in Table 3-3). 
Clinical information for the de-identified samples is limited by the ethics permission 
granted to access these samples. 
Table 3-1. Individuals who consented to provide an additional sample for research (details removed 
from library copy of thesis to protect patient anonymity). 
Patient 
number 




B2     M 
 
B3     M 
B4     M 
B5     M 
B6     M 
B8     B 
B9     B 
B10     B 
 
Table 3-2. Individuals whose samples were analysed for ANKHD1 expression in CD34+ cells.  
Patient number Gender Age Indication 
CD34 1 F 70 Autologous 
CD34 2 F 67 Autologous 
CD34 3 F 30 Unknown 
CD34 4 F 30 Unknown 
CD34 5 F 36 Unknown 






Table 3-3. Patient characteristics of the individuals whose de-identified blood or marrow samples 
were analysed for ANKHD1 expression in haematological malignancies.  
Patient 
number 
Gender Age Diagnosis Marrow (M) or blood 
(B) 
A1 F 37 AML M 
A2 F 66 Acute leukaemia B 
A3 M 81 Acute leukaemia B 
A4 65 65 AML, relapsed M 
A5 M 90 AML M 
A6 M 50 ALL (B lymphocytic) M 
A7 M 76 Myelodysplastic syndrome 
with CD34+ cells in blood 
M 
A8 M 63 MF with circulating CD34+ 
cells in blood 
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3.2.2 Quantitative real time PCR 
mRNA of full-length ANKHD1 can be detected in bone marrow mononuclear cells 
(BMMCs). BMMCs for this stage of the study were extracted from bone-marrow 
aspirate from patients with a range of haematological malignancies undergoing bone 
marrow biopsy for remission monitoring or prior to stem cell transplantation. The 
level of mRNA expression (relative to β actin mRNA) is about one third to two 
thirds of that found in HeLa cells (Figure 3-1 A). This is consistent with a previous 
study showing higher ANKHD1 mRNA expression in cell lines than PBMCs 
(Traina, Favaro et al. 2006).  
 
3.2.3 Western Blotting 
Having established that mRNA for ANKHD1 could be detected in BMMCs, I went 
on to determine whether ANKHD1 protein could be detected in protein extracts from 
these cells, and cells from other patients. No full length ANKHD1 was detected in 
protein extracts from patient cells (Figure 3-1 B). In some cases actin was not 
detected in the protein extract, suggesting a problem with the method for sample 
preparation. However, even in the samples where actin was readily detected no 
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Figure 3-1. Detection of ANKHD1 in PBMCs and BMMCs. (A) ANKHD1 mRNA can be 
detected in BMMCs, but levels are lower than those in HeLa cells. Actin was used as a 
reference gene, and quantification performed using the delta delta ct method. (B) No 
protein of the molecular weight corresponding to full-length ANKHD1 (269kDa) can be 
detected in BMMCs and PBMCs using western blotting, although bands are seen at 
approximately 75, 100 and 150 kDa. See section 3.2.1 for details of the patients from 
whom these samples were obtained. C Full length ANKHD1 can be detected in primary 

































































































 bands corresponding to proteins of lower molecular weight (approximately 150kDa, 
100kDa, 75kDa and 25kDa) were seen. It is not clear if these correspond to shorter 
isoforms of ANKHD1 or if they are indicative of non-specific antibody binding. 
Some erythrocytes may have been retained in the BMMC separation procedure, and 
would contribute to the actin band.   
 It is possible that the failure to detect ANKHD1 in PBMC and BMMC 
samples is because of the lack of sensitivity of western blotting and the signal-to-
noise ratio. BMMCs or PBMCs comprise a heterogeneous group of cells, and 
ANKHD1 could be expressed only in a sub-group of normal cells. Furthermore, 
ANKHD1 may be expressed only in certain malignancies but not in the 
corresponding normal cell type. The patients for whom bone marrow aspirate was  
examined at this stage of the study were clinically well and had their bone marrow 
biopsies taken for remission monitoring or prior to stem cell transplantation. The 
peripheral blood samples were from patients who had AML and circulating blast 
cells, but the percentage of blasts was relatively low. It is possible that in all these 
patients ANKHD1 was present in the malignant cells but not detected because the 
malignant cells were rare relative to other cells in the population. 
 To address this and examine whether ANKHD1 is expressed in malignant 
cells, primary cells growing in culture from a patient with plasma cell leukaemia 
were examined. Full length ANKHD1 was detected in these cells using western 
blotting (Figure 3-1 C.) 
 To further examine whether ANKHD1 was expressed only in particular sub-
populations of normal or malignant blood cells flow cytometry and 
immunofluorescence microscopy methods were developed to examine ANKHD1 
expression.  
 
3.2.4 ANKHD1 expression in normal blood cells 
Flow cytometry 
ANKHD1 was is found in monocytes and lymphocytes, but absent from neutrophils, 
a result which was consistent across all five individuals (Figure 3-2). 
Immunofluorescence 
Immunofluorescent staining of blood films corroborated these results (Figure 3-3). 
Immunofluorescence showed qualitatively similar results across all five individuals  


























Figure 3-2. Flow cytometry shows ANKHD1 is absent from neutrophils but expressed in 
lymphocytes and monocytes. A Histograms show Alexa Fluor 488 fluorescence in the 
presence of anti-ANKHD1 primary antibody (red) or IgG isotype control primary 




































Figure 3-3. Immunofluorescence shows ANKHD1 is absent from neutrophils but found in 
monocytes and lymphocytes. No staining was seen with secondary antibody only (data 




(data not shown). For the immunostaining, cell type was determined by examining 
nuclear morphology using DAPI staining. The characteristic nuclei of neutrophils 
enabled identification, but distinction between monocytes and lymphocytes, 
particularly activated lymphocytes, may have been less reliable.  
 
3.2.5 ANKHD1 in haematopoietic stem cells 
To consider whether ANKHD1 may play a role in blood cell development, I wished 
to determine the expression of ANKHD1 in haematopoietic stem and progenitor 
cells (HSCs). These cells are found within the population of cells in the blood and 
bone marrow expressing the cell-surface glycoprotein CD34, although CD34 is also 
found on epithelial cells.   
 Peripheral blood from individuals undergoing stem cell harvest for an 
autologous or allogeneic transplant was used to examine ANKHD1 expression in 
CD34+ cells. There was variation between individuals in the ANKKHD1 expression 
in CD34+ cells, with the cells of some individuals showing an increase in 
fluorescence when stained with anti-ANKHD1, and others showing only a small 
difference in fluorescence intensity compared to isotype control Figure 3-4). This 
may have been related to variations between experimental runs, as well as variations 
between individuals.  
 
3.2.6 ANKHD1 in haematological malignancies 
ANKHD1 expression was examined in the malignant clone of cells in 
haematological malignancies using flow cytometry. The samples examined 
represented a combination of samples from individuals who were recruited to the 
study and provided an additional sample specifically for the study, and samples 
obtained from the diagnostic haematology laboratory as de-identified samples. The 
diseases examined depended upon the samples which were being analysed by the 
diagnostic laboratory. Most samples were from individuals with acute leukaemia. 
However, the group also includes a sample from an individual with myelofibrosis 
and an individual with myelodysplasia, both of whom had high counts of circulating 
CD34+ cells. 
In all samples from patients with acute leukaemia in whom blasts were 
identified, the median fluorescence intensity of the ANKHD1-stained blasts was  
CD34 1                                      CD34 2                                     CD34 3



































Figure 3-4. ANKHD1 is expressed in CD34+ cells in individuals undergoing 
harvests for stem cell transplants, but there is variation between individuals. A 
Histogams showing fluorescence with ANKHD1 primary antibody (red) compared 
to IgG isotype control antibody (blue). B Staining index for the six samples 




higher than that of isotype-stained blasts (Figure 3-5). Immunofluorescence on a 
blood film from one patient showed blasts that expressed ANKHD1 (Figure 3-6). 
 For the two individuals with high counts of circulating CD34+ cells, 
ANKHD1 expression was examined in the CD34+ cells. ANKHD1 expression in the 
CD34+ cells in the individual with PMF was low, comparable to that in the cells 
from the individuals undergoing apheresis at the lower end of the range of ANKHD1 
expression (Figure 3-7 A). For the individual with myelodysplasia and circulating 
CD34+ cells, the CD34+ population appeared to contain two sub-populations of 
cells, one of which expressed ANKHD1 and one of which was apparently ANKHD1 
negative (Figure 3-7 B). However, in the IgG-isotype-stained cells from the same  
sample a similar bimodal pattern of fluorescence was seen and there was 
considerable overlap between the cell populations.  
 
3.2.7 Summary of ANKHD1 expression in blood cells 
The ANKHD1 staining indices of all the normal and malignant cell populations 
examined are summarised in Figure 3-8. It is notable that ANKHD1 expression in 
blasts from patients with acute leukaemia is higher than other cell types. Comparison 
of these populations (excluding the MF and MPN groups, which each included only 
one individual) showed a significant difference between them (P = 0.0004, one way 
ANOVA). The groups between which there were significant differences were acute 
leukaemia blasts and neutrophils (P < 0.001), acute leukaemia blasts and monocytes 
(P < 0.01) and acute leukaemia blasts and CD34+ HSCs (P < 0.05) (Tukey’s 
multiple comparisons test). 
 
3.3 Discussion 
ANKHD1 mRNA expression is increased in acute leukaemia and myeloma, and in 
laboratory models contributes to the malignant behaviour of cancer cells. In this 
study I have established the expression of ANKHD1 protein in normal blood cells 






















Figure 3-5 ANKHD1 protein is expressed in blast cells in patients with acute leukaemia. A 
Histograms showing the difference in fluorescence intensity in cells stained for ANKHD1 (red) 
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Figure 3-6. Immunofluorescence shows that ANKHD1 is expressed in blast cells in the 












Figure 3-7. ANKHD1 expression in CD34+ cells from two patients with high CD34+ 
counts due to haematological malignancies. A Fluorescence of CD34+ cells from a 
patient with MF (Patient A8) stained with an anti-ANKHD1 antibody (red) is comparable 
to that of cells stained with polyclonal IgG isotype antibody (blue). The staining index is 
0.76 and the fold change in median fluorescence intensity is 1.6, comparable to the 
CD34+ cells from patients undergoing apheresis at the lower end of the range of 
ANKHD1 expression. B Fluorescence of CD34+ cells from a patient with MDS (Patient 
A7) stained with anti-ANKHD1 antibody (red) appear to contain two sub-populations of 
cells, with different levels of ANKHD1 expression. Staining with IgG isotype (blue) shows 
a similar bimodal pattern of fluorescence, and there is considerable overlap between the 



















































Figure 3-8. Summary of ANKHD1 staining indices for the different normal and malignant 







3.3.1 Assessment of ANKHD1 expression with qPCR and western 
blotting, and modification of original experimental design 
qPCR suggests that ANKHD1 is expressed in bone marrow at the mRNA level, 
albeit at about one tenth of the level seen in HeLa cells. No ANKHD protein was 
detected in BMMCs and PBMCs using western blotting, but it was highly expressed 
in primary cells derived from a patient with plasma cell leukaemia. It is possible that 
these differences were due to the amount of protein loaded. These results suggested 
that a technique that allowed assessment of individual cells in a heterogeneous 
population would be more informative, so a flow cytometry protocol was developed.  
I had problems recruiting adequate numbers of patients. Specifically, it was 
difficult to obtain an additional sample of blood or marrow from patients at a time 
when the malignant clone of cells was likely to be large enough to be detected using 
western blotting. It was a requirement of the ethics permission that potential study  
participants had at least 24 hours to consider study participation. Most individuals 
undergoing bone-marrow biopsies as outpatients, who received study information in 
the post, were having their biopsies for remission monitoring or prior to transplant, 
so would be anticipated to have very low numbers of malignant cells. Many 
inpatients had their diagnosis made in a district hospital before being referred to 
Sheffield. For individuals undergoing a bone marrow biopsy in Sheffield, often there 
was insufficient time for participants to consider the study.  
The development of flow cytometry as an assay for ANKHD1 expression 
partially overcame problems of patient recruitment as sufficient data could be 
gathered from small sample volumes (100µ1) using flow cytometry. This meant that 
additional bone marrow and blood draws were not necessary as samples which were 
surplus to requirements for clinical testing that would otherwise be discarded as 
waste could be used. Furthermore, if samples were de-identified by NHS laboratory 
staff it is considered ethically acceptable for such surplus ‘waste’ samples to be used 
for research without  obtaining specific patient consent. I obtained approval from the 
Research Ethics Committee for a substantial amendment to my study that enabled 
the use of surplus de-identified samples from the NHS haematology lab, increasing 




3.3.2 Flow cytometry as an approach to examine ANKHD1 
expression 
I developed a method to examine ANKHD1 expression in normal blood cells and in 
haematological malignancies using flow cytometry. This technique was chosen as it 
enabled analysis of single cells, including rare populations, in part by utilising the 
expertise of the Sheffield Haematology-Oncology Diagnostic Service.  
I encountered challenges developing a flow cytometry assay for ANKHD1 as 
no fluorescently-conjugated antibodies against ANKHD1 are commercially 
available. I used an approach employing a fluorescently labelled secondary antibody, 
and a polyclonal IgG as an isotype control. Although there are arguments against 
using an isotype control in flow cytometry, its use can be justified here. As samples 
were gathered prospectively and analysed in several batches, the isotype provides 
some control for variations in experimental runs, although the use of saved 
instrument settings and daily quality control of the cytometer in the diagnostic lab 
should have also minimised this. The protein concentration of both antibodies was 
known, so the same concentration could be used for test and control. The use of a 
secondary antibody reduces problems with fluorophore ratio that can occur when 
conjugated test and isotype antibodies are used. ANKHD1 is an intracellular antigen 
necessitating a permeabilisation step. The use of an isotype should have controlled 
for nonspecific retention of antibody within cells. When examining blood cells, 
antibody binding to Fc receptors is relevant. The isotype ought to control for this, 
although an Fc-blocking reagent could have been used as an alternative.   
It has been difficult to choose an appropriate statistical analysis for the flow 
cytometry data. Other published work has shown superimposed histograms for 
isotype and test antibodies, or used the fold change in fluorescence intensity for 
comparison. However, I have been unable to find literature indicating what statistical 
test to use to determine whether the fold change is significant. Choice of statistical 
tests ought to take account of the non-parametric data produced by flow cytometry. 
The resolution index and staining index are two statistics used in flow cytometry to 
compare test and control antibodies, and they carry the advantage over consideration 
of fold changes in fluorescence intensity that the spread of the data is considered 
(Hulspas, O'Gorman et al. 2009). However, I have not been able to find information 
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on how to interpret these values to determine whether a difference is significant. In 
this work, the reduction in fluorescence intensity when ANKHD1 is knocked down 
in cultured cells, and the apparent lack of ANKHD1 in neutrophils acting as an 
internal negative control, must be used as an indicator of the validity of the approach.  
 
3.3.3 ANKHD1 expression in normal peripheral blood cells 
This work adds to our knowledge of ANKHD1 expression in blood cells. Previous 
studies of ANKHD1 in blood cells have been limited to mRNA. The only study to 
examine ANKHD1 protein failed to show ANKHD1 in PBMCs using western 
blotting, and demonstrated immunofluorescence only of PBMCs rather than specific 
cell types.  
Based on my work, ANKHD1 appears to be expressed in lymphocytes and 
monocytes, but absent from neutrophils. This variation in expression suggests 
ANKHD1 function may relate to aspects of the behaviour of monocytes and 
lymphocytes which is not required in neutrophils. These results are consistent across 
samples from five patients, but a larger sample size would give a more reliable 
assessment of ANKHD1 expression. 
 ANKHD1 expression in erythrocytes was not examined using flow 
cytometry, with a red-cell-lysis step being included in the flow cytometry protocol. 
Some assessment of ANKHD1 in erythrocytes can be made from the 
immunofluorescence of blood films. The fluorescence of red cells stained with 
ANKHD1 did not seem qualitatively different to that in films with secondary 
antibody only. It did look as though some bright puncta of antibody staining were 
present at the periphery of the cells (Figure 3-3), but as there was not an IgG control 
for these slides it is not clear whether this is an artefact.  
 It would be interesting to perform a more detailed examination of ANKHD1 
expression in sub-types of blood cells. Flow cytometry would be a suitable approach 
for this since antibodies against CD markers can be used to define cell types. In 
particular, examining variations in ANKHD1 expression amongst lymphocyte sub-
types would be interesting. Both the flow cytometry data here, and 
immunohistochemical examination of ANKHD1 in tonsil performed whilst 
optimising antibody staining for melanoma tissues suggest that a small proportion of 




3.3.4 ANKHD1 in haematopoietic stem cells and haematological 
malignancies 
Previous studies of ANKHD1 expression in haematological malignancies have used 
real-time PCR to examine mRNA expression. This work corroborates published data 
that showed expression of ANKHD1 mRNA in acute leukaemias by demonstrating 
that ANKHD1 protein is expressed in blasts in these patients. The limited clinical 
data available on the patients from whom these samples were obtained means 
comparison cannot be made with the corresponding normal myeloid or lymphoid 
lineage. This work also adds to our knowledge of ANKHD1 expression in myeloma, 
which had previously been examined using qPCR and in cell lines. 
 This work suggests that ANKHD1 is expressed in haematopoietic stem cells, 
although there is some apparent variation between individuals. Examination of 
samples from a much larger group is needed to establish this. Furthermore, some of 
the differences observed may be due to variations related to the experimental run, 
rather than variations between individuals. A caveat to my examination is that the 
cells I examined are from individuals who received G-CSF to mobilise stem cells. 
The stem cells mobilised by G-CSF differ slightly from bone-marrow resident stem 
cells, for example they are skewed towards the myeloid lineage. It should also be 
noted that G-CSF is a JAK/STAT pathway ligand, although I was not examining 
JAK/STAT activation in these cells. Examination of CD34+ stem cells from normal 
bone marrow would be informative here. Bone marrow considered to be near to 
normal, for example marrow obtained during orthopaedic surgery or normal bone 
marrow biopsies performed for disease staging in individuals with lymphoma might 
be easier to obtain. 
 The data on ANKHD1 expression in CD34+ cells in individuals with 
malignant diseases affecting the CD34+ compartment is interesting preliminary data, 
although a larger number of individuals must be examined to draw any conclusions. 
CD34+ cells from an MPN patient do not appear to have higher expression of 
ANKHD1 than normal CD34+ cells, suggesting it may not be involved in 
pathogenesis. The apparent presence of a population of CD34+ cells lacking 
ANHKD1 expression in an individual with myelodysplasia appeared notable, until 
the isotype control indicated that this was a feature of antibody binding, not specific 
115 
 
to the ANKHD1 antibody. ANKHD1 expression in myelodysplasia would 
nonetheless be an interesting avenue for future investigation. In some patients, 
myelodysplasia is associated with a deletion of the long arm of chromosome 5, the 
chromosomal location of ANKHD1. Furthermore, altered RNA metabolism appears 
to play a role in the pathogenesis of myelodysplasia, as mutations affecting 
components of the splicing machinery are common and altered ribosome biology is 
implicated in 5q syndrome. The KH domain in ANKHD1, a domain which binds 




This work is the first to examine ANKHD1 protein expression in sub-types of cells 
in peripheral blood, suggesting that it is expressed in lymphocytes and monocytes 
but absent from neutrophils. ANKHD1 appears to be expressed in haematopoietic 
stem cells, and in the malignant clone of cells in several haematological 
malignancies. Further work in well-defined cohorts of patients is needed to confirm 
these findings. It remains to be determined what cellular functions ANKHD1 
performs in these cells, whether it affects intracellular signalling, and whether 
ANKHD1 expression carries any prognostic information for patients with 





Chapter 4: ANKHD1 in melanoma 
4.1 Introduction 
Malignant melanoma is a malignant neoplasm of melanocytes, neural-crest-derived 
cells. Cutaneous primary tumours are the most common, although melanoma can 
also arise in other sites where melanocytes are present, for example ocular melanoma 
and mucosal melanomas. UV exposure is an important aetiological factor. Melanoma 
is the fifth commonest cancer in the UK, with an incidence of around 13,000 new 
cases per year. 10 year survival is about 90%, but this varies according to tumour 
stage. For patients with melanoma at an early stage, 5 year survival is comparable to 
matched populations. For those with melanoma that has metastasised beyond local 
lymph nodes, however, 5 year survival is 8% in men and 25% in women 
(CancerResearch-UK). 
 Primary melanoma is treated by surgical excision, and patients monitored for 
recurrence or metastasis. Patients with metastatic melanoma are treated with BRAF 
inhibitors and checkpoint inhibitors. At present, for patients who have had surgical 
excision of a primary melanoma there is no adjuvant treatment to reduce the risk of 
recurrence. However, BRAF inhibitors and checkpoint inhibitors are now being 
investigated in this setting. To guide investigation of adjuvant treatments, methods to 
identify patients at risk of recurrence are needed. Tumour thickness is the most 
important predictor of recurrence risk. It is reported in terms of the Breslow 
thickness, measured from the granular layer of the epidermis to the deepest point of 
tumour invasion. Histological features such as lymphovascular invasion, mitotic rate 
and the briskness of the tumour infiltrating lymphocyte response may add to this. 
However, better approaches to predict recurrence risk are needed.  
 
Histopathology of melanoma 
Melanoma can be classified into several histological sub-types, the major groups 
being superficial spreading melanoma, lentigo maligna melanoma, nodular 
melanoma and acral lentiginous melanoma. Superficial spreading melanoma is the 
commonest histological sub-type. It is found in young and middle-aged patients, on 
skin sites that are intermittently sun exposed. Lentigo maligna melanoma classically 
occurs in elderly patients, in skin sites which have been persistently exposed to 
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sunlight. Nodular melanoma occurs in middle age and is commonest on the trunk 
and limbs. Acral lentiginous melanomas are those on the palms, soles and around the 
nails. Rarer sub-types of melanoma include desmoplastic, naevoid and spizoid 
melanomas. The histopathological diagnosis of these melanoma types can be 
challenging. 
An important histological feature in the assessment of melanoma is the 
Breslow thickness. This is related to the growth phase of the melanoma. In the radial, 
or horizontal, growth phase malignant cells are found only in the epidermis and 
superficial dermis. Melanoma cells at this stage are thought to lack the potential to 
metastasise. As the tumour progresses the properties of the cells change and they 
acquire the capacity to invade. In the vertical growth phase melanoma cells are found 
deeper in the dermis, where they proliferate and form an expanding tumour mass. 
Nodular melanoma consists entirely of tumour in the vertical growth phase, whereas 
the other common sub-types may consist of only radial growth phase, or have 
components of radial growth phase and vertical growth phase (McKee 2005, 
Underwood and Cross 2013, Elder 2015).  
 
Signalling pathways in melanoma 
Aberrant activation of intracellular signalling pathways plays a role in disease 
pathogenesis in melanoma. Targeting signalling via the Ras/Raf/MEK/ERK 
signalling pathway with BRAF inhibitors, and more recently combining a BRAF 
inhibitor and MEK inhibitor, has shown some success as a therapeutic strategy in 
patients with metastatic melanoma (Chapman, Hauschild et al. 2011, Long, 
Stroyakovskiy et al. 2014). However, development of resistance to these therapies 
prevents responses from being sustained. Further understanding of the mechanisms 
leading to activation and regulation of Ras/Raf/MEK/ERK signalling, and other 
intracellular signalling pathways activated in melanoma, should lead to improved 
treatment options for patients with melanoma. Strategies that use molecular 
approaches to classify disease and help to refine prediction of prognosis and 
treatment response may contribute to this.       
 Other signalling pathways activated in melanoma include JAK/STAT 
signalling and Hippo signalling. The presence of nuclear pSTAT3 is associated with 
increased risk of recurrence and death in patients with melanoma, and suppressing 
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STAT3 activation leads to apoptosis in melanoma cell lines (Messina, Yu et al. 
2008, Bill, Fuchs et al. 2010). Nuclear localization of the transcriptional regulators 
YAP and TAZ, effectors of the Hippo pathway, has been described in some 
melanoma tissue samples. Cell and mouse models suggest YAP and TAZ promote 
tumour invasiveness in melanoma. The upstream signaling events that cause this 
nuclear localization in melanoma have not yet been identified. Interestingly, nuclear 
localization of YAP and TAZ is also observed in some benign naevi (Nallet-Staub, 
Marsaud et al. 2014). 
 
Investigation of ANKHKD1 in melanoma 
ANKHD1 has been identified as a positive regulator of JAK/STAT, 
Ras/Raf/MEK/ERK and Hippo signalling in Drosophila (Smith, Carroll et al. 2002, 
Müller, Kuttenkeuler et al. 2005, Sidor, Brain et al. 2013). ANKHD1 has also been 
shown to positively regulate JAK/STAT and Hippo signalling in human cancer cell 
lines (Müller 2012, Sansores-Garcia, Atkins et al. 2013). ANKHD1 promotes 
progression through the cell cycle, and suppresses expression and activity of the 
CDK inhibitor p21 (Dhyani, Machado-Neto et al. 2015). 
          As ANKHD1is a modulator of several intracellular signaling pathways known 
to be involved in melanoma, and promotes aspects of the malignant phenotype in 
other types of cancer cells, I hypothesized that ANKHD1 might play a role in 
melanoma. Little is currently known about ANKHD1 expression in melanoma. The 
human protein atlas shows immunohistochemistry for ANKHD1 for twelve samples 
of melanoma, three of which are metastatic, in a tissue microarray. Further 
information about histological sub-types is not available, however (Uhlen, Oksvold 
et al. 2010). To determine whether further investigation of ANKHD1 in melanoma 
would be informative, I wished to profile ANKHD1 expression in melanoma. I 
examined the expression of ANKHD1 and proteins in the signaling pathways with 
which it interacts in two melanoma cell lines. I then examined ANKHD1 expression 
in an in vitro model of melanoma invasion in engineered skin. Following these initial 
experiments in cell lines, ANKHD1 protein expression and localization in surgically 





4.2.1 ANKHD1 expression in melanoma cell lines 
To investigate ANKHD1 expression in melanoma cells two cell lines, representing 
an invasive (C8161) and a less invasive (HBL) melanoma phenotype were examined.  
 Western blotting shows that ANKHD1 is expressed in both cell lines, and its 
expression can be knocked down using siRNA targeting ANKHD1 mRNA. The 
C8161 cell line shows a greater reduction in ANKHD1 protein levels following 
knockdown than the HBL line (Figure 4-1A).  Cellular localisation of ANKHD1 in 
these two cell lines was examined using immunofluorescence. In both cell lines 
ANKHD1 was found in the cytoplasm and the nucleus, but in HBL cells it was 
found predominantly in the cytoplasm, whereas C8161 cells showed a more even 
distribution between nucleus and cytoplasm, and there is accentuation around the 
nucleus (Figure 4-1B). 
 
4.2.2 Expression of signalling pathway proteins in melanoma cell 
lines 
Proteins in signalling pathways modulated by ANKHD1 were also examined in these 
cell lines. Western blotting shows that both cell lines express JAK2, STAT1 and 
STAT3 (Figure 4-2A). However, no constitutive phosphorylation of these 
JAK/STAT pathway components could be detected with western blotting (data not 
shown).  
YAP is seen in both cell lines, but in HBL cells it is predominantly located in 
the nucleus whereas in C8161 cells there is no prominent localisation of YAP to the 
cytoplasm (Figure 4-2B). It is difficult to make comparisons between the two cell 
lines as in these images the C8161 cells are more confluent than HBL cells. Contact 
with neighbouring cells is known to cause loss of nuclear localisation of YAP.  
Western blotting shows that p21 can be detected in HBL cells, but appears to 
be absent from C8161 cells (Figure 4-3 A). Immunofluorescence to examine p21 in 
HBL cells shows it to be located in the nucleus and expression levels to vary 
between cells, as would be expected for a protein involved in cell-cycle regulation 
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Figure 4-1. Examination of ANKHD1 expression in melanoma cell lines. (A) Western 
blotting shows that ANKHD1 is expressed in the melanoma cell lines HBL and C8161. 
ANKHD1 expression can be knocked down with shRNA targetting ANKHD1. Comparison is 
shown with cells treated with a non-target shRNA. A greater reduction in protein expression 
is seen in C8181 cells compared to HBL cells. (B) Immunofluorescence shows that in HBL 
cells ANKHD1 is found predominantly in the cytoplasm, but is also in the nucleus. In C8161 
cells there is a more even distribution of ANKHD1 between the nucleus and cytoplasm, 
with some accentuation of the nuclear membrane. Green Alexa Fluor 488 anti-rabbit 
secondary antibody, anti ANKHD1 primary antibody. Blue DAPI. Scale bar 50µM.
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Figure 4-2. Expression of signalling pathway proteins in melanoma cell lines. Western blotting 
shows that the melanoma cell lines HBL and C8161 express JAK2 and STATs 1 and 3. Lysate 
from HeLa cells is loaded as a positive control. B Immunofluorescence shows that the Hippo 
pathway effector YAP is expressed in melanoma cell lines. Nuclear localisation of YAP is seen 
in HBL cells. There is no prominent nuclear localisation of YAP in C8161 cells, although in 
these images the C8161 cells are more confluent than the HBL cells. Green anti-rabbit Alexa 
Fluor 488 conjugated secondary antibody, anti-YAP primary antibody. Blue DAPI. Scale bar 
50µm.
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Figure 4-3 Examination of p21 protein expression in melanoma cell lines. (A) Western blotting 
shows that p21 can be detected in HBL cells but not C8161 cells. (B) Immunofluorescence shows 
p21 localised in the nucleus of HBL cells. Expression varies between cells, as would be expected 
of a cell-cycle protein. Green anti-rabbit Alexa Fluor 488 conjugated secondary antibody, anti p21 




4.2.3 ANKHD1 expression in invasive melanoma in engineered skin 
There are limitations to the inferences about cell behaviour that can be made from 
examining cell lines growing in a monolayer in tissue culture vessels. To gain a 
better understanding of ANKHD1 expression and localisation in melanoma, samples 
of engineered skin containing invading cells from the melanoma cell line C8161 
were examined (see section 2.1.1 for details of tissue engineered skin). Formalin-
fixed paraffin-embedded samples were examined using immunohistochemistry. In 
this context, C8161 cells show ANKHD1 expression in the nucleus and cytoplasm, 
with stronger expression in the nucleus. Keratinocytes also show ANKHD1 
expression, with stronger expression in the nucleus than the cytoplasm (Figure 4-4). 
 
4.2.4 Patient Characteristics and histological features 
Having established that ANKHD1 is expressed in two melanoma cell lines, I went 
on to examine ANKHD1 expression in surgically excised melanoma tissue samples 
from 34 patients. All patients had cutaneous melanoma. Patient characteristics are as 
follows: 
Table 4-1. Patient characteristics of patients from whom melanoma samples were obtained 
Age Mean 60 years 
Range 24 to 86 years  
Standard deviation 16 years  
Site Arm 7 
Back 6 
Chest 2 
Face or head 7 
Leg 10 
Lymph node metastasis 1 
Lung metastasis 1 
Histological sub-type Desmoplastic 1 















Standard deviation 2.3 
Range 0-11.5 
 
4.2.4 Immunohistochemistry and tumour histological features 
ANKHD1 expression and localisation was examined by visualising sites of anti-
ANKHD1 antibody binding using diaminobenzidine (DAB), a brown stain. Melanin 
was rarely prominent in the sections, and where present could be distinguished from 
DAB by its granular distribution. Furthermore, each sample was compared to an 
adjacent section prepared with a polyclonal IgG rabbit antibody which also enabled 
consideration of nonspecific antibody binding and endogenous peroxidase activity. 
The cellular location and intensity of staining was assessed.  
Slides were examined by Dr. Nick Tiffin, a consultant Dermatopathologist at 
the Royal Hallamshire Hospital. Histological features were assessed on a 
haematoxylin and eosin stained section. In addition to the histological features 
described above, an assessment was also made of other histological features which 
influence prognosis: mitotic rate, the presence of perineural and vascular invasion, 
the presence of microscopic satellites, whether regression had occurred, whether 
there was ulceration, and the tumour infiltrating lymphocyte response. The mitotic 
rate is the total number of mitotic figures in 1mm2 in the region of the tumour where 
they are most abundant. Higher mitotic rate is associated with worse prognosis. 
Vascular invasion, with tumour cells present within blood vessels, in the walls of 
vessels or around the exterior of vessels is associated with reduced survival. 
Perineural invasion is associated with increased risk of recurrence, although this may 
be partly attributable to its prevalence in desmoplastic melanoma, which carries a 
worse prognosis than some other histological variants. Microscopic satellites are 
nests of tumour cells separate from the main tumour mass and deep to the thickest 
region of the tumour. The presence of microscopic satellites is associated with 
increased risk of recurrence and reduced survival. Regression refers to the presence 
of areas within the tumour which have been replaced by fibrous tissue. It is  
Figure 4-4. Cells of the melanoma cell line C8161 invading into tissue engineered skin show cyto-
plasmic and nuclear staining of ANKHD, with moderate to strong nuclear staining. Keratinocytes 
show a similar expression pattern. (A) H&E stained section. (B) Immunohistochemistry for ANKHD1 
in adjacent section. Scale bar 100µm.










associated with worse prognosis, possibly because it is an indicator of previous 
tumour thickness. Ulceration, where the continuity of the epithelium over the tumour 
is lost, is associated with increased risk of metastasis. Tumour infiltrating 
lymphocytes (TIL), defined as lymphocytes which infiltrate the tumour and are in 
contact with the melanoma cells, carry prognostic significance. A brisk TIL response 
is associated with better survival than non-brisk or absent TIL (McKee 2005, Elder 
2015).      
  
4.2.5 ANKHD1 staining patterns 
Qualitative assessment of staining patterns in histological sub-types  
Superficial spreading melanoma is the commonest histological type at the population 
level and in the samples in this study. The melanoma cells in superficial spreading 
melanoma in radial growth phase often showed moderate or strong nuclear staining 
(Figure 4-5). Superficial spreading melanoma in vertical growth phase appeared to 
have a different staining pattern, with relatively low nuclear and cytoplasmic 
ANKHD1 (Figure 4-6). In superficial spreading melanoma where intra-epidermal 
cells were prominent these generally had stronger nuclear staining than the 
corresponding dermal tumour cells in the same patient. The three samples of nodular 
melanoma showed relatively low levels of nuclear and cytoplasmic ANKHD1 
expression, similar to that in vertical growth phase superficial spreading melanoma 
(Figure 4-7). Four samples of metastatic melanoma were available although one of 
these samples consisted entirely of necrotic tumour and did not contain enough cells 
for analysis. The samples of metastatic melanoma show a similar pattern of 
ANKHD1 expression to that seen in nodular melanoma, with relatively low nuclear 
and cytoplasmic expression (Figure 4-8). Qualitatively the examination of ANKHD1 
staining suggested that thinner melanomas and intra-epithelial melanoma cells 
showed more nuclear staining for ANKHD1 than thicker melanomas. 
 
Quantitative assessment of staining patterns in histological sub-types  
To make a quantitative assessment of ANKHD1 expression a scoring system was 
devised. Nuclear staining and cytoplasmic staining were assessed separately, and 
each was categorised as strong, moderate, weak or absent. Examples of these 
categories of staining are shown in Figure 4-9. In each slide the category of nuclear  
B
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Figure 4-5. Superficial Spreading Melanoma in radial growth phase showing some cells with strong 
nuclear staining. Melanoma thickness in this specimen was 0.6mm. A H&E stained section. B 
Immunohistochemistry for ANKHD1 in adjacent section. Scale bar 100µM. 
A
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Figure 4-6. Superficial Spreading melanoma in vertical growth phase, showing mostly weak nuclear 
staining for ANKHD1 and moderate and weak cytoplasmic staining. Melanoma thickness in this 
specimen was 1.1mm. A. H&E stained section B. Immunohistochemistry for ANKHD1 in adjacent 
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Figure 4-7. Nodular melanoma shows uniform weak cytoplasmic staining for ANKHD1 and uniform 
weak nuclear staining, note the visibility of the nuclear counterstain in many cells. This specimen 
was a thick melanoma, 7mm thick. a H&E stained section, b immunohistochemistry for ANKHD1 in 
adjacent section. Scale bar 100µm.
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Figure 4-8. Metastatic melanoma shows uniform cytoplasmic staining for ANKHD1 and variable 
nuclear staining. A H&E stained section, B immunohistochemistry for ANKHD1 in adjacent section. 
Scale bar 100µm.
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Figure 4-9. Four categories of staining intensity were assigned to the nucleus and cytoplasm, most 
of which are shown in this 40x magnification image from an individual with metastatic melanoma. 
Scale bar 10µM. A Whole image. B Expanded images of cells with examples of nuclear staining 
categories. B Expanded images of cells with examples of cytoplasmic staining categories.
1. Nuclear staining absent. 2. Nuclear staining weak - details of nuclear architecture clearly visible
3. Nuclear staining moderate - nuclear arthitecture can be distinguished, intermediate between 
weak and strong.4. Nuclear staining strong - no nuclear architecture discernable. 
5. Cytoplasmic staining weak. 6. Cytoplasmic staining moderate. Absent cytoplasmic staining and 
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and cytoplasmic staining was assessed in 100 melanoma cells. For samples in which 
intra-epidermal tumour cells were prominent, these were assessed separately to cells 
in the dermal component of the tumour. 
To give a visual overview of ANKHD1 expression patterns across all 
samples in the study the percentage of cells with each category of cytoplasmic and 
nuclear staining in each patient is displayed in Figure 4-10 and Figure 4-11 (the three 
samples of metastatic melanoma have not yet been quantified, and are not included 
in this analysis). Almost all tumour cells across the histological sub-types examined 




The quantitative data was used to test three hypotheses suggested by the qualitative 
data: 1) Radial growth phase superficial spreading melanoma shows stronger nuclear 
staining than vertical growth phase superficial spreading melanoma or nodular 
melanoma. 2) Thinner melanomas show stronger nuclear staining than thicker 
melanomas. 3) Intra-epidermal tumour cells show stronger nuclear staining than the 
corresponding dermal tumour cells.  
Statistical analysis did not support these hypotheses. The mean percentage of 
cells with strong or moderate nuclear staining in nodular melanoma was 6%, in 
radial growth phase superficial spreading melanoma it was 36% and in vertical 
growth phase superficial spreading melanoma it was 35%. There was no significant 
difference between these values when examined with a one-way ANOVA (P = 0.36) 
although this may be related to the small number of samples in the nodular 
melanoma group.  To examine the relationship between melanoma thickness and 
nuclear ANKHD1 staining intensity the percentage of cells with moderate or strong 
nuclear staining was plotted against melanoma thickness (Figure 4-12). This did not 
show a clear relationship. The correlation coefficient for the relationship was      -
0.33, but this was not statistically significant (P = 0.08) (Pearson’s correlation 
coefficient, two-tailed significance test). The percentages of intra-epithelial cells 
with moderate or strong nuclear staining were compared to the percentage of dermal 
cells with moderate or strong nuclear staining using a paired t test. The difference 
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Figure 4-10. Pattern of cytoplasmic staining in malignant melanoma. 100 tumour cells were 
examined in each sample. Each bar represents one patient, identified by the numbers 
below the bars. The bar represents 100 cells and is coloured to show the proportion of 
cells  with each grade of cytoplasmic staining intensity. Within each group samples are 
arranged in order of staining intensity, with the samples with the highest proportion of cells 
staining strongly on the left. (A) Staining in histological sub-types which are rare in this 
cohort. (B) Staining in superficial spreading melanoma, with tumours in radial growth 
phase and vertical growth phase separated. (C) Staining in vertical growth phase 
superficial spreading melanoma in which intra-epidermal tumour cells are present. Cells in 
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Figure 4-11. Pattern of nuclear staining in malignant melanoma. 100 tumour cells were 
examined in each sample, bars show the proportion of cells with each category of staining 
intensity. Numbers identify individual patients. (A) Staining in histological sub-types which 
are rare in this cohort. (B) Staining in superficial spreading melanoma, with tumours in 
radial growth phase and vertical growth phase separated. (C) Staining in superficial 
spreading melanoma in which intra-epidermal tumour cells are present. Cells in the dermal 
component of the tumour are compared to the intra-epidermal tumour cells, with radial 
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Figure 4-12. Scatter plot to examine for a correlation between melanoma thickness and 
percentage of cells with moderate or strong nuclear staining for ANKHD1. r = -0.33 (95% 





In laboratory models, ANKHD1 promotes activation of several intracellular 
signalling pathways thought to contribute to disease pathogenesis in melanoma. In 
this study I have profiled the expression of ANKHD1 in tissue samples from patients 
with a range of histological sub-types of malignant melanoma, to determine whether 
further investigation of the role of ANKHD1 in melanoma is likely to be 
informative.  
 
4.3.1 Expression and cellular localisation of ANKHD1 in melanoma 
ANKHD1 is expressed in melanoma. It is found in the nucleus and cytoplasm. There 
are variations in ANKHD1 expression within and between individuals, and 
histological sub-types. Initial examination suggested that there were qualitative 
differences in ANKHD1 distribution according to histological sub-type, with 
stronger nuclear staining for ANKHD1 in thinner melanomas, and in intra-epidermal 
tumour cells. However, a semi-quantitative assessment of staining intensity did not 
confirm this. The number of samples examined in this study was relatively small so 
it is possible that these apparent trends might have been statistically significant had a 
larger sample size been examined. However, as there is no clear pattern in this 
variation of ANKHD1 expression that would suggest it provides an insight into 
disease pathogenesis or would be diagnostically useful, examination of further 
samples would probably not be worthwhile.  
 Caveats to the quantitative analysis of ANKHD1 expression are associated 
with the use of a scoring system to categorise staining intensity. In particular, a 
continuous range of levels of ANKHD1 expression have been arbitrarily divided into 
categories, and this study has not included a consideration of intra and inter-observer 
variability (Cross 1998).  
A notable feature of the data presented here is the observation of nuclear 
localised ANKHD1. Early studies of ANKHD1 described it as a cytoplasmic protein 
but more recently ANKHD1 has also been observed to be localised to the nucleus, a 
feature that relates to its function in modulation of the Hippo pathway  (Sansores-
Garcia, Atkins et al. 2013, Sidor, Brain et al. 2013, Machado-Neto, Lazarini et al. 
2014) and as a repressor of transcription of the cell-cycle regulator p21/WAF/CIP 
(Dhyani, Machado-Neto et al. 2015). The observation of nuclear localised ANKHD1 
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here contrasts to the previous description of ANKHD1 in melanoma in the Human 
Protein Atlas, where it is seen only in the cytoplasm.    
 
4.3.2 Ongoing and possible future work 
The samples from individuals with metastatic melanoma remain to be quantitatively 
analysed. An investigation of ANKHD1 expression in benign naevi is also 
underway. Samples from 20 benign naevi have been stained for ANKHD1. An initial 
examination of these slides indicates that ANKHD1 is expressed in melanocytes in 
benign naevi, and that there is less heterogeneity in expression in naevi compared to 
melanoma. The samples are awaiting quantitative analysis.  
 This study used only one anti-ANKHD1 antibody. Polyclonal rabbit IgG was 
used as a control for nonspecific antibody binding, but it does not control for 
antibody cross-reactivity. Repeating the immunohistochemistry with an anti-
ANKHD1 antibody directed against a different epitope of the protein would be an 
important experiment to increase our confidence that the results truly represent 
ANKHD1 distribution. Erroneous data produced by antibody cross-reactivity is a 
prevalent problem in research, and in cancer biology in particular (Baker 2015). 
 It would be interesting to determine whether there is any relationship 
between ANKHD1 expression and JAK/STAT and Hippo pathway activation in 
melanoma. Studies of STAT3 activation and YAP/TAZ nuclear localisation have 
shown that this occurs only in some cells in some melanoma samples – it is possible 
that these are samples with high levels of ANKHD1 expression and ANKHD1 
nuclear localisation, respectively. Immunohistochemistry could be carried out on 
adjacent tissue sections to determine this. A greater insight could be gained from 
performing two-colour immunohistochemistry, to try to determine whether there is a 
relationship between ANKHD1 expression and pSTAT3 levels or YAP/TAZ 
localisation at the level of individual cells.  
 The data from this study does not indicate that further investigation of 
ANKHD1 in melanoma is likely to be clinically useful. However, it would still be of 
interest to examine whether ANKHD1 might contribute to the malignant phenotype 
of melanoma cells. Investigation of the effects of ANKHD1 knockdown and 
overexpression upon proliferation, migration and apoptosis in melanoma cell lines 





This work has shown that ANKHD1 is expressed in melanoma. However, the wide 
variation in ANKHD1 expression patterns even within a single histological sub-type 
of melanoma suggests that further investigation of ANKHD1 in melanoma is 






Chapter 5: Methotrexate is an inhibitor of JAK/STAT 
signalling 
5.1 Introduction 
Prior to the start of my PhD, the Zeidler group identified methotrexate and 
aminopterin as suppressors of JAK/STAT signalling in a Drosophila cell-based 
screen of drugs, natural products and bioactive compounds (Figure 5-1).  
 
Figure 5-1. Methotrexate and aminopterin cause significant suppression of JAK/STAT pathway 
activation, assessed using a reporter of STAT responsive transcription. z score for firefly 
luminescence/Renilla luminescence = median/ median absolute deviation on a plate-by plate basis. z 
score values are considered significant when >3 or <3. Data generated by Katie Fisher and Steve 
Brown (Thomas, Fisher et al. 2015). 
 
Low-dose methotrexate is used in the treatment of inflammatory conditions such as 
rheumatoid arthritis, but its mechanism-of-action in this setting is incompletely 
understood. Given that the JAK/STAT signalling pathway is involved in the 
inflammatory response (O'Shea and Plenge 2012) and that an inhibitor of JAK3 has 
shown benefit in patients with rheumatoid arthritis (Fleischmann, Kremer et al. 
2012), this result suggested that inhibition of JAK/STAT signalling might contribute 
to the action of methotrexate in inflammatory conditions. Further investigation of 
this effect might also lead to the use of methotrexate to treat other conditions 
associated with increased activation of JAK/STAT signalling.  
 The screen result provided a starting point for a more detailed investigation 
of the effect of methotrexate on JAK/STAT signalling. The JAK/STAT signalling 
pathway in Drosophila is simpler than that in humans, with the major components 
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being three ligands (Unpaired, Unpaired 2 and Unpaired 3), one receptor (Domeless) 
one JAK (Hopscotch) and one STAT (STAT92E) (Zeidler and Bausek 2013). This 
relative simplicity and lack of redundancy makes the Drosophila JAK/STAT 
pathway a good model in which to perform screens. However, further investigation 
is needed to determine effects in the more complex JAK/STAT system of humans. 
 I investigated the effects of methotrexate on different mechanisms of 
JAK/STAT pathway activation in Drosophila cells, and extended this to investigate 
the effect of methotrexate on JAK/STAT signalling in vivo in a fly strain with an 
activating mutation in Hop. I then determined the effect of methotrexate upon 
JAK/STAT activation in human cell lines. To establish the relevance of the effect of 
methotrexate on JAK/STAT signalling in disease I investigated the effects on 
pathway activation caused by the JAK2V617F mutation found in patients with 
MPNs.     
 
5.2 Results 
5.2.1 Methotrexate reduces JAK/STAT activation caused by ligand-
binding and activation caused by constitutive kinase activation in 
Drosophila cultured cells 
In the screen which identified methotrexate and aminopterin as suppressors of 
JAK/STAT pathway activation, activation of the pathway was produced by 
overexpression of Unpaired (Upd). To test whether the effects of methotrexate and 
aminopterin were specific to pathway activation caused by ligand activation, the 
effect on JAK/STAT activity in cells where the pathway is activated by Upd 
secretion was compared to its effect in cells where the pathway is activated by 
overexpression of a constitutively active mutant of Hopscotch (Hop). HopTum-l 
contains a glycine to glutamic acid substitution at residue 341 in the JH4 domain, 
which causes JAK/STAT activation (Luo, Hanratty et al. 1995). When JAK/STAT 
pathway activation was assessed using a STAT responsive transcriptional luciferase 
assay, methotrexate and aminopterin both caused a dose-dependent reduction in 
JAK/STAT activation when the pathway was activated by expression of HopTum-l as 
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Figure 5-2. Methotrexate and aminopterin suppress STAT responsive transcription in 
Drosophila Kc167 cells when the JAK/STAT pathway activation is caused by Upd secretion 
(A) or expression of a constitutively active Hop (B). FL/RL = firefly luciferase 
luminesence/ Renilla luciferase luminescence. Values are normalised to those in cells 
treated with DMSO alone. Bars show mean and standard deviation of four replicates. ns 







5.2.2 Methotrexate does not affect JAK/STAT dependant tumour 
formation in vivo in Drosophila 
The original screen which identified methotrexate as a JAK/STAT inhibitor was 
performed in a Drosophila cell line. I wished to establish whether methotrexate 
affects JAK/STAT signalling in vivo in flies. Flies possessing a mutation in hop 
which causes a glutamic acid to lysine substitution at position 695, in the JH2 
domain, develop melanotic tumours due haematopoietic abnormalities (Luo, Rose et 
al. 1997). JAK/STAT activation causes proliferation of plasmatocytes, a phagocytic 
haemocyte present in embryos, and their premature differentiation into lamellocytes, 
cells that participate in encapsulation reactions. These lamellocytes form melanised 
tumours, and alterations in the number and size of these tumours have been used to 
identify modulators of JAK/STAT signalling in flies (Shi, Calhoun et al. 2006). I 
hypothesised that methotrexate would reduce tumour formation in hopT42 flies. 
 I first established what range of methotrexate concentrations could be 
tolerated by wild-type larvae without substantially reducing the number of adult flies 
that hatch (Figure 5-3A). Based on this data, concentrations of 0.1µM, 0.5µM and 
0.75µM were selected for further investigation. 
 Methotrexate did not have any significant effect on tumour formation in flies 
heterozygous for hopT42 (Figure 5-3B). 
 It is possible that no effect was observed because of the pharmacokinetics of 
methotrexate in flies, if concentrations of methotrexate in the tissues of the 
developing flies were substantially lower than concentrations in the food. However, 
flies at the 0.5µM and 0.75µM methotrexate concentrations showed wing 
abnormalities that have previously been described as a consequence of methotrexate 
treatment (Affleck, Neumann et al. 2006), suggesting that methotrexate was being 
absorbed in sufficient quantities to affect development (Figure 5-3C). 
 
5.2.3 Examination of expression and phosphorylation of JAK/STAT 
pathway components in human cell lines 
To examine the effect of methotrexate on JAK/STAT signalling in human cells I 
used the Hodgkin lymphoma cell lines HDLM-2 and L-540 which have previously 
been found to show constitutive phosphorylation of certain JAK/STAT pathway 
components (Cochet, Frelin et al. 2006), and used to examine the effects of drugs on  
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Figure 5-3. Effect of methotrexate in vivo in Drosophila. (A) High doses of methotrexate 
significantly reduce survival of wild-type Drosophila from egg laying to adulthood. Bars 
show mean and standard deviation of two replicates. One-way ANOVA with Dunnetts 
multiple comparisons test. ns P > 0.05, * P < 0.05. (B) Methotrexate does not affect 
tumour index in hop     mutants. Bars show mean and standard deviation (median in 
each group is 0). One-way ANOVA does not show a significant difference between 
groups. (C) A proportion of flies raised on methotrexate have wing notching, as shown 
on the image on the right  of a fly raised on 0.5µM methotrexate. This is not present in 





JAK/STAT signalling (Kim, Oh et al. 2010). Prior to using these cell lines to 
examine the effects of methotrexate and aminopterin on JAK/STAT signalling I 
determined the expression and phosphorylation of JAK and STAT family members 
using western blotting. These were compared to JAK and STAT phosphorylation in 
HeLa cells with and without JAK/STAT pathway stimulation with oncostatin M 
(Figure 5-4A). 
 Constitutive phosphorylation of JAK3 has previously been observed in L-540 
cells, but no pJAK3 was detected in these cells in my hands (Kim, Oh et al. 2010). 
pJAK3 was detected after cells were stimulated with IL-2, confirming a lack of 
constitutive JAK3 phosphorylation rather than a problem with the antibody used in 
western blotting (Figure 5-4B). 
 
5.2.4 Methotrexate and aminopterin reduce JAK phosphorylation 
Methotrexate and aminopterin reduce levels of pJAK1 and pJAK2 in HDLM-2 cells 
at higher drug concentrations (Figure 5-5A and B). This effect is more marked for 
pJAK1 than pJAK2.  
 The effect of methotrexate on JAK3 phosphorylation was investigated in L-
540 cells in which JAK3 phosphorylation was stimulated by IL-2 treatment. 
However, methotrexate treatment affected total JAK3 in these cells, appearing to 
produce protein degradation, making the blots difficult to interpret (Figure 5-5C). 
 
5.2.5 Methotrexate does not affect the activity of JAK2 in in vitro 
kinase assays, and has little effect on other kinases 
The reduction in JAK phosphorylation produced by methotrexate treatment 
suggested methotrexate may be acting as a direct inhibition of JAK activity. This 
was examined in a cell free assay of kinase activity (Hastie, McLauchlan et al. 
2006). A kinome screen examining the effect of methotrexate upon 50 kinases was 
performed by the International Centre for Kinase profiling at the University of 
Dundee (Table 5-1). In this assay methotrexate had no effect upon JAK2 activity - 
the mean activity in the presence of methotrexate was 102% of usual activity, with a 
standard deviation of 10%. Methotrexate had little effect on most of the kinases 
examined, where the mean percentage kinase activity was close to 100%, and the 

















































Figure 5-4. Hodgkin lymphoma cell lines HDLM-2 and L-540 show constitutive 
phosphorylation of certain JAK and STAT family members. (A) Basal expression 
and phosphorylation of JAKs and STATs in the the Hodgkin lymphoma cell lines is 
compred to that seen in unstimulated HeLa cells and in HeLa cells in which the 
JAK/STAT pathway has been activated by stimulation wih Oncostatin M at 10ng/ml 
for 30 minutes. HDLM-2 cells show constitutive phosphorylation of JAK1 and 
JAK2. Both lines express JAK3 but no phospho-JAK3 was detected. Both Hodgkin 
lymphoma cell lines show constitutive phosphorylation of STATs 1, 3 and 5. (B) 
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Figure 5-5. Methotrexate and aminopterin reduce constitutive JAK phosphorylation. (A) 
Western blotting shows a reduction in pJAK1 and pJAK2 at high drug concentrations, but 
little effect on total JAK levels. (B) Quantification of western blot band intensities. Bars 
show mean and standard deviation of three independent experimental replicates. Values 
were adjusted for loading using actin and normalised to the values for cells treated with 
vehicle alone. One-way ANOVA with Dunnett’s multiple comparisons test. *** P < 0.001,  
* P < 0.05. (C) Methotrexate and aminopterin reduce pJAK3 in L-540 cells stimulated 

























































A. No Change                           B. Increased activity                C. Decreased activity
Table 5-1. Methotrexate does not affect JAK2 activity in an in vitro kinase assay, and 
has modest effects on other kinases. Columns show mean and standard deviation 
(SD) of the percentage activity remaining after exposure to 10µM methotrexate, for 
duplicate experiments. Kinases have been arranged according to the degree to 
which they are affected by methotrexate. Only those kinases for which mean - SD or 
mean + SD did not cross 100 were considered as having increased or decreased 




or decrease in activity. Most notable amongst these is Lck (Lymphocyte Specific 
Protein Tyrosine Kinase), for which kinase activity was reduced to 68% with a 
standard deviation of 3%. Lck is a Src family kinase involved in T cell receptor 
activation. This relationship is consistent with the anti-inflammatory properties of 
methotrexate. Based on a literature search and search in the EMBL-EBI IntAct 
Molecular Interaction Datbase (Orchard, Ammari et al. 2014) no interaction between 
Lck and methotrexate has previously been described. Of significance for the 
interpretation of my results, Lck is known to phosphorylate and activate STAT3 and 
STAT5. 
 
5.2.6 Methotrexate and aminopterin have selective effects on STAT 
phosphorylation in HDLM-2 cells 
Given that methotrexate and aminopterin substantially reduce STAT-responsive 
transcription in Drosophila cells and reduce JAK phosphorylation in human cell 
lines, I next examined whether these drugs affect STAT phosphorylation in HDLM-2 
cells. Both drugs produced a dose-responsive reduction in STAT1 phosphorylation 
and STAT5 phosphorylation, but had little effect on STAT3 phosphorylation. Levels 
of total STATs appeared unaffected by the drug treatments (Figure 5-6 A and B). 
 
5.2.7 The effects of methotrexate on STAT phosphorylation are not 
the consequence of a global reduction in protein phosphorylation 
It is possible that the reduction of STAT1 and STAT5 phosphorylation could be an 
indication that methotrexate has non-specific effects on intracellular protein 
phosphorylation, rather than evidence of a selective effect on JAK/STAT signalling. 
To address this I examined the effect of methotrexate on three serine/threonine or 
tyrosine phosphorylated proteins in other intracellular signalling pathways - ERK 
1/2, Akt and c Jun). Phosphorylation of these proteins was not affected by 
methotrexate, even at the highest concentrations tested (Figure 5-6C).  
 
5.2.8 STAT phosphorylation caused by the JAK2 V617F mutation is 
reduced by methotrexate 
In Drosophila cell culture experiments methotrexate reduced JAK/STAT signalling 
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Figure 5-6. Methotrexate and aminopterin reduce STAT1 and STAT5 phosphorylation, 
with little effect on total STATs, STAT3 phosphorylation or other intracellular 
phosphorylated proteins. (A) Western blots showing the effect of methotrexate and 
aminopterin treatment on total and phosphorylated STATs. (B) Quantification of 
western blot band intensities. Bars show mean and standard deviation of three 
independent experimental replicates. Values were adjusted for loading using actin 
and normalised to the values for cells treated with vehicle alone. One-way ANOVA 
with Dunnett’s multiple comparisons test. *** P < 0.001, ** P <0.01, * P < 0.05. (C) 
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kinase activation. To investigate whether methotrexate produces the same effect in 
human malignancies caused by JAK mutations which confer constitutive kinase 
activation I examined the effect of methotrexate on phosphorylation of JAK/STAT 
pathway components in the HEL cell line. This cell line is homozygous for the JAK2 
V617F mutation (Baxter, Scott et al. 2005), and shows constitutive STAT 
phosphorylation that is dependent on JAK2 activity (Anand, Stedham et al. 2011). 
Methotrexate treatment led to a reduction in STAT3 and STAT5 
phosphorylation in HEL cells. There was also a mild reduction in the levels of the 
un-phosphorylated form of these STATs (Figure 5-7A). The changes in pSTAT 
levels were statistically significant, whereas the changes in total STAT levels were 
not (Figure 5-7B). 
 The effect of methotrexate on STAT5 phosphorylation in HEL cells becomes 
apparent after 24 hours of methotrexate treatment (Figure 5-7C).  
5.2.7 The effects of methotrexate on STAT phosphorylation appear 
after 24 hours of methotrexate treatment 
The time taken for methotrexate to affect STAT phosphorylation may give 
information about its likely mechanism of action. In HDLM-2 cells it takes 24 hours 
for a reduction in STAT phosphorylation to be observed (Figure 5-7A). 
 
5.2.8 The effect of methotrexate on STAT phosphorylation is not 
reversed by folinic acid 
Methotrexate exerts its effects as a chemotherapy drug through impairment of folate 
metabolism, via competitive inhibition of dihydrofolate reductase (DHFR). This 
inhibition reduces intracellular levels of intermediate compounds required for 
nucleotide synthesis, resulting in impaired DNA replication and repair that 
ultimately causes cell death (Li and Kaminskas 1984). Folinic acid is given 
following methotrexate in chemotherapy regimens, in order to bypass the block in 
folate metabolism caused by inhibition of DHFR (Visentin, Zhao et al. 2012). 
Patients taking low dose methotrexate for rheumatoid arthritis are also usually given 
folate supplementation to reduce adverse effects of folate antagonism, and this does 
not have a marked effect on the efficacy of methotrexate in these patients (Whittle 
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Figure 5-7. Methotrexate reduces STAT3 and STAT5 phosphorylation in HEL cells, and 
this effect becomes apparrent after 24 hours. (A) Western blots showing the effect of 
methotrexate on total and phosphorylated STATs in HEL cells. (B) Quantification of 
western blot band intensities. Bars show mean and standard deviation of three 
independent experimental replicates. Values were adjusted for loading using actin and 
normalised to the values for cells treated with vehicle alone. One-way ANOVA with 
Dunnett’s multiple comparisons test. *** P < 0.001, ** P <0.01, * P < 0.05. (C) The 
reduction in pSTAT5 becomes apparent after 24 hours of methotrexate treatment, and is 




To establish whether the effects of methotrexate on JAK/STAT signalling 
might be linked to inhibition of DHFR I examined the effect of folinic acid on STAT 
phosphorylation in methotrexate treated HEL cells. The ability of methotrexate to 
suppress STAT5 phosphorylation persisted in the presence of folinic acid (Figure 5-
8A). However, the magnitude of the suppression was reduced. These results suggest 
that the inhibition of JAK2/STAT5 in these cells is at least partly independent of 
perturbation of folate metabolism. It is also consistent with the continuing anti-
inflammatory and immunosuppressive effects of methotrexate in patients with 
rheumatoid arthritis receiving folate supplementation. 
 
5.2.9 Methotrexate-treated cells can activate JAK/STAT signalling 
in response to EPO 
JAK/STAT pathway activity is essential for multiple developmental and 
physiological processes including haematopoiesis and immunity. As a result, 
thrombocytopaenia, anaemia and susceptibility to infection have been significant 
side effects of JAK inhibitors used in clinical practice (Fleischmann, Kremer et al. 
2012, Harrison, Kiladjian et al. 2012). If methotrexate were to be used clinically to 
treat patients with MPNs it would be desirable for the suppression of JAK/STAT 
signalling to occur in such a way that pathway inhibition can be overcome by 
physiological stimuli. To test whether this was the case for methotrexate-induced 
pathway suppression we stimulated methotrexate-treated HEL cells with 
recombinant EPO. The normal range for serum EPO is large, so to recapitulate EPO 
levels produced by the physiological stimulus of hypoxia we used an EPO 
concentration calculated to correspond to that measured in the serum of individuals 
with secondary erythrocytosis (Spivak 2002). Strikingly, STAT5 phosphorylation in 
methotrexate-treated cells was increased following EPO stimulation, and was 
comparable to that observed in control cells (Figure 5-8B). 
 
5.2.10 Suppression of STAT5 phosphorylation by methotrexate is 
comparable to that produced by ruxolitinib 
I wished to determine whether the effects of methotrexate on STAT phosphorylation 
in HEL cells were comparable to the effects of ruxolitinib, which is used clinically to 








































Figure 5-8. (A) Western blots showing the effect of exogenous folinic acid on the 
suppression of STAT5 phosphorylation in HEL cells treated with methotrexate. (B) 
Western blots showing the effect of EPO stimulation of the JAK/STAT pathway in HEL 
cells treated with methotrexate. (C) Comparison of the effects of ruxolitinib and 
methotrexate on STAT5 phosphorylation in HEL cells.
























resulted in a clear suppression of STAT phosphorylation (Figure 5-8C). Taking into 
account peak serum concentrations measured in patients taking the drugs orally, 0.4 -
0.8μM for methotrexate and 1μM for ruxolitinib (Shilling, Nedza et al. 2010, Hobl, 
Mader et al. 2012), ruxolitinib produced a more profound suppression of STAT 
phosphorylation than methotrexate. However the effects of both drugs on STAT5 
phosphorylation were comparable at pharmacologically realistic concentrations. 
 
5.3 Discussion 
This study has established that methotrexate suppresses activation of the JAK/STAT 
signalling pathway, including JAK/STAT activation caused by JAK2V617F. These 
results have implications for understanding the biology of methotrexate when used 
as an anti-inflammatory drug, and suggest that it may provide a novel treatment 
option for patients with malignancies associated with JAK/STAT pathway 
activation. 
 
5.3.1 JAK/STAT suppression as a mechanism of action for 
methotrexate as an anti-inflammatory drug 
Methotrexate has been used for many years to treat inflammatory disorders including 
rheumatoid arthritis, but its mechanism of action in these conditions is not fully 
understood (Wessels, et al 2008). The JAK/STAT signalling pathway is involved in 
inflammation and immunity (O'Shea and Plenge 2012) and activation of JAK/STAT 
signalling is seen in many inflammatory diseases. JAK/STAT activation is known to 
contribute to disease pathogenesis in rheumatoid arthritis (Walker and Smith 2005), 
and a specific inhibitor of JAK3 has shown efficacy in clinical trials in patients with 
rheumatoid arthritis (Fleischmann, et al 2012). It is also notable that leflunomide, 
used in the treatment of inflammatory conditions including rheumatoid arthritis, has 
been observed to inhibit JAK/STAT signalling (Siemasko, Chong et al. 1998). 
Our data suggests that suppression of JAK/STAT activation may contribute 
to the action of methotrexate in inflammatory conditions. Methotrexate produces a 
clear suppression of STAT phosphorylation at drug concentrations equivalent to the 
peak plasma concentrations measured in patients taking oral methotrexate to treat 
rheumatoid arthritis (0.4uM) (Hobl, Mader et al. 2012). Caution is needed when 
extrapolating results from in vitro drug treatments to speculate on what might occur  
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in patients, however. The plasma concentrations referred to are peak plasma 
concentrations. Methotrexate has a relatively short plasma half-life (4 hours) due to 
uptake into cells and excretion by the liver and kidneys. It is possible that adding 
methotrexate to media for 48 hours exposes cells to higher concentrations of 
methotrexate for longer periods than would occur in patients. Conversely, as 
methotrexate is rapidly and actively absorbed into cells by folate carriers, whose 
expression is upregulated on cancer cells, it may be that all the methotrexate is 
absorbed into cells within a short time frame and the methotrexate concentration in 
the media for most of the experiment is negligible. To better recapitulate 
physiological conditions methotrexate-containing media could be replaced with fresh 
media after a few hours. 
 
5.3.2 What is the mechanism through which methotrexate 
suppresses JAK/STAT signalling? 
This work has not established the mechanism through which methotrexate reduces 
the activation of the JAK/STAT pathway. Nonetheless, some inferences can be 
drawn to generate hypotheses. The data in Drosophila cells comparing STAT-
responsive transcriptional activation due to Upd and HopTum-l suggests that 
methotrexate acts downstream of ligand secretion. Examination in HDLM-2 cells 
suggests that it selectively affects levels of phosphorylated JAK/STAT pathway 
intermediates without having a global effect on all intracellular phosphorylated 
proteins. The persistence of the suppression of STAT phosphorylation in the 
presence of folinic acid suggests that the effect of methotrexate is at least partially 
independent of its known effects upon folate metabolism. 
One possible mechanism through which methotrexate might reduce 
JAK/STAT pathway activation is by acting as a direct inhibitor of JAK kinase 
activity. The dose dependent reduction in JAK1 phosphorylation produced by 
methotrexate in HDLM-2 cells supports this hypothesis (although the effect on JAK1 
phosphorylation is not statistically significant). Modelling of the possible molecular 
interactions between methotrexate and the kinase pocket of JH1 of JAK2 (John 
Sayers and Martin Zeidler, unpublished data) suggests methotrexate could dock in 
the kinase pocket under physiological conditions, in a manner comparable to 




Figure 5-9. Modelling of methotrexate occupying the ATP-binding pocket of JH1 of JAK2. John 
Sayers and Martin Zeidler, unpublished data. 
 
However, some evidence is not consistent with this hypothesis. Firstly, the effects of 
methotrexate on JAK2 and JAK3 were less clear than the effect on JAK1, and in 
general the effect on JAK phosphorylation is less marked than the effect on STAT 
phosphorylation. Secondly, 10uM methotrexate did not affect JAK2 activity in in 
vitro kinase assays. It is possible that a metabolised form of methotrexate, such as 
methotrexate polyglutamates, is the biologically active drug, accounting for the lack 
of effect in kinase assays. Consistent with this, methotrexate treatment takes 24 
hours to produce a change in STAT phosphorylation when examined with western 
blotting. 
 One intriguing possible mechanism through which methotrexate may 
suppress JAK/STAT signalling is as an indirect result of its effects on adenosine 
metabolism. Methotrexate causes adenosine accumulation indirectly via inhibition of 
the enzyme 5-aminoimidizole 4-carboxamideribonucleotide (AICAR) (Tian and 
Cronstein 2007). Recently adenosine analogues have been shown to act as JAK 
inhibitors (Liu 2014).   
 When considering possible mechanisms for the effect of methotrexate on 
JAK/STAT signalling, the role of folates merits further discussion. Administration of 
folinic acid, which bypasses the block in folate metabolism caused by inhibition of 
DHFR, reduced but did not reverse the suppression of STAT phosphorylation 
observed here. The concentration of folinic acid was equivalent to that which is 
found in patients taking folinic acid to treat methotrexate toxicity (Whittle and 
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Hughes 2004). This suggests that the effects of methotrexate may be independent of 
effects on folate metabolism. This is supported by RNAi screening for genes that 
modulate JAK/STAT pathway activation in Drosophila, where there is no interaction 
between multiple enzymes in the folate biosynthetic pathway and STAT 
transcriptional activity (Fisher, Wright et al. 2012). The partial restoration of STAT 
phosphorylation in the presence of folinic acid could be due to reduced cellular 
uptake of methotrexate, since the compounds compete for uptake via the same 
transporter (Dixon 1991, Visentin, Zhao et al. 2012). Conversely, there is evidence 
in the existing literature to support the hypothesis that the methotrexate effects are 
related to DHFR inhibition since pyrimethamine, an anti-parasitic drug which 
inhibits DHFR, has been shown to reduce STAT phosphorylation (Takakura, Nelson 
et al. 2011).  
Further work will be required to determine the mechanism through which 
methotrexate inhibits JAK/STAT activation. This does not negate its potential 
clinical usefulness as a treatment for JAK/STAT associated disorders, however, 
especially as it is a drug whose safety profile is already well understood from its use 
in inflammatory conditions. 
 
5.3.2 Methotrexate as a potential treatment for patients with MPNs 
The demonstration that methotrexate reduces JAK/STAT pathway activation caused 
by the JAK2V617F mutation suggests that methotrexate may be a suitable treatment 
for patients with myeloproliferative neoplasms. Although the cytoreductive drugs 
busulphan and hydroxyurea are used to treat patients with MPNs, a literature search 
has not identified any reports of the use of methotrexate in these conditions. Our data 
shows that suppression of STAT5 phosphorylation occurs at methotrexate 
concentrations equivalent to those measured in the plasma of patients, both those 
receiving methotrexate for chemotherapy and those taking methotrexate for 
rheumatoid arthritis (Hobl, Mader et al. 2012, Radtke, Zolk et al. 2013).  
 These effects are comparable to the effects of ruxolitinib, although ruxolitinib 
caused greater suppression of STAT phosphorylation at comparable concentrations 
in vitro. Methotrexate-treated cells retained the capacity to activate the JAK/STAT 
pathway in response to ligand stimulation, which has implications for its possible use 
to treat patients with MPNs. Methotrexate may ‘dampen’ the pathological basal 
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over-activation of the JAK/STAT pathway sufficiently to control the disease, 
without preventing physiological activation when needed for haematopoiesis and the 
response to infection. Levels of STAT5 phosphorylation in CD34+ cells from 
patients with MPNs are only about 1.5 fold greater than in CD34+ cells from normal 
healthy individuals (Anand, Stedham et al. 2011), suggesting that a relatively mild 
suppression of pathway activation may be sufficient to control the disease. This is 
important in the context of the effects of ruxolitinib, which produces a more 
profound inhibition of STAT phosphorylation, but for which thrombocytopaenia and 
to a lesser extent anaemia and susceptibility to infection are significant side effects 
(Harrison, Verstovsek et al. 2012).     
There is a need for new treatments for patients with myeloproliferative 
neoplasms. Ruxolitinib is recommended by the British Committee for Standards in 
Haematology (BCSH) for patients with myelofibrosis and splenomegaly or 
constitutional symptoms (Reilly, McMullin et al. 2014). However, the high cost of 
ruxolitinib means that the National Institute for Clinical Excellence (NICE) has 
placed limitations on its use (NICE 2013). There is also evidence from a phase 3 trial 
that ruxolitinib benefits patients with PV (Vannucchi, Kiladjian et al. 2015), 
although it is not currently recommended for patients with PV in the UK. 
Hydroxyurea is widely used, but a proportion of patients do not respond to 
hydroxyurea or experience intolerable side-effects (Hernandez-Boluda 2010, 
Alvarez-Larrán, Pereira et al. 2012). The ability of methotrexate to inhibit 
JAK/STAT pathway activation might may make it a suitable alternative treatment 
for patients with myeloproliferative neoplasms.  
 
5.3.3 Methotrexate as a potential treatment for patients with other 
haematological malignancies associated with activation of 
JAK/STAT signalling 
The suppression of STAT phosphorylation observed was not specific for JAK/STAT 
pathway activation caused by JAK2V617F. This suggests that methotrexate may 
benefit patients with other  haematological malignancies in which JAK/STAT 
activation plays a role in pathogenesis, such as those arising from fusion genes of 
JAK2 with PCM1, ETV6 and BCR (Bain and Ahmad 2014), T-cell large granular 
lymphocytic leukaemia (Koskela, Eldfors et al. 2012), chronic lymphoproliferative 
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disorders of natural killer cells (Jerez, Clemente et al. 2012) Waldenstrom’s 
Macroglobulinaemia (Hodge 2014) chronic myeloid leukaemia (Warsch 2013) and 
chronic lymphocytic leukaemia (Rozovski, Wu et al. 2014)). Low-dose methotrexate 
is already used for the treatment of large granular lymphocytic leukaemia, which is 
associated with activating mutations in STAT3, where its effectiveness may result at 
least partly from its capacity to suppress JAK/STAT pathway activation (Lamy and 
Loughran 2011). In a recent phase 2 study of immunosuppressive drugs in LGL 
leukaemia the presence of the commonest activating STAT3 mutation, Y640F (a 
tyrosine to phenylalanine substitution), was strongly predictive of a clinical response 
to methotrexate (Loughran 2014).  
 
5.4 Conclusions 
This work has established that methotrexate suppresses JAK/STAT signalling in 
human cell lines in-vitro. The effect occurs following treatment at drug 
concentrations equivalent to those measured in patients taking high dose 
methotrexate as a chemotherapy drug, and the lower oral doses used to treat 
rheumatoid arthritis. This suggests that inhibition of JAK/STAT signalling may 
contribute to the mechanism through which methotrexate suppresses inflammation. It 
also suggests that methotrexate treatment might be beneficial in haematological 
malignancies associated with JAK/STAT pathway activation. Further work is needed 
to establish to what extent these effects observed after in vitro treatment of cell lines 








Chapter 6: Effects of methotrexate on patient cells 
 
6.1 Introduction 
In order to determine whether the effects of methotrexate on JAK/STAT signalling 
observed in Drosophila and human cell lines were relevant for diseases involving 
increased JAK/STAT activation, I wished to examine the effect of methotrexate 
upon primary human cells. Primary cells involved in disease pathogenesis from 
patients with two categories of disease involving JAK/STAT activation were 
examined; fibroblast-like synoviocytes from patients with rheumatoid arthritis and 
haematopoietic stem and progenitor cells from patients with myelofibrosis.  
 
Rheumatoid arthritis fibroblast-like synoviocytes  
In patients with rheumatoid arthritis, the synovium of affected joints contains a 
characteristic cell type, the rheumatoid arthritis fibroblast-like synoviocyte (RA-
FLS) which is not present in healthy joints, and is thought to be central to disease 
pathogenesis. These cells produce matrix-degrading enzymes and cytokines which 
contribute to the recruitment and activation of inflammatory cells (Huber, Distler et 
al. 2006). Synovial fibroblasts can be isolated from synovial tissue of patients with 
arthritis during arthroscopic surgery and maintained in culture. In contrast to 
synovial fibroblasts from patients with osteoarthritis, a type of arthritis in which 
immunity plays little role in the pathogenesis, RA-FLS show increased expression 
and phosphorylation of STAT1 when assessed using western blotting (Kasperkovitz, 
Verbeet et al. 2004).  
 
Haematopoietic stem and progenitor cells 
Myeloproliferative neoplasms arise from haematopoietic stem cells (HSC), and 
patients with MPNs have increased numbers of circulating cells with characteristics 
of HSCs, compared to normal individuals (Jamieson, Gotlib et al. 2006). The cell-
surface glycoprotein CD34 is expressed on early haematopoietic stem and progenitor 
cells and used as a marker to identify HSCs, since CD34+ cell populations are 
enriched for cells which morphologically resemble blasts and have colony-forming 
abilities (Krause, Fackler et al. 1996). CD34 positive cells can be isolated from 
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patients with MPNs and show increased levels of STAT5 phosphorylation compared 
to CD34 positive cells obtained from healthy individuals (Anand, Stedham et al. 
2011).   
Patients with myelofibrosis who are undergoing a stem cell transplant 
provide an opportunity to obtain HSCs for research. The best outcomes for these 
patients are achieved when they undergo an allogeneic transplant, receiving stem 
cells from a donor. However, they also have their own cells harvested by apheresis 
and stored as a ‘back-up’ so that an autologous transplant can be performed if there 
are problems with the allogeneic transplant. For individuals in whom the allogeneic 
transplant has been successful, this apheresis material is surplus to requirements for 
clinical care, and provides a source from which the cells involved in disease 
pathogenesis can be isolated. 
 
6.2 Results 
6.2.1 RA-FLS show constitutive phosphorylation of STAT1 
Patient characteristics of the three individuals from whom RA-FLS were obtained 
are not known. RA-FLS from the first patient grown in media containing 5% FBS 
show constitutive phosphorylation of STAT1, and some phosphorylation of STAT3. 
Stimulation with OSM leads to a massive increase in STAT1 phosphorylation and 
increased STAT3 phosphorylation, and pJAK1 becomes detectable (Figure 6-1).  
 
6.2.2 The suppression of STAT1 phosphorylation by methotrexate 
varies between patients 
The effect of methotrexate on constitutive STAT1 phosphorylation was examined in 
two further patients. In one patient methotrexate appeared to suppress STAT1 
phosphorylation, whereas in the second STAT1 phosphorylation appeared to be 
unaffected (Figure 6-2). 
 
6.2.3 MF Patient characteristics 
Five patients were recruited, four of whom had samples analysed. Patient 
















Figure 6-1. Profile of JAK and STAT expression, basal phosphorylation and 
phosphorylation following stimulation with OSM in RA-FLS (rheumatoid arthritis 
fibroblast-like synoviocytes) from one patient. JAK1 is not detected, but some pJAK1 
is seen following OSM stimulation suggesting that it is present. JAK2 is seen but 
there is no basal or OSM-stimulated phosphorylation. JAK3 is not detected. STAT1 
is present and shows constitutive phosphorylation. OSM stimulation leads to a 
massive increase in STAT1 phosphorylation. STAT3 is present and shows 
constitutive phosphorylation, and an increase in phosphorylation following OSM 
stimulation. No STAT5 is detected in these cells.
    -     +                     OSM stimulation 
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Figure 6-2. Methotrexate treatment reduces constitutive STAT1 phosphorylation in 
patient-derived RA-FLS (rheumatoid arthritis fibroblast-like synoviocytes), although 
this effect varies between patients. In cells from patient A, pSTAT1 levels are 
reduced at all methotrexate concentrations examined, with a more marked effect at 
higher concentrations. In cells from patient B uneven loading makes the blot difficult 




Table 6-1. Patient characteristics of patients from whom apheresis material was used for isolation of 
HSCs (details deleted from library copy to protect patient anonymity). 































Patient 2  491 
Patient 3  41 
Patient 4  237 
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6.2.4 Isolation of CD34 positive cells 
Magnetic labelling was successfully used to isolate CD34 positive cells1 from 
cryopreserved apheresis material from patients with MPNs. From 0.5ml aliquots of 
apheresis material the number of cells initially isolated in the CD34 positive fraction 
ranged from 0.3 x 106 to 1.2 x 106 (mean 0.8 x 106 standard deviation 0.47 x 106) 
with the number of cells isolated being roughly proportional to the patient’s CD34+ 
count prior to harvest. The isolated cells were large round cells which grew in 
suspension, as expected for these cells (Figure 6-3). 
 Flow cytometry was used to determine the proportion of CD45+ cells which 
were CD34+, following culture for 48 – 72 hours. In the first patient analysed, the 
proportion of CD34+ cells in the mixed apheresis material prior to magnetic sorting 
was 12%. Following sorting, this percentage rose to 74% in the CD34 positive 
fraction, a 6 fold enrichment. In the CD34 negative fraction 2% of cells were CD34+ 
(Figure 6-4). 
 Comparison of the forward-scatter and side-scatter properties of the pre-sort, 
CD34 positive and CD34 negative fractions showed that the CD34 positive fraction  
  
                                                 
1 Note on terminology: ‘CD34+’ will be used to refer to cells which are identified with CD34-PerCP 
using flow cytometry. ‘CD34 positive’ will be used to refer to the cell population obtained following 
magnetic sorting which is enriched for CD34+ cells but also contains variable numbers of CD34- 
cells. 
Figure 6-3. The cells in the CD34 positive fraction following magnetic sorting are round 
cells that grow singly in suspension (note that the brightness and contrast of the image 





Figure 6-4. Magnetic sorting produces a cell population enriched for CD34+ cells. See 
materials and methods for gating strategy. Note the events to the left of the ‘cells’ gate 
are debris and dead cells. (A) In the mixed population of cells prior to magnetic sorting 
12% of CD45+ cells are CD34+. (B) Following magnetic sorting, in the cell fraction that 
should be enriched for CD34+ cells this proportion rises to 74%. (C) In the cell fraction 
that should be depleted of CD34+ cells the proportion falls to 2%. Back gating shows that 
the CD34+ population (red) is CD45 dim, when compared to the overall population of 
single cells (grey). The CD34+ cells have distinctive forward scatter and side scatter 
characteristics, being larger and more granular than the other cells obtained from 
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contained a large and distinctive population of large, relatively granular cells which 
were CD45 dim, as expected for HSCs (Figure 6-4).   
In the samples from three subsequent patients these enrichments were 
sufficient to produce an 89 – 99% pure population (Figure 6-5).  
 
6.2.4 Viability of CD34 positive cells 
Flow cytometry with Annexin V-FITC and propidium iodide was used to assess 
viability in the CD34 positive cell fraction at the time of the phenotyping analysis 
described above, i.e. after 48 – 72h in culture following isolation. The cultures 
contained a large proportion of dead cells (Figure 6-6). The dead cells had a 
characteristic pattern of forward scatter and side scatter and could be excluded from 
viability analyses in subsequent patients. As there was such extensive cell death in 
this initial culture phase it was not meaningful to look at percentages of live cells, 
however, a substantial proportion of the isolated cells from each patient were live 
(Figure 6-7). High numbers of dead cells were expected at this stage, when it is 
considered that cells must survive not only the freeze-thaw cycle, but also several 
hours of processing to isolate CD34+ cells immediately after thawing. 
 
 
6.2.5 Maintenance of phenotype in culture 
The proportion of cells in the CD34 positive fraction which were CD34+ fell during 
prolonged culture, with CD34+ cells no longer detected amongst the CD45+ 
population after 14 days in culture (Figure 6-8). This change is not unexpected as 
culture conditions are very different to the bone marrow microenvironment, but 
suggests that the degree to which the cells in culture indicate what happens in 
patients is limited. 
 
6.2.6 Flow cytometry as a method to detect changes in STAT5 
phosphorylation 
It was anticipated that the number of cells available to examine drug effects of 
methotrexate in primary samples would be low. A flow cytometry protocol to 
determine pSTAT5 levels was developed, as this would allow examination of cells in 
numbers potentially too small to detect with western blotting.  
Figure 6-5. In three further patients, magnetic sorting produces a cell population enriched 
for CD34+ cells. Plots shown are for CD45+ cells (see materials and methods for gating 
strategy). For patient 2 the proportion of CD34+ cells rises from 72% to 99% (1.4 fold 
enrichment), for patient three the proportion rises from 0.65% to 89% (136 fold 

















































Figure 6-6. Live cells are found in the CD34 positive fraction following magnetic sorting. 
Figures are from the data from patient 1. (A) gating strategy to identify cells. Live cells do 
not take up propidium iodide and do not bind Anexin V. Cells that have entered apoptosis 
bind Annexin V, and those which are dead also take up propidium iodide. (B) Projection of 
the cell populations identified based on Annexin V and propidium iodide indicates that 
these populations of cells can also be identified by distinctive pattrns of forward scatter 
and side scatter. Grey shows all events represented on the forward scatter/side scatter 
plot, red live cells, orange early apoptotic cells and green late apoptotic and dead cells. (C) 
Re-positioning the gates confirms that the large number of events with low forward scatter 
(excluded by the gating strategy in A) represent dead cells.
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Figure 6-7. Live cells are obtained following magnetic isolation of CD34 positive cells from 


















































Figure 6-8. After fourteen days in culture, the CD45+ cell population originally 
derived from the CD34 positive fraction following magnetic separation contains very 











In HEL cells, flow cytometry could detect a dose-responsive reduction in 
pSTAT5 following treatment with ruxolitinib. At low drug concentrations the two 
techniques were comparable, whereas at higher drug concentrations the magnitude of 
the reductions measured with flow cytometry was smaller than that seen with 
western blotting done in cells from the same population (Figure 6-9).  
Following treatment with methotrexate, a dose responsive reduction in 
pSTAT5 in HEL cells was seen with flow cytometry. The reduction was smaller than 
that observed when western blotting was used as the detection method (Figure 6-10). 
The forward-scatter and side-scatter properties of methotrexate-treated cells differed 
from those in DMSO-treated or ruxolitinib-treated cells. The pattern of pSTAT5 
staining was also different, with a biphasic staining pattern indicating two 
populations of cells, with high and low levels of staining for pSTAT5. This may be 
indicative of a true difference in STAT5 phosphorylation, or may be a consequence 
of uneven staining or of the gating strategy used. In particular, it is possible that 
inclusion of dead cells might give this pattern. 
For the CD34 positive cells from patients with MF, flow cytometry was 
chosen to examine the effects of methotrexate in the cells available 48 hours after 
isolation. If cells were available in subsequent passages, they were used for western 
blotting.  
 
6.2.7 Effect of methotrexate on STAT5 phosphorylation in HSCs 
In the first patient analysed there was a substantial difference in fluorescence in cells 
stained with anti-pSTAT5 compared to isotype (a fourfold change in median 
fluorescence intensity). However, there was no decrease in pSTAT5 in cells treated 
with methotrexate, or the control cells treated with ruxolitinib. Median fluorescence 
intensity was in fact slightly higher in the ruxolitinib-treated and methotrexate-
treated cells compared to DMSO-treated cells. However, this was probably due to a 
change in nonspecific antibody binding, since fluorescence in these cells stained with 
isotype antibody was also increased. The apparent increase in pSTAT5 is lost when 
the fold-change in median fluorescence intensity is calculated for each drug 
treatment (Figure 6-11).  
In the three subsequent patients analysed the fluorescence intensity in the 
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Figure 6-9. Flow cytometry can be used to detect dose-responsive changes in STAT5 
phosphorylation in HEL cells treated with ruxolitinib.
A. Western blot showing reduction in pSTAT5 in populations of HEL cells treated with the 
indicated concentrations of ruxolitinib, compared to cells treated with DMSO alone. Note 
that the control and drug treated lanes are imaged from the same experimental replicate 
and blot, the intervening lanes which have been removed for clarity show methotrexate 
treated cells from the same experiment (see figure 7-10). 
B. Histograms showing the dose-responsive reduction in pSTAT5 which can be detected 
with flow cytometry. Histograms have been smoothened to facilitate comparisons 
between doses. The percentage reductions in pSTAT5 measured using flow cytometry 
are comparable to those measured using western blotting in figure A at low drug 
concentrations, but at higher drug concentrations the inhibition seen with western blotting 
is greater than that seen with flow cytometry. 
C. The dose-responsive reduction in STAT5 phosphorylation which can be detected with 
flow cytometry is apparrent when dot-plots of cells treated with a range of drug 
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Figure 6-10. Flow cytometry can be used to detect dose-responsive changes in STAT5 
phosphorylation in HEL cells treated with methotrexate (see materials and methods for 
gating strategy). 
A. Western blot showing the reductions in pSTAT5 in populations of HEL cells treated with 
the indicated concentrations of methotrexate, compared to cells treated with DMSO alone. 
B. Histograms showing the slight dose-responsive reduction in STAT5 phosphorylation in 
HEL cells treated with methotrexate that can be detected with flow cytometry. Histograms 
have been smoothened to facilitate comparison. There is a biphasic pattern of staining 
that is much more marked than in the ruxolitinib-treated cells. In the cell population 
examined, the reduction in pSTAT5 detected using flow cytometry is not as marked as that 
which is detected with western blotting. MFI = median fluorescence intensity.
C. When dot plots of methotrexate-treated HEL cells are superimposed, it is difficult to 
clearly see the dose-dependent reduction in STAT5 phosphorylation. Note that the number 
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Figure 6-11. Methotrexate treatment does not reduce pSTAT5 in HSCs when 
examined using flow cytometry. However, in this experiment there was also no 
reduction in pSTAT5 following treatment with ruxolitinib. MFI = median fluorescence 
intensity. Methotrexate and ruxolitinib appear to increase pSTAT5 slightly, but this is 
probably in fact a change in antibody binding, possibly to dead cells, since MFI in 
these cells is also increased with the isotype control. When the fold-change in MFI  
(MFI pSTAT5 / MFI isotype) is considered, this apparent effect of methotrexate is lost. 
 Drug treatment  MFI pSTAT5 Fold change in 
MFI  
 None, Isotype 143  
 None 593 4.1 
 DMSO 553 4.1 
 0.1uM methotrexate 718 3.8 
 1uM methotrexate 703 3.9 
 50uM methotrexate 774 4.3 





stained cells, suggesting either that the HSCs from these patients did not have 
phosphorylated STAT5 or that there was a problem with this experimental run (data 
not shown).  
 
6.2.8 Methotrexate causes apoptosis in HSCs 
Compared to DMSO alone, methotrexate causes substantial cell death in 
haematopoietic stem and progenitor cells (Figure 6-12). There is a significant 
reduction in the number of live cells following treatment with 1µM methotrexate 
compared to treatment with DMSO (P = 0.005, paired t test).  This is in contrast to 
treatment with ruxolitinib, where there is not a significant difference in the number 
of live cells compared to treatment with DMSO alone (P = 0.38). The proportion of 
live cells following methotrexate or ruxolitinib treatment varies between patients. It 
should be noted that for patient 2 and patient 3, for which the lowest number of live 
cells were recorded, drug treatment and analysis were done in the same batch. The 
differences between patients may be due to experimental conditions. 
 
6.2.9 Changes in STAT5 phosphorylation in HSCs following 
methotrexate treatment can be detected with western blotting 
For patient 1, enough CD34 positive cells were available in a subsequent passage to 
the flow cytometry experiments for drug treatment experiments to be performed 
again and effects of methotrexate examined using western blotting. Experimental 
conditions were slightly different, as by this stage most cells in the population were 
not CD34+, and the media was not supplemented with factors that promote HSC 
growth. Constitutive phosphorylation of STAT5 could be detected in these cells. 
pSTAT5 was reduced by methotrexate treatment in a dose-dependent manner. 
However, levels of total STAT5 were also reduced to a similar extent (Figure 6-13). 
 
6.3 Discussion 
In this study I have investigated the effect of methotrexate on STAT phosphorylation 
on primary cells from patients with diseases associated with JAK/STAT pathway 
activation treated in vitro. The work has involved development of techniques for 
HSC isolation and to assess JAK/STAT pathway activation. The results are less 
conclusive than those obtained from experiments in cell lines, but nonetheless add to  
  Patient 1                         Pateint 2                         Patient 3                        Patient 4
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Figure 6-12. Treatment with methotrexate causes substantial apoptosis of HSCs. The 
























































Figure 6-13. Methotrexate produces a dose-responsive reduction in pSTAT5 in 
primary cells from a patient with MF. However, the reduction in total STAT5 is similar 
to that seen for pSTAT5. A. Western blot. B. Quantification of band intensities of 
western blot. Band intensities have been adjusted for loading using the intensity of 
the actin band, then normalised to the value for the cells with no treatment. 0 no 
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our understanding of the effects of methotrexate, ultimately contributing to 
consideration of whether these effects are likely to occur in patients.  
 
6.3.1 Development of experimental methods 
This work has demonstrated that viable CD34+ HSCs can be isolated from 
cryopreserved apheresis harvest surplus to requirements for clinical care. This may 
be of utility for other research examining haematopoietic stem and progenitor cells 
by providing a source of cells, particularly as it may be possible to use cells which 
are past their expiry date for transplant and would otherwise be disposed of. It has 
not been determined, however, whether similar results would be seen with cells from 
individuals without MPNs. 
 The protocol established to examine pSTAT5 using flow cytometry could be 
adapted for a future clinical study. Specifically, pSTAT5 could be examined in 
leucocytes in whole blood drawn from individuals prior to and following 
methotrexate treatment. Combining the protocol to examine pSTAT5 with staining 
using antibodies against cell surface markers that identify specific sub-population of 
cells would be particularly informative. However, there were problems with the 
protocol for flow cytometry, and further repetitions are required to determine 
whether failure to detect pSTAT5 in HSCs from three patients was due to problems 
with the experimental technique. 
 
6.3.2 JAK/STAT signalling in RA-FLS 
Methotrexate appeared to supress STAT1 phosphorylation in RA-FLS from one 
patient, and have little effect on cells from a second patient. This might suggest that 
suppression of JAK/STAT activation contributes to the effects of methotrexate in 
patients with rheumatoid arthritis. No clinical details about the patients from whom 
the cells were obtained were available, although it is interesting to speculate that 
these individuals might have differed in their response to methotrexate treatment. 
 STAT1 was examined because a preliminary profile of JAK/STAT pathway 
component expression and phosphorylation indicated STAT1 was constitutively 
phosphorylated in these cells in vitro, whereas phosphorylation of other STATs was 
weak or not detected. However, there is controversy over the role of STAT1 
phosphorylation in rheumatoid arthritis, where it may well play a role in suppressing 
180 
 
rather than promoting inflammation (Walker and Smith 2005). This is suggested by a 
mouse model in which joint inflammation is exacerbated in STAT1 knockout mice 
compared to wild-type mice (de Hooge, van de Loo et al. 2004). Furthermore, there 
is evidence that the pattern of JAK/STAT activation in the cytokine-rich 
microenvironment of the inflamed synovium is very different to that seen in a 
homogeneous culture of RA-FLS (Kasperkovitz, Verbeet et al. 2004).  
Finally, an examination of the effects of methotrexate upon JAK/STAT 
signalling in leucocyte sub-groups in rheumatoid arthritis would be highly relevant. 
In peripheral blood, 30 minutes incubation in 10µM methotrexate does not have any 
effect on ligand-stimulated STAT phosphorylation in CD4+ T lymphocytes, B 
lymphocytes or monocytes when assessed with flow cytometry (Prof. Olli 
Silvennoinen and Dr. Pia Isomäki, personal communication). Given that my 
experiments in cell lines indicated that the effects of methotrexate take around 24 
hours to become apparent, it would be interesting to examine whether methotrexate 
has effects on leucocytes following a longer exposure. 
 
6.3.3 JAK/STAT signalling in HSCs from patients with 
myelofibrosis 
Examination of methotrexate effects in primary cells from patients with MPNs adds 
substantially to the data from cell lines when considering whether suppression of 
STAT phosphorylation by methotrexate may be clinically relevant. It is 
disappointing that, due to challenges with working with very small numbers of cells 
and potential problems with flow cytometry, data on the effects of methotrexate on 
STAT5 phosphorylation is only available for one of the four patients. 
          Interpretation of the data is not straightforward. For this patient, western 
blotting suggested that methotrexate suppressed STAT5 phosphorylation, whilst also 
lowering levels of total STAT5, in a late passage of cells. Flow cytometry on 
methotrexate-treated cells from the same patient from an earlier passage, however, 
showed no effect of methotrexate or ruxolitinib on pSTAT5 but indicated that 
approximately 50% of the methotrexate-treated cells were dead. This disparity could 
relate to experimental techniques – western blotting examines mixed cell population 
of live and dead cells. If the rate of turnover of pSTAT5, or indeed tSTAT5, in dead 
cells was faster than that of actin this would appear as a reduction in STAT5 
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phosphorylation on a western blot. It was notable that in other patients in whom 
pSTAT5 was not detected with flow cytometry (although it is not clear whether this 
was a true feature of the cells or an experimental problem) the proportion of live 
cells was much lower. One approach to address this would be to develop a multi-
colour flow cytometery protocol that included a viability marker alongside staining 
for pSTAT5, with the caveat that the approach to assess viability would have to be 
suitable for permeabilised cells.  
Differences in culture conditions could also contribute to the conflicting 
results, since the early passage cells were treated in the presence of a cytokine 
supplement to favour HSC expansion that included TPO, a JAK/STAT pathway 
ligand. Given that experiments in HEL cells suggested that JAK/STAT pathway 
stimulation with EPO could overcome pathway suppression by methotrexate this 
may have led to the effect of methotrexate being masked. 
 The cell populations in the early and late passage will have been different, as 
no CD34+ cells remained after 14 days in culture. It is not clear whether this is due 
to differentiation leading to downregulation of CD34 expression or due to selective 
expansion of the, initially small, population of CD34 negative cells in this 
population. It is interesting that others have observed CD34 positive cells to be 
relatively resistant to JAK inhibition, whereas CD34 negative cells, representing a 
more differentiated myeloid population, did show a reduction in STAT5 
phosphorylation following treatment with a JAK inhibitor (Anand, Stedham et al. 
2011).  
Finally, the extent to which these primary cells reflect what methotrexate 
might do in patients with myelofibrosis needs to be considered. Specifically, it is not 
known what proportion of cells in the CD34 positive population are from the 
malignant clone, and what proportion are normal HSCs. Although of little relevance 
in my patient group, which included only one individual with the JAK2V617F 
mutation, it is interesting that others have been able to examine STAT 
phosphorylation (Chen, Beer et al. 2010) and drug effects (Wyspianska, Bannister et 
al. 2014) in JAK2 mutant and wild-type cells from the same patient, by performing 





This data tentatively supports the idea that effects of methotrexate as a suppressor of 
JAK/STAT signalling in cell lines also apply in primary patient cells, although it 
highlights problems with western blotting as a technique to examine drug effects. It 
suggests methotrexate may suppress JAK/STAT phosphorylation in patients. 
Strategies to examine JAK/STAT phosphorylation in patients taking methotrexate as 




Chapter 7: Conclusions and future directions 
7.1 Overview  
Activation of the JAK/STAT signalling pathway is observed in haematological 
malignancies and solid tumours. JAK/STAT activation contributes to the malignant 
phenotype of cancer cells and there is an association between activation of certain 
pathway components and prognosis in many types of cancer (Bowman, Garcia et al. 
2000, Chen, Staudt et al. 2012). There is evidence of the success of targeting 
JAK/STAT signalling as a therapeutic strategy from clinical trials in 
myeloproliferative neoplasms (Harrison, Kiladjian et al. 2012, Vannucchi, Kiladjian 
et al. 2015), and pre-clinical studies suggest that targeting the pathway may be 
beneficial in solid tumours (Rath, Naidu et al. 2014). 
 Some of the molecular events leading to aberrant JAK/STAT pathway 
activation in cancer are understood. However, in many cases the causes of pathway 
activation, and the factors which modulate activation of the pathway, are not well 
defined. A better understanding of the regulation of JAK/STAT pathway activation 
in cancer may ultimately lead to improved treatments for patients, if it helps to refine 
diagnostic classifications and predict prognosis, and predict responses to therapies. 
Furthermore, patients would also benefit from access to a wider range of therapies 
which target the pathway. 
 The aim of this work was to improve our understanding of genetic and 
chemical modulators of JAK/STAT signalling. The role of the gene ANKHD1, 
known to positively regulate JAK/STAT signalling in Drosophila and cell lines, was 
investigated in haematological malignancies and the skin cancer malignant 
melanoma. The effect of methotrexate on JAK/STAT signalling in human cell lines 
and primary cells was examined, to build on the identification of methotrexate as a 
suppressor of JAK/STAT pathway activation in a high-throughput screen. 
 
7.2 Summary of findings 
This work has established the expression patterns of ANKHD1 in normal blood cell 
types, where it is found in monocytes and lymphocytes but absent from neutrophils. 
ANKHD1 also appears to be variably expressed in CD34+ haematopoietic stem 
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cells, and expressed in blasts in acute myeloid leukaemia and acute lymphocytic 
leukaemia.  
 In melanoma, ANKHD1 can be found in the nucleus and the cytoplasm and 
is expressed in all the histological sub-types of melanoma examined. The level of 
nuclear and cytoplasmic expression is variable, although there is no clear 
relationship between expression patterns and histological sub-type or melanoma 
thickness.  
 The study of methotrexate shows that methotrexate suppresses STAT 
phosphorylation in human cell lines, with some effect on JAK phosphorylation. This 
effect occurs at concentrations of methotrexate equivalent to those measured in 
patients receiving high-dose intravenous methotrexate as a chemotherapy drug, and 
low dose oral methotrexate for the treatment of rheumatoid arthritis. Methotrexate 
suppresses STAT phosphorylation due to JAK2V617F, and has an effect comparable 
to the JAK2 inhibitor ruxolitinib which is currently in use clinically. The suppression 
of STAT phosphorylation is partially independent of the effects of methotrexate on 
folate metabolism, and can be overcome with ligand stimulation.  There is some 
evidence that the effect of methotrexate on STAT phosphorylation in cell lines also 
occurs in disease-relevant primary cells from patients with rheumatoid arthritis and 
myelofibrosis. 
 
7.3 Future work 
ANKHD1 
The work on ANKHD1 expression in blood cells, haematological malignancies and 
melanoma was carried out in a relatively small number of samples. A more robust 
indication of ANKHD1 expression would be obtained from examination of a larger 
number of samples, and could enable examination of the relationship between 
ANKHD1 expression and disease features. However, to justify profiling ANKHD1 
expression in a larger number of patient samples a better understanding of the role 
ANKHD in normal cells and in these diseases is needed.  
 To investigate the function of ANKHD1 in normal blood a mouse model 
could be created. Knockout of ANKHD1 appears to cause embryonic lethality 
(S.Constantinescu, unpublished observation). Generating a model in which 
ANKHD1 was conditionally knocked down only in certain blood cell lineages might 
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overcome this, however. An alternative approach would be to attempt to reconstitute 
haematopoiesis in lethally irradiated mice using stem cells in which ANKHD1 is 
knocked down with shRNA from a lentiviral vector.  
 The rationale for investigating ANKHD1 expression in haematological 
malignancies and melanoma is based on evidence that it affects Ras/Raf/MEK/ERK, 
Hippo and JAK/STAT signalling. Further data would be useful to validate these 
findings, particularly for the effects on Ras/Raf/MEK/ERK and JAK/STAT 
signalling. Determining the effects of ANKHD1 knockdown and overexpression 
upon constitutive and ligand-stimulated STAT and ERK phosphorylation in cell 
lines, which could be done with immunofluorescence and western blotting, may be 
informative here. There is also the potential to identify which domains of ANKHD1 
are responsible for the signalling effects as I have plasmids encoding tagged 
fragments of the protein containing only certain domains. These could also be used 
for co-immunoprecipitation experiments to examine which regions of the protein 
mediate the known physical interactions with Hippo and JAK/STAT pathway 
components.   
 
Methotrexate 
There are two questions to be addressed in future work on the effects of methotrexate 
on JAK/STAT signalling: establishing the mechanism through which methotrexate 
suppresses the signalling pathway, and determining whether methotrexate may be a 
suitable treatment for patients with JAK/STAT associated malignancies, in particular 
MPNs. 
 There is some evidence to suggest methotrexate might be binding to and 
inhibiting JAKs. Methotrexate appeared to reduce JAK1 phosphorylation in HDLM-
2 cells. Furthermore, in silico modelling suggested that methotrexate could bind the 
kinase pocket of JAK2 and that the energy involved in this binding was 
physiologically realistic. Equipment to directly measure protein-substrate 
interactions is available in the department of biomedical science. A caveat to this 
approach is the impact that ATP concentration is likely to have on these binding 
interactions. Although the screen for effects on in vitro kinase assays did not show 
an effect on JAK activity, it may nonetheless be relevant to examine methotrexate 
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effects in in vitro kinase assays further, particularly if it was possible to examine 
polyglutamated forms of methotrexate in these assays.  
 To consider the mechanism through which methotrexate may be affecting 
JAK/STAT signalling, a more conclusive determination is needed of whether the 
effects are secondary to inhibition of DHFR. This could be addressed by examining 
the effects of methotrexate on JAK/STAT signalling in the presence of 
hypoxanthine, which should rescue the effects of methotrexate on nucleotide 
synthesis. 
 Several approaches may be used to generate further data needed to determine 
whether investigating methotrexate as a treatment for MPNs in a clinical trial would 
be worthwhile. Further investigation of the in vitro effects of methotrexate in CD34+ 
and CD34- cell fractions from patients with MPNs is needed. Approaches to isolate 
these cells from peripheral blood might enable a larger number of patients to be 
examined than was possible using apheresis samples. It would also be of interest to 
examine STAT phosphorylation in peripheral blood cells of patients taking 
methotrexate as part of their routine clinical care (both patients with inflammatory 
conditions and those receiving methotrexate as part of a chemotherapy regime). This 
would allow the pharmacokinetics of methotrexate to be taken into account. Basal 
levels of JAK/STAT pathway activation in blood cell types would need to be 
determined to establish whether this approach would be informative. 
 Finally, the effect of methotrexate could be examined in mouse models of 
MPNs. Effects on disease features such as haematocrit and spleen weight could be 
examined. However, some direct examination of effects on JAK/STAT pathway 
activation would be needed. Methotrexate toxicity, due to effects on folate 
metabolism, would lead to cytopaenias and it would be important to distinguish this 
from a specific effect on JAK/STAT signalling.  
     
7.4 Impact 
The impact of this work arises from the study of methotrexate as a suppressor of 
JAK/STAT signalling. If subsequent experiments suggest pursuing an investigation 
of methotrexate as a treatment for patients with MPNs is worthwhile, it has the 
potential to improve quality of life and potentially prolong life in this group of 
patients. Furthermore, the relatively low cost of methotrexate means that its use as a 
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treatment for MPNs could bring financial benefits by reducing the cost of care for 
these patients.   
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